| Date | Title | | | May.20.13 | Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company| - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -
- Expands Portfolio and Pipeline in Core Areas of Women's Health and Urology -
- Adds Gastroenterology and Dermatology Franchises and Infrastructure -
- Stronger Commercial Presence to Support Expanded Brand Pipeline -
- Immediately Accretive With Opportunities for Substantial Operational Synergies and Tax Savings -
- Combination Expected to Generate Strong EBITDA and Cash from Operations -
- All Stock Transaction Fu... |
|  | | May.14.13 | Announcement Under Irish Takeover Rules Relevant Securities in Issue| PARSIPPANY, N.J., May 14, 2013 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Rules, Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, (the "Company") confirms that, as at the latest practicable date prior to the making of this announcement, the Company's issued share capital consisted of 133,305,212 ordinary shares, excluding treasury shares, par value US$0.033 per share (the "Ordinary Shares"). The International Securities Identification Number for these ... |
| | | May.13.13 | Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA| PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy.
The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. The acceptance for f... |
| | | May.13.13 | Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference| PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has cancelled its appearance at the upcoming Bank of America Merrill Lynch Healthcare Conference. Actavis had been scheduled to present on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada.
About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on ... |
| | | May.10.13 | Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc| PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies. Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives.
About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a glob... |
| | | May.09.13 | Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit| PARSIPPANY, N.J., May 9, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 (the '720 Patent) valid and infringed by Actavis' generic version of Shire's Lialda® (mesalamine extended-release tablets). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal.
Lialda® is indicated for the induction of remission in patie... |
| | | May.07.13 | Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference| PARSIPPANY, N.J., May 7, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Actavis' Investo... |
| | | May.03.13 | Actavis to Host Annual Meeting of Stockholders on May 10, 2013| PARSIPPANY, N.J., May 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), today announced that the Company will host its 2013 Annual Meeting of Stockholders on Friday, May 10, 2013 beginning at 8:30 AM Eastern Daylight Time. The meeting will be held at the Parsippany Sheraton in Parsippany, NJ, and will be open to in-person stockholders of record only.
Actavis will not be providing a formal update on the business at the meeting, but rather will consider and vote on certain routine matters, ... |
| | | May.02.13 | Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion| - 21% Increase in Q1 2013 Non-GAAP EPS to $1.99; GAAP Earnings (Loss) Per Share of $(0.79) -
- 26% Increase in Adjusted EBITDA to $464 million -
- Company Increases 2013 Forecast -
PARSIPPANY, N.J., May 2, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 24 percent to $1.90 billion for the first quarter 2013, compared to $1.52 billion in the first quarter 2012. On a non-GAAP basis, diluted earnings per share for the first quarter 2013 was $1.99, comp... |
| | | May.01.13 | Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel| PARSIPPANY, N.J. and MONTREAL, May 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Actavis Specialty Brands (the "Company") has acquired worldwide rights to Valeant's Metronidazole 1.3% Vaginal Gel antibiotic development product, a topical antibiotic for the treatment of bacterial vaginosis.
Under the terms of the agreement, Actavis Specialty Brands is acquiring the product for approximately $55 m... |
| | | Apr.26.13 | Actavis Announces OxyContin® Patent Challenge Settlement| PARSIPPANY, N.J., April 26, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that it has entered into an agreement with Purdue Pharma to settle all outstanding patent litigation related to Actavis' generic version of the currently marketed abuse-deterrent formulation of OxyContin®.
Under the terms of the agreement, Actavis will be licensed to market a specified number of bottles of its generic OxyContin® beginning on January 1, 2014.... |
| | | Apr.25.13 | Actavis Reaches Agreement with Shire to Launch a Generic Version of Intuniv® in December 2014| - 180 Days of Exclusivity -
PARSIPPANY, N.J., April 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic version of INTUNIV® (guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder. The settlement also resolves outstanding litigation against legacy Watson's Abbr... |
| | | Apr.16.13 | Actavis Confirms Favorable Ruling in Generic Yaz® Patent Suit| PARSIPPANY, N.J., April 16, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has re-launched Vestura™ (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz® oral contraceptive product, following a ruling from the United States Court of Appeals for the Federal Circuit that United States Patent No. RE 37,564 (the RE '564 Patent) is invalid.
Actavis first launched Vestura™ in January 2012, but removed the product... |
| | | Apr.10.13 | Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®| PARSIPPANY, N.J. and MONTREAL, Quebec, April 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX), today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant Pharmaceuticals International, Inc., resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application (ANDA) for Clindamycin and Tretinoin Gel, a generic version of Ziana®, as... |
| | | Apr.10.13 | Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast| PARSIPPANY, N.J., April 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), announced today that it intends to release first quarter 2013 financial results on Thursday, May 2, 2013, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2013 to discuss its financial results. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 34092217... |
| | | Apr.05.13 | Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape| PARSIPPANY, N.J. and MONTREAL, QUEBEC, April 5, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have entered into an agreement, effective immediately, for Actavis to be the exclusive marketer and distributor of an authorized generic of Valeant's Zovirax® ointment (acyclovir 5%) product. Additionally, Valeant has granted Actavis the exclusive right to co-promote Zovirax® cream (acyclovir 5%) to obste... |
| | | Apr.03.13 | Actavis Confirms Court Issues TRO Related to Generic Pulmicort RESPULES® Distribution| PARSIPPANY, N.J., April 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has granted a motion by AstraZeneca seeking a temporary restraining order (TRO) to prevent Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25, 0.5 mg products. Actavis' sales of generic Pulmicort RESPULES® have been enjoined until April 12, 2013 to permit A... |
| | | Apr.01.13 | Actavis Confirms Generic AndroGel® 1.62% Patent Challenge| PARSIPPANY, N.J., April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1.62%. Actavis' ANDA product is a generic version of AbbVie Inc.'s AndroGel ® 1.62%, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Unimed Pharmaceuticals, LLC, wh... |
| | | Apr.01.13 | Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit| PARSIPPANY, N.J., April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has ruled that Actavis' generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25, 0.5 mg, and 1 mg vials do not infringe United States Patent No. 7,524,834 (the '834 Patent) and that United States Patent No. 6,598,603 (the '603 Patent) is invalid. Actavis intends to launch the 0.25 and 0.5 mg products... |
| | | Mar.25.13 | Actavis Reaches Agreement with AstraZeneca to Launch a Generic Version of Crestor® in 2016| - Launch to occur 67 days ahead of expiry of pediatric exclusivity -
PARSIPPANY, N.J., March 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor® tablets, as well as Actavis' rosuvastatin zinc alternate salt product... |
| | | Mar.08.13 | Actavis Confirms Generic Exelon® Patch Patent Challenge|
PARSIPPANY, N.J., March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength. Actavis' ANDA product is a generic version of Novartis' Exelon® Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Pa... |
| | | Mar.01.13 | Actavis Confirms Generic Fortesta® Patent Challenge|
PARSIPPANY, N.J., March 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone gel 10mg/0.5g. Actavis' ANDA product is a generic version of Endo Pharmaceuticals' Fortesta®, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Endo and... |
| | | Feb.27.13 | Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference|
PARSIPPANY, N.J., Feb. 27, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Barclays 2013 Global Healthcare Conference on Tuesday, March 12, 2013 at 10:15AM ET at The Loews Miami Hotel in Miami, Florida. The presentation will be webcast live and can be accessed on Actavis' Investor Relations Web site ... |
| | | Feb.25.13 | Actavis' Generic Suboxone® Receives FDA Approval|
PARSIPPANY, N.J., Feb. 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone®.
Actavis intends to begin shipping the product immediately. Suboxone® is indicated for maintenance treatment of opioid ... |
| | | Feb.20.13 | Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference|
PARSIPPANY, N.J., Feb. 20, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, President, Actavis Pharma, will provide an overview and update of the Company's business at the Cowen & Company 33rd Annual Health Care Conference on Tuesday, March 5, 2013 at 11:20am ET at The Boston Marriott Copley Place in Boston, MA. The presentation will be webcast live and can be accessed on Actavis' Investor Relations Web site ... |
| | | Feb.19.13 | Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion| - 26% Increase in Full Year 2012 Non-GAAP EPS to $6.00; GAAP EPS $0.76 -
- Fourth Quarter 2012 Net Revenue of $1.75 Billion -
- Fourth Quarter 2012 Non-GAAP EPS of $1.59; GAAP EPS $0.21 -
- Company Reaffirms 2013 Forecast -
PARSIPPANY, N.J., Feb. 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 13 percent to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011. On a non-GAAP basis, diluted earnings pe... |
| | | Feb.14.13 | Actavis Reaches Settlement with Mallinckrodt Over Exalgo® 32 mg Dosage Strength|
PARSIPPANY, N.J, Feb. 14, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release) tablets.
In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Mallinckrodt filed it... |
| | | Feb.12.13 | Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference|
PARSIPPANY, N.J., Feb. 12, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at 3:35pm ET at The New York Palace in New York, NY. The presentation will be webcast live and can be accessed on Actavis' Investor Relations Web site at ... |
| | | Feb.01.13 | Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast|
PARSIPPANY, N.J., Feb. 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), announced today that it intends to release fourth quarter 2012 financial results on Tuesday, February 19, 2013, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, February 19, 2013 to discuss its financial results. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and ... |
| | | Jan.31.13 | Actavis Confirms District Court Ruling In Generic Rapamune® Patent Suit|
PARSIPPANY, N.J., Jan. 31, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found United States Patent No. 5,100,899 (the '899 Patent) valid and infringed by Actavis' generic version of Pfizer Inc.'s Rapamune® (sirolimus). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
Rapamune® tablets are indicated for the prophylaxis of organ... |
| | | Jan.25.13 | Actavis Details Strategy for Continued Long-Term Growth| - 2012 Revenue Forecast to be Approximately $5.9 Billion -
- 2012 Non-GAAP EPS Expected to be at the High-end of Previous Forecast -
PARSIPPANY, N.J., Jan. 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), formerly Watson Pharmaceuticals, Inc., today provides an in-depth look into the newly combined company's global commercial operations, diversified business structure and outlook for continued long-term growth during its fourth annual Investor Meeting in New York.
In conjunction ... |
| | | Jan.24.13 | Watson Pharmaceuticals, Inc. is Now Actavis, Inc.| - Company Begins Trading as "ACT" -
- Multi-year Rebranding Campaign Underway -
- Redesigned Logo Celebrates Emergence as Global Pharmaceutical Leader -
PARSIPPANY, N.J., Jan. 24, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today announced that the company has adopted Actavis, Inc. (NYSE: ACT) as its new global name and will today begin trading under a new symbol — ACT — on the New York Stock Exchange.
The company first announced its intention to change its name last year, fo... |
| | | Jan.23.13 | Watson Confirms Opana® ER Patent Challenge|
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets. Actavis' ANDA product is a generic version of the currently marketed formulation of Endo Health Solutions' Opana® ER... |
| | | Jan.23.13 | Watson Acquires Uteron Pharma SA| - Expands Global Women's Health Franchise and Development Pipeline -
- Enhances Watson Growth 2015+ -
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone payments. The acquisition of Uteron expands Watson's Global Brands pipeline of Women's Health products including two potenti... |
| | | Jan.11.13 | Watson To Host 2013 Investor Meeting January 25 In New York|
PARSIPPANY, N.J., Jan. 11, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 25, 2013 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously.
The meeting will be hosted by Watson's executive leadership team and will offer an in-depth look into the combined company following the acquisition of the Actavis Group.
... |
| | | Jan.03.13 | Watson's Generic Lysteda® Receives FDA Approval|
PARSIPPANY, N.J., Jan. 3, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. – Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda®.
Watson intends to begin shipping the product immediately. Lysteda® is indicated for the treatment of cyclic heavy menstrua... |
| | | Dec.28.12 | Watson Confirms Velcade® Patent Challenge|
PARSIPPANY, N.J., Dec. 28, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib. Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade ® (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration, approved ... |
| | | Dec.21.12 | Watson to Present at the 31st Annual J.P. Morgan Healthcare Conference|
PARSIPPANY, N.J., Dec. 21, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 7:30 am PST (10:30 am EST) at the Westin St. Francis Hotel, San Francisco, California. The presentation will be webcast live and can... |
| | | Dec.20.12 | Watson to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top|
PARSIPPANY, N.J., Dec. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top conference on Thursday, January 3, 2013 at 1:45 pm EST at the Goldman Sachs Conference Center in New York. The presentation will be webcast live... |
| | | Nov.14.12 | Watson to Present at the 2012 Piper Jaffray Health Care Conference|
PARSIPPANY, N.J., Nov. 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Piper Jaffray Health Care Conference on Wednesday, November 28, 2012 at 11:00 am EST at the New York Palace Hotel in New York. The presentation will be webcast live and can be accessed on Watson Pharmaceuti... |
| | | Nov.12.12 | Watson's Generic Revatio® Receives FDA Approval|
PARSIPPANY, N.J., Nov. 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio®. Watson intends to begin shipping the product in the near future. Revatio® is indicated for the treatment of pulmonary arterial hypertens... |
| | | Nov.06.12 | Watson to Present at the 2012 Annual Credit Suisse Healthcare Conference|
PARSIPPANY, N.J., Nov. 6, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Annual Credit Suisse Health Care Conference on Wednesday, November 14, 2012 at 11:30 am MST (1:30 pm EST) at the Arizona Biltmore Hotel in Phoenix. The presentation will be webcast live and can be accessed on... |
| | | Nov.06.12 | Watson to Present at the Jefferies 2012 Global Healthcare Conference|
PARSIPPANY, N.J., Nov. 6, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Watson's President, Global Generics, will provide an overview and update of the Company's business at the Jefferies 2012 Global Healthcare Conference on Thursday, November 15, 2012 at 8:40 am GMT (3:40 am EST) in London, England. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Rel... |
| | | Nov.01.12 | Watson Third Quarter 2012 Non-GAAP Diluted EPS Increases 24% to $1.35; Net Revenue Increases 19% to $1.29 Billion| - GAAP Earnings of $0.60 per diluted share -
- 18% Increase in Adjusted EBITDA -
- Company Updates 2012 Forecast Including Actavis Acquisition -
- Company Provides Preliminary 2013 Outlook -
PARSIPPANY, N.J., Nov. 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the third quarter 2012 increased 24.2 percent to $172.3 million or $1.35 per diluted share on a non-GAAP basis, compared to $138.7 million or $1.09 per diluted share in the th... |
| | | Oct.31.12 | Watson Announces Global Generics Management Team|
PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the Global Generics management team, following the announcement of the completion of the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.
"Since the announcement of our intention to acquire Actavis in April 2012, we have b... |
| | | Oct.31.12 | Watson Announces New Name -- Actavis -- for Global Operations| - Implementing Name Change in 2013 -
- Redesigned Logo Captures Power of Global Combination -
- Global Registration of Actavis in Place -
PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will adopt a new global name – Actavis – effective in 2013. The Company said it will initiate a multi-year rebranding campaign for its facilities, operations and commercial presence, and will transition to trading under a new symbol on th... |
| | | Oct.31.12 | Watson Completes Actavis Acquisition| - Creates 3rd largest global generics company with presence in 60+ markets -
- $8.0+ billion anticipated pro forma combined 2012 revenue -
- Combined management structured to immediately maximize combination value -
PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with... |
| | | Oct.29.12 | Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC|
PARSIPPANY, N.J., Oct. 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has sold its Rugby over-the-counter ("OTC") pharmaceutical products and trademarks to The Harvard Drug Group, LLC, a leading distributor and provider of private label OTCs and generic prescription products, for approximately $117 million. The transaction received clearance from the U.S. Federal Trade Commission on October 19, 2012 und... |
| | | Oct.26.12 | Watson Confirms FDA Denies Appeal Related to Prochieve® NDA for the Prevention of Preterm Birth|
PARSIPPANY, N.J., Oct. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Food and Drug Administration (FDA) denied the Company's Formal Dispute Resolution Request (FDRR) related to its pending New Drug Application (NDA) for Prochieve for the prevention of preterm birth in women with a short cervical length. The Company said it intends to review possible options related to the continued pursuit of the NDA. Watson filed its FDRR in August of 2012... |
| | | Oct.26.12 | Watson Receives FDA Approval for Generic Actos®|
PARSIPPANY, N.J., Oct. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Watson has launched a generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. Food and Drug Administration (FDA). Watson began shipping the product immediately.
On August 15, 2012, Watson announced that it had filed suit against the FDA challenging the Agency's decision regarding Watson's entitlement to... |
| | | Oct.22.12 | Watson to Host Third Quarter 2012 Earnings Conference Call and Webcast|
PARSIPPANY, N.J., Oct. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that the Company intends to release its third quarter 2012 financial results on November 1, 2012, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on November 1, 2012 to discuss its financial results and provide an update on the Company's outlook for 2012. The dial-... |
| | | Oct.22.12 | Watson Receives Favorable Court Decision Regarding Generic Actos® Approval| - Court Instructs FDA to Approve Watson's ANDA -
PARSIPPANY, N.J., Oct. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that U.S. District Court for the District of Columbia has granted summary judgment in favor of Watson and ordered the U.S. Food and Drug Administration (FDA) to approve Watson's generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets). Watson plans to begin shipping the product immediately upon receipt of final ... |
| | | Oct.22.12 | Watson Sells Minority Shareholding Position in Moksha8; Expands Development and Commercialization Agreement|
PARSIPPANY, N.J., Oct. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has sold its minority ownership position in Moksha8, Inc. ("Moksha8"), a leading pharmaceutical company in Latin America, for approximately $47 million. Watson acquired a minority ownership stake in Moksha8 in 2010 after investing $30 million in the company as part of Moksha8's Series 3 financing.
Watson also simultaneously announced that it is expanding its ongoing sales and ... |
| | | Oct.15.12 | Watson Receives FTC Clearance for Actavis Acquisition|
PARSIPPANY, N.J., Oct. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies. The unanimous vote in support of the transaction follows Watson's agreement to a proposed consent order, pursuant to which Watson has agreed to divest certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals require... |
| | | Oct.12.12 | Watson's Generic Sanctura XR® Receives FDA Approval|
PARSIPPANY, N.J., Oct. 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. – Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Trospium Chloride Extended-release Capsules, the generic equivalent to Allergan's Sanctura XR®. Watson intends to begin shipping the product immediately. Sanctura XR® is indicated for the treatment of overactive b... |
| | | Oct.12.12 | Watson's Generic Avapro® Receives FDA Approval|
PARSIPPANY, N.J., Oct. 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Irbesartan Tablets USP, 75 mg, 150 mg and 300 mg, the generic equivalent to Sanofi's Avapro®. Watson intends to begin shipping the product immediately.
Avapro® is indicated for the treatment of hypertension when used ... |
| | | Oct.05.12 | Watson Receives Approval from European Commission for Pending Actavis Acquisition|
PARSIPPANY, N.J., Oct. 5, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the European Commission (EC) has approved the company's pending acquisition of the privately held Actavis Group.
"Approval from the EC represents a significant milestone as we work toward the completion of the combination of Watson and Actavis later this year," said Paul Bisaro, Watson's President and CEO.
The transaction remains subject to regulatory approval in the United St... |
| | | Oct.01.12 | Watson Confirms Favorable District Court Ruling in Androgel® 1% Antitrust Litigation|
PARSIPPANY, N.J., Oct. 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that on September 28, 2012, the United States District Court for the Northern District of Georgia granted summary judgment in favor of Watson, and all other defendants, on all remaining claims in the pending antitrust lawsuit related to settlements of patent litigation concerning Androgel® 1% testosterone gel.
The court found that the plaintiffs' claims were unsustainable because the ... |
| | | Sep.27.12 | Watson Announces Offering of Senior Unsecured Notes|
PARSIPPANY, N.J., Sept. 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is offering approximately $3.75 billion aggregate principal amount of five, ten and thirty year senior unsecured notes in a registered public offering.
Watson intends to use the net proceeds from the offering to fund a portion of the cash consideration for Watson's previously announced acquisition of the privately-held Actavis Group. The senior unsecured notes offering is not... |
| | | Sep.27.12 | Watson Prices $3.9 Billion of Senior Unsecured Notes|
PARSIPPANY, N.J., Sept. 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the pricing of a debt offering of $1.2 billion of 1.875% senior notes due 2017, $1.7 billion of 3.250% senior notes due 2022 and $1.0 billion of 4.625% senior notes due 2042, for a total offering of $3.9 billion in aggregate principal amount. The offering is expected to close on October 2, 2012, subject to market conditions and other factors.
Watson intends to use the ... |
| | | Sep.21.12 | Watson Issues Voluntary Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized and Superpotent Tablets|
PARSIPPANY, N.J., Sept. 21, 2012 /PRNewswire/ -- Watson Laboratories, Inc. today issued a voluntary nationwide recall for two lots of Hydrocodone Bitartrate and APAP Tablets, USP 10 mg/500 mg. A customer complaint was received for tablets that were thicker and darker shade than the other tablets. It is possible that some tablets from lots 519406A and 521759A exceed the weight specification and may contain higher than indicated amounts of the ingredients Hydrocodone Bitartrate and/or Acetam... |
| | | Aug.29.12 | Watson to Present at the 2012 Bank of America Merrill Lynch Global Healthcare Conference|
PARSIPPANY, N.J., Aug. 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Bank of America Merrill Lynch Global Healthcare Conference on Wednesday, September 12, 2012 at 10:25AM Eastern Time (3:25PM London Time) at Merrill Lynch Financial Center in London. The presentation will be ... |
| | | Aug.27.12 | Watson to Present at the Morgan Stanley 2012 Global Healthcare Conference|
PARSIPPANY, N.J., Aug. 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Watson's President, Global Generics, will provide an overview and update of the Company's business at the Morgan Stanley 2012 Global Healthcare Conference on Monday, September 10, 2012 at 10:00AM Eastern Time at the Grand Hyatt in New York, New York. The presentation will be webcast live and can be accessed on Watson Pharma... |
| | | Aug.23.12 | Watson's Generic Lidoderm(R) Receives FDA Approval|
PARSIPPANY, N.J., Aug. 23, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm®. Watson plans to launch the product in September of 2013 pursuant with its settlement agreement with Endo Pharmaceuticals Inc. and beli... |
| | | Aug.20.12 | Watson Launches Generic Xopenex®|
PARSIPPANY, N.J., Aug. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of Xopenex® (levalbuterol HCl) Inhalation Solution as part of an agreement with Sunovion Pharmaceuticals, Inc. Watson began shipping the product today. Xopenex® Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway d... |
| | | Aug.15.12 | Watson Sues FDA Regarding Delay of Generic Actos® Approval|
PARSIPPANY, N.J., Aug. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding Watson's entitlement to shared exclusivity for its generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets). As a result of FDA's decision, Watson's abbreviated new drug application (ANDA) could be delayed for up to six months. Watson noted tha... |
| | | Aug.02.12 | Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines|
PARSIPPANY, N.J., Aug. 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today applauded the publication of the fourth annual Generic Pharmaceutical Association (GPhA) Generic Drug Savings Study demonstrating that the generic pharmaceutical industry has saved the U.S. healthcare system more than $1 trillion in the last decade. The study is available on the GPhA website: www.gphaonline.org.
The study, based on an independent analysis of data by IMS Health — the world's leadi... |
| | | Aug.01.12 | Watson's Generic Version of Pulmicort RESPULES® Receives FDA Approval|
PARSIPPANY, N.J., Aug. 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's Pulmicort RESPULES®. Watson is currently involved in patent litigation with Astra... |
| | | Jul.30.12 | Watson Confirms Xopenex HFA® Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Levalbuterol Tartrate Inhalation Aerosol,0.045 mg/actuation. Watson's ANDA product is a generic version of Sunovion Pharmaceuticals, Inc.'s Xopenex HFA® which is indicated ... |
| | | Jul.30.12 | Watson Confirms Epiduo® Gel Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%. Watson's ANDA product is a generic version of Galderma Laboratories, L.P. Epiduo® Gel is a topical ointment prescription... |
| | | Jul.26.12 | Watson Second Quarter 2012 Non-GAAP Diluted EPS Increases 41% to $1.42; Net Revenue Increases 25% to Over $1.3 Billion| - GAAP Earnings (Loss) of $(0.49) per share on Acquisition Charges -
- 37% Increase in Adjusted EBITDA -
- Company Updates 2012 Forecast -
PARSIPPANY, N.J., July 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the second quarter 2012 increased 42 percent to $181.4 million or $1.42 per diluted share on a non-GAAP basis, compared to $127.9 million or $1.01 per diluted share in the second quarter 2011. Net revenue increased 25 percent to $... |
| | | Jul.13.12 | Watson's Generic Version of Plan B One-Step® Receives FDA Approval|
PARSIPPANY, N.J., July 13, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice™ ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step®. Watson plans to launch the product immediately.
For the twelve months ending May 31, 20... |
| | | Jul.12.12 | Watson and Actavis Receive FTC Second Request|
PARSIPPANY, N.J., July 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of Actavis Group. The information request was issued under notification requirements of the Hart.Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effec... |
| | | Jul.11.12 | Watson's Generic ARTHROTEC(R) Receives FDA Approval|
PARSIPPANY, N.J., July 11, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC®. Watson plans to launch the product in the fourth quarter of 2012.
For the twelve months ending M... |
| | | Jul.05.12 | Watson to Host Second Quarter 2012 Earnings Conference Call and Webcast|
PARSIPPANY, N.J., July 5, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its second quarter 2012 financial results on Thursday, July 26, 2012 prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on July 26, 2012 to discuss its financial results and provide an update on the Company's outlook for 2012. The di... |
| | | Jun.25.12 | Watson Confirms Pristiq® Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg. Watson's ANDA product is a generic version of Pfizer's Pristiq®, which is indicate... |
| | | Jun.25.12 | Watson Announces Completion of New $1.8 Billion Term Loan Facility|
In the news release, Watson Announces Completion of New $1.8 Billion Term Loan Facility, issued 25-Jun-2012 by Watson Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a new senior unsecured term loan facility in an aggregate principal amount of $1.8 billion" rather than "Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it h... |
| | | Jun.18.12 | Watson Confirms Favorable Appeals Court Decision in Sanctura XR® Patent Suit|
PARSIPPANY, N.J., June 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR® (trospium chloride extended-release capsules) are invalid. Watson's Abbreviated New Drug Application ... |
| | | May.29.12 | Watson Announces Lidoderm® Patent Challenge Settlement| - Provides Select Distribution of Endo's Branded Lidoderm® Product Beginning January 1, 2013 -
- Allows Launch of Watson Lidocaine Patch on September 15, 2013 if Approved by FDA -
- Adds significant exclusive value to both 2013 and 2014; removes uncertainty -
PARSIPPANY, N.J., May 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiy... |
| | | May.29.12 | Watson to Present at Goldman Sachs Global Healthcare Conference 2012|
PARSIPPANY, N.J., May 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Goldman Sachs Global Healthcare Conference 2012 on Wednesday, June 6, 2012 at 8:00AM Pacific Time at the Terranea Resort in Rancho Palos Verdes, California. The presentation will be webcast live and can be... |
| | | May.25.12 | Watson to Present at the Jefferies 2012 Global Healthcare Conference|
PARSIPPANY, N.J., May 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Siggi Olafsson, Watson's President of Global Generics, will provide an overview and update of the Company's business at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 11:00AM Eastern Time at the Grand Hyatt in New York, New York. The presentation will be webcast live and can be accessed o... |
| | | May.24.12 | Watson Confirms Testim® Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim® 1%. Testim®1% is indicated for testosterone replacement t... |
| | | May.18.12 | Watson Confirms Lo Loestrin® Fe Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg and 0.01 mg and 75 mg. Watson's ANDA product is a generic versi... |
| | | May.18.12 | Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference|
PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 4:00PM Eastern Time at the Waldorf-Astoria Hotel in New York, New York. The presentation will be webcast live ... |
| | | May.09.12 | Watson Announces Formation of Global Integration Management Office to Support Pending Actavis Acquisition| - Marc Lehnen, Ph.D., Named Senior Vice President, Global Integration Management
PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has created a Global Integration Management Office, reporting directly to Paul M. Bisaro, President and Chief Executive Officer, and focusing on planning and implementing the integration of Actavis, following the announcement of Watson's intention to acquire the Zug, Switzerland-based company. Marc Le... |
| | | May.09.12 | Watson Confirms Lialda® Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda®.
Shire Development LLC, Shir... |
| | | May.04.12 | Watson Names Lisa DeFrancesco Vice President, Global Investor Relations|
PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Lisa M. DeFrancesco has been promoted to the position of Vice President, Global Investor Relations, effective immediately. In this position, Ms. DeFrancesco reports to Charles Mayr, Chief Communications Officer – Global. She succeeds Patricia Eisenhaur, who is leaving Watson on June 1, 2012.
In this position, Ms. DeFrancesco is responsible for Watson's proactive global investor re... |
| | | May.04.12 | Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference|
PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be ... |
| | | May.01.12 | Watson Pharmaceuticals To Webcast Annual Meeting Of Stockholders On May 11, 2012|
PARSIPPANY, N.J., May 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that the Company will conduct a live webcast of its 2012 Annual Meeting of Stockholders on Friday, May 11, 2012 beginning at 9:00 AM Eastern Daylight Time. As part of the meeting, Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business.
The webcast can be accessed on Watson Pharmaceuticals' Investor Rela... |
| | | Apr.30.12 | Watson First Quarter 2012 Non-GAAP EPS Increases 84% to $1.64; Net Revenue Increases 74% to $1.5 Billion| - GAAP EPS $0.43, Compared to $0.36 Q1 2011 -
- 70% Increase in Adjusted EBITDA -
- Company Updates 2012 Forecast -
PARSIPPANY, N.J., April 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011. On a GAAP basis, net revenue increased 74 percent to $1.5 bil... |
| | | Apr.27.12 | Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses| - Sigurdur Oli Olafsson Named President, Global Generics
- G. Frederick Wilkinson Named President, Global Brands
- Robert A. Stewart Named President, Global Operations
- David A. Buchen Named Chief Legal Officer - Global
- R. Todd Joyce Named Chief Financial Officer - Global
- Charles M. Mayr Named Chief Communications Officer - Global
- Patrick J. Eagan Named Senior Vice President Human Resources - Global
PARSIPPANY, N.J., April 27, 2... |
| | | Apr.26.12 | Watson and Antares Announce the Introduction of Gelnique 3%(TM), for the Treatment of Overactive Bladder| Gelnique 3%(TM) Available in US Pharmacies Beginning April 26 --
PARSIPPANY, N.J. and EWING, N.J., April 26, 2012 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced the launch of Gelnique 3%(TM) (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. Gelnique 3%(TM) is a clear, odorless topical gel that has been shown to be an effective and ... |
| | | Apr.25.12 | Video: Watson to Acquire Actavis Group for EUR4.25 Billion| PARSIPPANY, N.J., Apr 25, 2012, 2012 (Canada NewsWire via COMTEX) --- Creates 3rd largest global generics company -
- ~$8.0 billion anticipated pro forma combined revenue in 2012 -
- Significantly increases scale of Watson's ex-U.S. generic business -
- Accelerates revenue and earnings growth -
- Immediately accretive to non-GAAP earnings, before synergies -
- Greater than $300 million annual synergies anticipated within 3 years -
- Strong combined cash flow allows for rapid pa... |
| | | Apr.25.12 | Watson to Acquire Actavis Group for EUR4.25 Billion|
- Creates 3rd largest global generics company -
- $8.0 billion anticipated pro forma combined revenue in 2012 -
- Significantly increases scale of Watson's ex-U.S. generic business -
- Accelerates revenue and earnings growth -
- Immediately accretive to non-GAAP earnings, before synergies -
- Greater than $300 million annual synergies anticipated within 3 years -
- Strong combined cash flow allows for rapid pay-down of debt -
- Additional earnout contingent on Actavis 2012 performance -... |
| | | Apr.20.12 | Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings| PARSIPPANY, N.J., April 20, 2012 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its first quarter 2012 financial results on Monday, April 30, 2012 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 30, 2012 to discuss its financial results and provide an update on the Company's outlook for 2... |
| | | Apr.19.12 | Watson Confirms Glumetza® Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., April 19, 2012 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Metformin Hydrochloride Extended-release Tablets USP, 1000 mg. Watson's Metformin Hydrochloride Extended-release Tablets are a generic version of Depomed, Inc.'s... |
| | | Apr.19.12 | Watson Launches Generic FORTAMET(R)| PARSIPPANY, N.J., April 19, 2012 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of FORTAMET® (metformin hydrochloride extended-release tablets) as part of an agreement with Shionogi, Inc. Watson began shipping the product today. FORTAMET® is indicated as an adjunct to diet and exercise to lower blood glucose for patients 17 years of age or older.
For the most recent twelve months ending February 28, 2012, F... |
| | | Apr.10.12 | Watson's Generic VANCOCIN® HCl Capsules Receive FDA Approval|
PARSIPPANY, N.J., April 10, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Vancomycin Hydrochloride Capsules, USP, 125 mg and 250 mg, generic versions of ViroPharma Incorporated's VANCOCIN® HCl capsules. Watson began shipping the products immediately.
VANCOCIN® HCl capsules had to... |
| | | Apr.03.12 | Watson Confirms LUMIGAN(R) and LATISSE(R) Patent Challenges| - Paragraph IV Litigations Underway -
PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bimatoprost Ophthalmic Solution, 0.01% and Bimatoprost Ophthalmic Solution, 0.03%. Watson's ANDA products are generic versions of Allergan, Inc.'s LUMIGAN® 0.01% and LATISSE® produ... |
| | | Apr.03.12 | Watson Confirms Favorable District Court Ruling in Generic Sanctura XR® Patent Suit|
PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978 (the '978 Patent), 7,759,359 (the '359 Patent), 7,781,448 (the '448 Patent), 7,781,449 (the '449 Patent) and 7,763,635 (the '635 Patent) for Sanctura XR® (trospium chloride extended-release capsules) are invalid. Watson's Abbreviated New Drug Applic... |
| | | Mar.20.12 | Watson's Generic BONIVA® 150mg Receives FDA Approval|
PARSIPPANY, N.J., March 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA® tablets. Watson intends to begin shipping the product in the second quarter. BONIVA® 150mg tablets had total U.S. sales of approximately $510 million ... |
| | | Mar.19.12 | Watson Confirms NIASPAN(R) Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., March 19, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN®.
Abbott Laboratories and Abbott Res... |
| | | Mar.14.12 | Watson Confirms BYSTOLIC(R) Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., March 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Nebivolol Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg. Watson's ANDA product is a generic version of Forest Laboratories' BYSTOLIC®, which is a beta-adrenergic blocking a... |
| | | Mar.12.12 | Watson Announces Initiation of Esmya(R) U.S. Phase 3 Clinical Trial| - Trial Underway for Women with Uterine Fibroids -
- Canadian New Drug Submission Planned by Mid 2012 Based on EU Clinical Data -
PARSIPPANY, N.J., March 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya® (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata ar... |
| | | Mar.02.12 | Watson Launches Generic PROMETRIUM(R)|
PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson has launched an authorized generic version of PROMETRIUM® (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM® Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They ... |
| | | Mar.01.12 | Watson to Present at the Barclays Capital 2012 Global Healthcare Conference|
PARSIPPANY, N.J., March 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13, 2012 at 8:30 am Eastern Time at the Loews Miami Hotel in Miami, Florida. The presentation will be webcast live and can be accessed on Wat... |
| | | Feb.27.12 | Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%|
PARSIPPANY and LIVINGSTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Columbia Laboratories, Inc. (Nasdaq: CBRX) today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimest... |
| | | Feb.22.12 | Watson to Present at the 2012 RBC Capital Markets' Healthcare Conference|
PARSIPPANY, N.J., Feb. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 RBC Capital Markets' Healthcare Conference on Tuesday, February 28, 2012 at 10:00 am Eastern Time at The New York Palace in New York, New York. The presentation will be webcast live and can be a... |
| | | Feb.16.12 | Watson to Present at the Citi 2012 Global Healthcare Conference|
PARSIPPANY, N.J., Feb. 16, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Citi 2012 Global Healthcare Conference on Monday, February 27, 2012 at 11:30 am Eastern Time at The Waldorf Astoria in New York, New York. The presentation will be webcast live and can be accessed... |
| | | Feb.14.12 | Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;| - Full Year 2011 Non-GAAP EPS Increases 39% To $4.77; GAAP EPS $2.06 -
- Fourth Quarter 2011 Net Revenue $1.54 Billion -
- Fourth Quarter 2011 Non-GAAP EPS $1.77; GAAP EPS $0.75 -
PARSIPPANY, N.J., Feb. 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue increased 62 percent to $1.5 billion for the fourth quarter ended December 31, 2011, compared to $952.7 million in the fourth quarter 2010. On a non-GAAP basis, net income for the fourth quarte... |
| | | Feb.13.12 | Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals|
LIVINGSTON, N.J. and PARSIPPANY, N.J., Feb.13, 2012 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.
Watson has full rights and regulatory r... |
| | | Feb.10.12 | Watson Confirms Beyaz(R) Patent Challenge| - Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Feb. 10, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is ... |
| | | Feb.08.12 | Watson Reaches Settlement With Janssen Pharmaceuticals, Inc. Over ORTHO TRI-CYCLEN(R) LO|
PARSIPPANY, N.J., Feb. 8, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc.) on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN® LO (norgestimate/ethinyl estradiol) tablets. Janssen filed its lawsuit on October 16, 2008 in the United States District Court fo... |
| | | Feb.03.12 | Watson Provides Update on Generic Lidoderm® Application|
PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm® patent challenge, Watson Pharmaceuticals, Inc. (NYSE: WPI) today issued the following statement:
"Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track. We believe questions related to the site where a biostudy supporting the ANDA was conducted have been addre... |
| | | Jan.30.12 | Watson Announces New Jersey-Based Global R&D Technology Center| - New Facility to Support Generic Pharmaceutical Product Development; Employ Approximately 50 Scientists, Chemists, Engineers, and Support Staff -
PARSIPPANY, N.J., Jan. 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey. The Company has signed a lease for a 32,000-square-foot facility at the New Jersey Economic Development Authority's Technology Centre of New J... |
| | | Jan.30.12 | Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2011 Earnings|
PARSIPPANY, N.J., Jan. 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2011 financial results on Tuesday, February 14, 2012 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on February 14, 2012 to discuss its financial results and provide an update on the Company... |
| | | Jan.26.12 | Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)|
PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets. Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Wats... |
| | | Jan.26.12 | Watson Confirms Court Stays Preliminary Injunction| - Permits Launch of Generic LOVENOX® -
PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States Court of Appeals for the Federal Circuit has granted Watson and Amphastar Pharmaceuticals, Inc's request for a stay of the preliminary injunction preventing the companies from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Federal Circuit's Or... |
| | | Jan.24.12 | Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77| - Preliminary Net Revenues Climb Approximately 28% to Approximately $4.57 Billion -
- Company Discusses Strategic Rationale for Ascent Acquisition and Advisory Committee Action Related to Progesterone Gel 8% -
- Provides 2012-2013 Forecast -
PARSIPPANY, N.J., Jan. 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced preliminary 2011 non-GAAP earnings per share of $4.75-$4.77, a 39 percent increase over 2010 full year earnings during its third annual Invest... |
| | | Jan.24.12 | Watson Acquires Ascent Pharmahealth for AU$375 Million| - Watson Becomes 5th Largest Generic Pharmaceutical Company in Australia; Builds on Existing Watson Assets
- Positions Watson as Largest Generics Company in Singapore with Broad Portfolio and Sales Organization
- Gains an Established Presence in Southeast Asia with Footprint in Malaysia, Hong Kong, Vietnam and Thailand
PARSIPPANY, N.J., Jan. 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that it has acquired Ascent Pharmahealth Ltd, the Australia and South... |
| | | Jan.20.12 | FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length| - Preterm birth is a significant and costly problem, affecting one in eight live-born infants in the U.S.; premature cervical shortening is strong risk predictor -
LIVINGSTON and PARSIPPANY, N.J., Jan. 20, 2012 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) did not recommend approval of pro... |
| | | Jan.18.12 | Watson Launches Generic Yaz(R)|
PARSIPPANY, N.J., Jan. 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product. Watson began shipping the product today. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 yea... |
| | | Jan.12.12 | Watson to Host Investor Meeting January 24 in New York City|
PARSIPPANY, N.J., Jan. 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 24, 2012 in New York City. The meeting will begin at 8:00 a.m. Eastern Time and will be simultaneously webcast.
At the meeting, the Company plans to provide a preliminary update on 2011 achievements as well as a business outlook for 2012 and beyond. Paul Bisaro, Watson's Presid... |
| | | Dec.28.11 | Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference|
PARSIPPANY, N.J., Dec. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 7:30 am Pacific Standard Time (10:30 am Eastern Standard Time) at the Westin St. Francis in San Francisco, California. T... |
| | | Dec.22.11 | Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top|
PARSIPPANY, N.J., Dec. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2012 at 1:45 pm Eastern Time at the Goldman Sachs Conference Center in New York, New York. The presentation will... |
| | | Dec.19.11 | Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars|
THOUSAND OAKS, Calif. and PARISIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expe... |
| | | Dec.08.11 | Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder| -- Novel Formulation Provides Convenience, Efficacy and Excellent Tolerability
-- Watson to Launch Product in Spring 2012 --
PARSIPPANY, N.J. and EWING, N.J., Dec. 8, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced that the U.S. Food and Drug Administration (FDA) has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder (OAB) with symptoms of urge urinary incont... |
| | | Dec.07.11 | Watson Launches Generic LoSEASONIQUE(R)| PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy. Terms of the settlement were not disclosed.
As a "first applicant" to s... |
| | | Nov.30.11 | Watson Launches Generic LIPITOR(R)| - Largest generic product launch in US history -
PARSIPPANY, N.J., Nov. 30, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR® (atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc. Watson began shipping the product today. LIPITOR® is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to ... |
| | | Nov.29.11 | Watson's Generic Yaz(R) Receives FDA Approval|
PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product. Watson is currently involved in patent litigation with Bayer concerning this product.
Yaz(R... |
| | | Nov.21.11 | Watson to Present at the 2011 Piper Jaffray Health Care Conference|
PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at 9:30 am EST at the New York Palace Hotel in New York. The presentation will be webcast live and can be accessed on Watson Pharmaceutic... |
| | | Nov.16.11 | Watson Wins Kentucky Drug Pricing Litigation|
PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that a jury in the drug pricing litigation trial in the Kentucky Circuit Court for Franklin County rendered a verdict in favor of Watson on all counts in the litigation.
Beginning in July 2002, the Company and certain of its subsidiaries, as well as numerous other pharmaceutical companies, were named as defendants in various states and federal court actions including the case decided to... |
| | | Nov.10.11 | Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA| Advisory Committee for Reproductive Health Drugs Meeting Scheduled for January 20, 2012
LIVINGSTON, N.J. and PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) is scheduled to review Columbia's New Drug Application (NDA) for progesterone vaginal gel for the reduction of risk of ... |
| | | Nov.10.11 | Watson' Launches Generic Kadian(R)| PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian®. Watson began shipping the product today. Kadian® is indicated to manage moderate to severe pain that continues around-the-clock and is expected to last f... |
| | | Nov.10.11 | Watson Confirms Exelon(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr. Watson's rivastigmine transdermal system patch is a generic version of Novartis' Exelon(R) Patch. Ex... |
| | | Nov.10.11 | Watson Confirms Appeals Court Decision Rejecting Teva's Motion to Enjoin Watson's Sales of Generic SEASONIQUE®| PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit affirmed the district court's June 16, 2011 denial of Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction to prevent Watson from selling generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)). Watson launched Amethia(TM) (levonorgestrel/ethinyl estradio... |
| | | Nov.01.11 | Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54|
- 31% Increase in Non-GAAP Net Income -
- 22% Increase in Adjusted EBITDA -
- Company Increases Full Year 2011 Forecast -
PARSIPPANY, N.J., Nov. 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million o... |
| | | Oct.28.11 | Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®| PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Company said that it was reviewing the ... |
| | | Oct.28.11 | Watson to Present at the 2011 Annual Credit Suisse Health Care Conference| PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Annual Credit Suisse Health Care Conference on Wednesday, November 9, 2011 at 8:00 am MST (10:00 am EST) at the Arizona Biltmore Hotel in Phoenix. The presentation will be webcast live and can be acce... |
| | | Oct.21.11 | FDA Approves Watson's Androderm® (testosterone transdermal system) 2 mg/day and 4 mg/day| New formulation represents 20% reduction in active ingredient; smaller patch size -
PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) approved its Androderm® (testosterone transdermal system) 2 mg and 4 mg formulation. The new smaller size and lower-dose testosterone patch provides highly effective testosterone administration with a 20 percent reduction in the active ingredient ... |
| | | Oct.17.11 | Watson Confirms Atelvia(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Risedronate Sodium Delayed-release Tablets, 35 mg. Watson's Risedronate Sodium Delayed-release Tablets are a generic version of Warner Chilcott (US), LLC's Atelvi... |
| | | Oct.14.11 | Watson Confirms Daytrana(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Transdermal System, 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs, and 30 mg/9 hrs. Watson's Methylphenidate Transdermal System products are generic versions of Nov... |
| | | Oct.08.11 | Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®| PARSIPPANY, N.J., Oct. 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The temporary restraini... |
| | | Oct.07.11 | Watson Confirms EMBEDA(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg. Watson's Morphine Su... |
| | | Oct.07.11 | Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)| PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary restraining order (TRO) preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection product, a generic equivalent to Sanofi-aventis' LOVENOX®. The temporary restraini... |
| | | Sep.26.11 | Watson Launches Generic FEMCON(R) Fe| PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
For the most rece... |
| | | Sep.23.11 | Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings| PARSIPPANY, N.J., Sept. 23, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its third quarter 2011 financial results on Tuesday, November 1, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on November 1, 2011 to discuss its financial results and provide an update on the Company's ... |
| | | Sep.22.11 | Watson Confirms Amphastar Patent Lawsuit| PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts. The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Mom... |
| | | Sep.22.11 | Watson to Present at the Jefferies 2011 Global Healthcare Conference| PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Watson's Executive Vice President, Global Generics, will provide an overview and update of the Company's business at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27, 2011 at 9:20 am BST (4:20 am EDT) in London, England. The presentation will be webcast live and can be accessed on Watson Pharm... |
| | | Sep.19.11 | Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R)| Fourth Quarter Launch Planned-
PARSIPPANY, N.J., Sept. 19, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths. Enoxaparin Sodium Injection is the generic equivalent to Sanofi-aventis' LOVENOX®, and is a low molecular weight heparin indica... |
| | | Sep.13.11 | Watson Launches Generic Keppra XR®| MORRISTOWN, N.J., Sept. 13, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam Extended-Release 500 mg and 750 mg tablets, the generic version of UCB, Inc.'s Keppra XR® following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Keppra XR® is indicated to treat partial onset seizures in ... |
| | | Sep.01.11 | Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference| PARSIPPANY, N.J., Sept. 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 15, 2011 at 8:55 am BST (3:55 am EDT) at Merrill Lynch Financial Center, London. The presentation will be webcast live ... |
| | | Aug.30.11 | Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference| PARSIPPANY, N.J., Aug. 30, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 1:35 pm Eastern Time at the Grand Hyatt New York in New York City. The presentation will be webcast live and can be access... |
| | | Aug.11.11 | Watson's Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS| Credits Partnership with Governor, Mississippi Development Authority In Decision to Invest $23.5 Million in Facility; Create Approximately 70 Jobs
PARSIPPANY, N.J., Aug. 11, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its Anda Distribution division will construct a 234,000 square foot, state-of-the-art pharmaceutical distribution facility in Olive Branch, DeSoto County, MS. The Company said the facility, which is expected to begin operation in... |
| | | Aug.10.11 | Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval| MORRISTOWN, N.J., Aug. 10, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received tentative approval from the United States Food and Drug Administration (FDA) for its rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a new salt form of AstraZeneca's Crestor® (rosuvastatin calcium) tablets.
On July 15, 2010, Watson Laboratories, Inc., filed a New Drug Application (N... |
| | | Jul.28.11 | Watson Launches Generic Seasonique(R)| PARSIPPANY, N.J., July 28, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has launched Amethia(TM) (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)), the generic equivalent of Duramed Pharmaceuticals Inc.'s Seasonique(R). Watson began shipping the product today, following a denial by the United States Court of Appeals for the Federal Circuit of a request for a temporary inj... |
| | | Jul.26.11 | Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01|
- 24% Increase in Net Revenue and Non-GAAP Net Income -
- 17% Increase in Adjusted EBITDA -
- Company Increases Full Year 2011 Revenue and Earnings Forecast -
PARSIPPANY, N.J., July 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010. On a non-GAAP basis, net income for the second quarter 2011 incr... |
| | | Jul.26.11 | Watson Enters into Agreement to Acquire Products Related to Perrigo's Acquisition of Paddock Laboratories| PARSIPPANY, N.J., July 26, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-approved products and two undisclosed development-stage products. Commercialized products in the portfolio include:
Ciclopirox shampoo 1% ... |
| | | Jul.22.11 | Watson Confirms JALYN(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market dutasteride and tamsulosin hydrochloride capsules. Watson's dutasteride and tamsulosin hydrochloride capsules are a generic version of GlaxoSmithKline's JALYN(TM)... |
| | | Jul.11.11 | Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))| Late Stage Development Product Further Extends Watson's Overactive Bladder Portfolio --
PARSIPPANY, N.J. and EWING, N.J., July 11, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada. A New Drug Application for the oxybutynin gel product is currently under review by the Food and Drug Admi... |
| | | Jul.07.11 | Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit| PARSIPPANY, N.J., July 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R) (Guaifenesin), Mucinex(R) D (Pseudoephedrine/Guaifenesin), and Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not infringe U.S. Patent No... |
| | | Jul.07.11 | Watson Confirms Vyvanse(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., July 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. Watson's lisdexamfetamine dimesylate capsules are a generic version of Shire LLC's Vyvanse®. Vyvanse® is a prescription medicine for th... |
| | | Jun.30.11 | Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings| PARSIPPANY, N.J., June 30, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its second quarter 2011 financial results on Tuesday, July 26, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on July 26, 2011 to discuss its financial results and provide an update on the Company's outloo... |
| | | Jun.27.11 | Columbia Laboratories' NDA for PROCHIEVE(R) Vaginal Progesterone Gel Accepted for Filing by FDA| LIVINGSTON, N.J. and MORRISTOWN, N.J., June 27, 2011 /PRNewswire via COMTEX/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE(R) (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. The acceptance of the NDA for filing means FDA ... |
| | | Jun.22.11 | Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility| Governor Gary R. Herbert Participates in Ground Breaking Ceremony -
SALT LAKE CITY, June 22, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today formally announced an approximately $44 million expansion of its Salt Lake City, Utah, Watson Laboratories, Inc. site. This facility is Watson's state-of-the-art pharmaceutical research, development and manufacturing facility for transdermal patches and topical gels. Governor Gary R. Herbert toured the facility and partic... |
| | | Jun.20.11 | Watson to Present at 2011 Wells Fargo Securities Healthcare Conference| PARSIPPANY, N.J., June 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Executive Vice President, Global Generics, will provide an overview and update of the Company's business at the 2011 Wells Fargo Securities Healthcare Conference on Thursday, June 23, 2011 at 8:00am Eastern Time at the InterContinental Boston in Boston, Massachusetts. The presentation will be webcast live and can be ... |
| | | Jun.20.11 | Watson Confirms AVODART(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dutasteride Capsules, 0.5 mg. Watson's Dutasteride Capsules product is a generic version of GlaxoSmithKline's AVODART(R), which is indicated for the treatment of sy... |
| | | Jun.17.11 | Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE(R)| PARSIPPANY, N.J., June 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The compan... |
| | | Jun.17.11 | Watson's Nabumetone Tablets Receive FDA Approval| PARSIPPANY, N.J., June 17, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.
Nabumetone had total U.S. sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health. Nabumetone is indicated for the relief of... |
| | | Jun.14.11 | Watson Confirms Pataday(TM) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%. Watson's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a generic version of Alcon, Inc.'s Pataday(TM) ... |
| | | Jun.07.11 | Watson's Generic Lybrel(R) Receives FDA Approval| PARSIPPANY, N.J., June 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel® tablets. Watson expects to launch the product shortly.
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )
Lybrel® had tota... |
| | | Jun.02.11 | Watson Confirms Viagra(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., June 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Sildenafil Citrate Tablets, 25, 50 and 100 mg. Watson's Sildenafil Citrate tablets are a generic version of Pfizer Inc.'s Viagra®, which is indicated for the treatment of ere... |
| | | Jun.01.11 | Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference| PARSIPPANY, N.J., June 1, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 11:00am Eastern Time at the Terranea Resort in Rancho Palos Verdes, California. The presentation will be webcast liv... |
| | | May.25.11 | Watson Acquires Specifar Pharmaceuticals|
- Adds Leading Pan-European Generic Development Business
- Enhances Watson's Commercial Capabilities in Key European Markets By Providing a Portfolio of Approved Products
- Expands Watson's Commercial Presence into EUR 6 Billion Greek Market
- Expected to be Immediately Accretive to Non-GAAP Earnings
- Esomeprazole Tablets in Development for International Markets Offers Upside Potential
- Adds Experienced European Management Team as well as Flexibility and Capabilities to Watson's Global ... |
| | | May.17.11 | Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|
- Treatment Reduces Symptoms and Improves Quality of Life -
- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS -
WASHINGTON, May 17, 2011 /PRNewswire via COMTEX/ --New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In the study presented at the annual meeting of the American Urological Association, RAPAFLO(R) also significantly improved u... |
| | | May.16.11 | Watson Launches Generic AMRIX (R)| PARSIPPANY, N.J., May 16, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal condi... |
| | | May.02.11 | Watson Launches Generic Concerta (R)| PARSIPPANY, N.J., May 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., has launched an authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets) as part of an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). Watson began shipping the product today. Concerta is approved for the treatment of attention deficit hyperactivity disorder (ADHD) in... |
| | | May.02.11 | Watson's Generess(TM) Fe, Unique, Low-Dose Oral Contraceptive Launched| "I am Generess(TM)" Companion Program Features Patient Cost Savings, Women's Charity Donation -
PARSIPPANY, N.J., May 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. commercial launch of Generess(TM) Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lig... |
| | | Apr.29.11 | Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th| PARSIPPANY, N.J., April 29, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), an integrated global specialty pharmaceutical company, announced today that the Company will conduct a live webcast of its 2011 Annual Meeting of Stockholders on Friday May 13, 2011 beginning at 9:00 AM Eastern Daylight Time. As part of the meeting, Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business.
The webcast can be a... |
| | | Apr.27.11 | Watson First Quarter 2011 Net Revenue Increases to $877 Million|
- First Quarter 2011 Non-GAAP EPS up 10% to $0.89 -
- Company Increases 2011 Earnings Forecast -
PARSIPPANY, N.J., April 27, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $876.5 million for the first quarter ended March 31, 2011, compared to $856.5 million in the first quarter 2010. On a non-GAAP basis, net income for the first quarter 2011 was $111.9 million or $0.89 per share, an increase of 12 percent, compared to $100.3 million or $... |
| | | Apr.26.11 | Columbia Laboratories Submits NDA for PROCHIEVE(R) Vaginal Progesterone Gel| LIVINGSTON and PARSIPPANY, N.J., April 26, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that Columbia has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PROCHIEVE(R) (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.
In the submission, Columbia requested Priority Review... |
| | | Apr.20.11 | Watson Confirms Welchol(R) Patent Challenge| Paragraph IV Litigation Underway -
PARSIPPANY, N.J., April 20, 2011 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo, Inc.'s Welchol(R).
Daiichi Sankyo and Genzyme Corporation filed... |
| | | Apr.13.11 | Watson Designates Parsippany, NJ Facility as Corporate Headquarters| New Parsippany Facility Supports Global Expansion; Unites NJ Operations in Single Location -
PARSIPPANY, N.J., April 13, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has formally designated its Parsippany, New Jersey facility as its Corporate Headquarters. The Company's new Corporate Headquarters address is Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054.
Previously, Watson Corporate Headquarters was located at ... |
| | | Apr.08.11 | Watson Confirms Vigamox(R) Patent Challenge| Paragraph IV Litigation Underway-
PARSIPPANY, N.J., April 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox(R), ... |
| | | Apr.06.11 | Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE(R) Vaginal Progesterone Gel Study Results| Data Demonstrate a Significantly Lower Rate of Preterm Birth before 33 Weeks Gestation among Women with a Shortened Cervix treated with PROCHIEVE vs. Placebo
LIVINGSTON and MORRISTOWN, N.J., April 6, 2011 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the publication of Phase III PROCHIEVE(R) (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-revie... |
| | | Apr.05.11 | Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings| PARSIPPANY, N.J., April 5, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its first quarter 2011 financial results on Wednesday, April 27, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 27, 2011 to discuss its financial results and provide an update on the Company's outl... |
| | | Mar.31.11 | Watson Announces Approval of Nulecit(TM), the First Generic Alternative to Ferrlecit(R) for the Treatment of Iron Deficiency Anemia| MORRISTOWN, N.J., March 31, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit(TM) (sodium ferric gluconate complex in sucrose injection), following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA). Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit(R). In July 2009 Watson signed a license agreement with GeneraMedix for the exc... |
| | | Mar.25.11 | Watson Confirms District Court Ruling in Generic Fentora(R) Patent Suit| MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora(R) (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.
Watson's Abbreviated New Drug Applicati... |
| | | Mar.25.11 | Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE(R) Patent Challenge| MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE(R)(levonorgestrel/ethinyl estradiol... |
| | | Mar.25.11 | Watson Confirms OxyContin(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., March 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiaries, Andrx Labs, LLC and Watson Laboratories, Inc. -- Florida, (collectively "Watson") filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxycodone Hydrochloride Extended-Release tablets in the 10,15, 20, 30, 40, 60 and 80 mg strengths. Watson's Oxycodon... |
| | | Mar.21.11 | Watson Launches Generic Famvir(R)| MORRISTOWN, N.J., March 21, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Famciclovir tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir(R) following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Famciclovir is an antiviral used in the treatment for immunocompetent adul... |
| | | Mar.14.11 | Watson Announces Favorable District Court Ruling in Generic Fentora(R) Patent Suit| MORRISTOWN, N.J., March 14, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora(R) (fentanyl buccal tablets C-II) does not infringe United States Patent Nos. 6,200,604 or 6,974,590 (the '604 and '590 Patents) and that the '604 and '590 Patents are invalid. A decision on United States Patent No. 6,264,981 remains outstanding and Watson remains ... |
| | | Mar.09.11 | Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President| MORRISTOWN, N.J., March 9, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a global integrated pharmaceutical company, announced today that David A. Buchen has been promoted to Executive Vice President, General Counsel and Secretary, and R. Todd Joyce has been promoted to Executive Vice President, Chief Financial Officer. Both continue to report to Paul M. Bisaro, President and Chief Executive Officer.
"These promotions not only recognize the substantial individual ... |
| | | Mar.08.11 | Watson to Present at the Barclay's 2011 Global Healthcare Conference| MORRISTOWN, N.J., March 8, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Barclay's 2011 Global Healthcare Conferenceon Tuesday, March 15, 2011 at 9:30a.m. (EDT). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at h... |
| | | Mar.01.11 | Watson to Present at the Cowen & Company 31st Annual Healthcare Conference| MORRISTOWN, N.J., March 2, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Todd Joyce, Watson's Senior Vice President and Chief Financial Officer, will provide an overview and update of the Company's business at the Cowen & Company 31st Annual Healthcare Conferenceon Tuesday, March 8, 2011 at 9:30 a.m. Eastern time. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Inv... |
| | | Feb.23.11 | Watson to Present at the 2011 Citi Global Healthcare Conference| MORRISTOWN, N.J., Feb. 23, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Citi Global Healthcare Conferenceon Tuesday, March 1, 2011 at 1:30 p.m. (EST). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://... |
| | | Feb.15.11 | Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million|
-- Fourth Quarter 2010 Non-GAAP EPS $0.93
-- Full Year 2010 Net Revenues of $3.6 Billion
-- Full Year 2010 Non-GAAP EPS $3.42
MORRISTOWN, N.J., Feb. 15, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue increased 21 percent to $952.7 million for the fourth quarter ended December 31, 2010, compared to $785.7 million in the fourth quarter 2009. On a non-GAAP basis, net income for the fourth quarter 2010 was $116.5 million or $0.93 per share, an... |
| | | Feb.09.11 | Watson Announces Favorable District Court Ruling in Generic Mucinex(R) Patent Suit| MORRISTOWN, N.J., Feb. 9, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida has ruled that Watson's generic versions of Mucinex(R), Mucinex(R) D and Mucinex(R) DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252 (the "'252 Patent").
Th... |
| | | Feb.07.11 | Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings| MORRISTOWN, N.J., Feb. 7, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2010 financial results on Tuesday, February 15, 2011 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on February 15, 2011 to discuss its financial results and provide an update on the Company's outlook ... |
| | | Jan.25.11 | Watson Confirms Welchol(R) Oral Suspension Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI powder for oral suspension, 1.875 gm/packet and 3.75 gm/packet. Watson's Colesevelam HCI powder for oral suspension is a generic version of Daiichi Sankyo, I... |
| | | Jan.21.11 | Watson Presents Outlook for Continued Long Term Growth| 2011 Revenue Forecasted to be $4.2 Billion; Adjusted Cash EPS of $3.85 to $4.15 and Adjusted EBITDA of $925 Million to $1.0 Billion -
NEW YORK, Jan. 21, 2011 /PRNewswire via COMTEX/ --During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. (NYSE: WPI) provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements... |
| | | Jan.12.11 | Watson Announces Preliminary Financial Performance for FY 2010|
- 2010 Net Revenue Estimated to Exceed $3.5 Billion -
- Company to Provide 2011 Outlook at January 21st Investor Day -
SAN FRANCISCO, Jan. 12, 2011 /PRNewswire via COMTEX/ --At the 29th Annual J.P. Morgan Healthcare Conference, Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that based on a preliminary review of 2010 results, it expects net revenues to increase more than 25 percent to more than $3.5 billion compared to 2009. Adjusted cash earnings per share is expected to be at or s... |
| | | Jan.10.11 | Watson's Generic Fentora(R) Receives FDA Approval| MORRISTOWN, N.J., Jan. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Fentanyl Buccal tablets, USP, in the 0.1, 0.2, 0.4, 0.6 and 0.8 mg strengths, the generic equivalent to Cephalon's Fentora (R) tablets.
Watson's Abbreviated New Drug Application (ANDA) for its generic version of FENTORA(R) is the first generic appl... |
| | | Jan.10.11 | Watson to Host Investor Day on January 21 in New York City| MORRISTOWN, N.J., Jan. 10, 2011 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will be hosting an Investor Day on January 21, 2011 in New York City. The presentations are scheduled to begin at 8:30 a.m., Eastern Time and will be simultaneously webcast.
At the meeting, the Company plans to provide a preliminary outlook for 2011. The presenters will include: Paul Bisaro, Watson's President and CEO; Todd Joyce, Senior Vice President and CFO; Sigurd O... |
| | | Dec.29.10 | Watson to Present at the 29th Annual JP Morgan Healthcare Conference| MORRISTOWN, N.J., Dec. 29, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 29th Annual JP Morgan Healthcare Conferenceon Wednesday, January 12, 2011 at 3:00 p.m. (PST), (6:00 p.m. EST). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor R... |
| | | Dec.22.10 | Watson Announces Novel Oral Contraceptive Approval| Chewable Low-Dose Oral Contraceptive Represents New Birth Control Option
MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product - the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the producti... |
| | | Dec.16.10 | Watson and Richter Announce Exclusive License Agreement for Esmya(TM)|
-- Late Stage Clinical Development Product for Uterine Fibroids (Myoma) Further Expands Watson's Women's Health Portfolio in U.S. and Canada --
-- First New Potential Therapy in Category in More Than 20 Years --
MORRISTOWN, N.J., and BUDAPEST, HUNGARY, Dec. 16, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) ("Watson") and Gedeon Richter Plc ("Richter") today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreemen... |
| | | Dec.14.10 | Watson Confirms Exalgo(TM) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Dec. 14, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg. Watson's Hydromorphone Hydrochloride Extended-release Tablets are a generic version o... |
| | | Dec.07.10 | Watson Confirms Development Agreement with Natco for Generic Revlimid(R)| First to File U.S. Market Opportunity -
MORRISTOWN, N.J. and HYDERABAD, India, Dec. 7, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) and Natco Pharma Limited (BSE: 524816) today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approva... |
| | | Dec.06.10 | PROCHIEVE 8% Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth|
PROCHIEVE 8% significantly reduced incidence of preterm birth at less than or equal to 32 6/7 weeks gestation vs. placebo
Management to hold investor conference call at 8:30 am ET today
LIVINGSTON, N.J. and MORRISTOWN, N.J., Dec. 6, 2010 /PRNewswire via COMTEX/ --Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE(R) 8% vaginal p... |
| | | Dec.01.10 | Watson Launches ella(R) (ulipristal acetate) Emergency Contraceptive| Only Emergency Contraceptive FDA Approved for Use Up to 5 Days after Unprotected Intercourse or a Known Contraceptive Failure
Extensive Educational Website for Consumers, Health Care Providers
MORRISTOWN, N.J., Dec. 1, 2010 /PRNewswire via COMTEX/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI), announced today that ella(R) (ulipristal acetate) 30 mg, a novel oral emergency contraceptive, is now available for patients by prescription in the U.S. ella(R) was approved by the U.S. Food and Drug ... |
| | | Nov.11.10 | Watson Announces Pricing of Secondary Offering By Selling Stockholder| MORRISTOWN, N.J., Nov. 11, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the underwritten public offering of 10,537,755 shares of its common stock held by Quiver Inc. has priced at $49.75 per share. Watson will not receive any proceeds related to the offering, and its total number of shares of common stock outstanding will not change as a result of the Offering.
J.P. Morgan Securities LLC. has acted as sole book-running manager and underwriter for t... |
| | | Nov.10.10 | Watson Announces Commencement of Secondary Offering by Selling Stockholder| MORRISTOWN, N.J., Nov. 10, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the underwritten public offering of 10,537,755 shares of its common stock held by Quiver, Inc. pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission (the "Offering") on August 17, 2009. The selling stockholder acquired its shares of Watson common stock in connection with Watson's acquisition of the Arrow Group. Watson will not recei... |
| | | Nov.10.10 | Watson Announces Top Line Uracyst(R) U.S. Pilot Study Results| MORRISTOWN, N.J., Nov. 10, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. pilot study evaluating Uracyst(R) (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.
"Unfortunately, the results of the pilot study failed to demonstrate efficacy despite numerical separation of response between Uracyst(R) and placebo on certain measurements," said Fred Wilkinson, Watso... |
| | | Nov.04.10 | Watson Q3 Net Revenue Climbs 33 Percent to $882 Million| - Third Quarter Adjusted Cash EPS of $0.85
- Adjusted EBITDA Increases 18 Percent to $211 Million
MORRISTOWN, N.J., Nov. 4, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue grew 33 percent for the third quarter ended September 30, 2010 to $882.4 million, compared to $662.1 million in the third quarter 2009. On an adjusted cash basis, net income increased 18 percent to $105.9 million or $0.85 per share, compared to $90.0 million or $0.78 per s... |
| | | Nov.02.10 | Watson Signs Exclusive Agreement to Distribute Authorized Generic Concerta(R)| MORRISTOWN, N.J., Nov. 2, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta(R) (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention defi... |
| | | Oct.29.10 | Watson To Present At The 2010 Credit Suisse Healthcare Conference| MORRISTOWN, N.J., Oct 29, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2010 Credit Suisse Healthcare Conference on Thursday, November 11, 2010 at 10:00am (MST), (12:00 Noon EST). The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Rela... |
| | | Oct.27.10 | Watson Confirms Crestor(R) Patent Challenge| - Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Oct 27, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed a new drug application under Section 505(b)(2) of the Federal Food and Drug Cosmetic Act (FFDCA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a new salt version of AstraZeneca... |
| | | Oct.15.10 | Watson's Generic Version of Lotrel (R) Receives FDA Approval| MORRISTOWN, N.J., Oct 15, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and 5/10mg capsules, the generic equivalent to Novartis' Lotrel(R) capsules. The ANDA was acquired as part of Watson's acquisition of the Arrow Group. Wat... |
| | | Oct.12.10 | Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings| MORRISTOWN, N.J., Oct 12, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its third quarter 2010 financial results on Thursday, November 4, 2010 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on November 4, 2010 to discuss its financial results and provide an update on the Company's o... |
| | | Oct.07.10 | Watson Reaches Settlement with Endo Over Opana(R) ER| MORRISTOWN, N.J., Oct 07, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Endo Pharmaceuticals, Inc. on outstanding patent litigation related to Endo's Opana(R) ER (Oxymorphone ER) product. Endo filed its lawsuit on March 4, 2010, following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for seeking approval to market ... |
| | | Oct.05.10 | Watson Confirms Azilect(R) Patent Challenge| - Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Oct 05, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets. Watson's rasagiline mesylate tablets are generic versions of Teva Neuroscience, Inc.'s Azilect(R) Tablets, which are indicated fo... |
| | | Oct.04.10 | Watson, Moksha8 Form Marketing Partnership for Brazil, Mexico; Watson Makes Initial $30 Million Investment| Watson Investment Part of $61 Million Moksha8 Financing
MORRISTOWN, N.J. and SAO PAULO, Oct 04, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Moksha8, based in Sao Paulo, Brazil, today announced that they have entered into an agreement that will expand Watson's commercial presence in Latin America's two largest markets, Brazil and Mexico. Watson will invest $30 million in Moksha8 as part of Moksha8's approximately $61 million USD financing that includes investmen... |
| | | Sep.28.10 | Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference| MORRISTOWN, N.J., Sept 28, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business in London at the Jefferies 2010 Global SpecPharma & European Healthcare Conference on Tuesday October 5, 2010 at 10:00am (BST), (5:00am EDT). The presentation will be webcast live and can be accessed on Watso... |
| | | Sep.17.10 | HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada| Agreement follows FDA approval of ella(R) in the U.S., where Watson will market the product
PARIS and MORRISTOWN, N.J., Sept 17, 2010 /PRNewswire via COMTEX/ --HRA Pharma, a privately-held, European pharmaceutical company that develops healthcare solutions in reproductive health and endocrinology and makes them available worldwide, and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that they have entered into a licensing agreement for the commercialization of HRA Pharma's next gener... |
| | | Sep.08.10 | Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference| MORRISTOWN, N.J., Sept 08, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America/Merrill Lynch Global Healthcare Conference on Wednesday, September 15, 2010 at 3:25pm (BST), (10:25am EDT) at Merrill Lynch Financial Center, London. The presentation will be webcast live a... |
| | | Sep.07.10 | Watson Confirms Combigan(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Sept 07, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%. Watson's Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5% is a generic versio... |
| | | Sep.07.10 | Watson's Generic Yasmin(R) Receives FDA Approval| MORRISTOWN, N.J., Sept 07, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zarah(TM) (drospirenone and ethinyl estradiol tablets) 3 mg/0.03 mg, the generic equivalent to Bayer's Yasmin(R). Watson has begun shipping the product. Bayer's lawsuit against Watson alleging that Watso... |
| | | Sep.01.10 | Watson to Present at the Morgan Stanley Global Healthcare Unplugged Conference| MORRISTOWN, N.J., Sept 01, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 13, 2010 at 8:00am Eastern Daylight Time. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' In... |
| | | Aug.13.10 | Watson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch| MORRISTOWN, N.J., Aug 13, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc.(NYSE: WPI),todayannounced that it intends to launch ella(R) (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella(R) by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours - or five days - post-unprotected intercourse (UPI) or contraceptive failure. ella(R) was developed by HRA Pharma speci... |
| | | Aug.05.10 | Watson Q2 Net Revenue Climbs 29 Percent to $875 Million|
- Second Quarter Adjusted Cash EPS of $0.83; 2010 GAAP EPS of $0.57
- Adjusted EBITDA Increases 26 Percent to $207 Million
MORRISTOWN, N.J., Aug 05, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 ... |
| | | Aug.04.10 | Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics| Olafsson Joins from Actavis Group; Succeeds Thomas R. Russillo Who is Retiring At Year-End
MORRISTOWN, N.J., Aug 04, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals (NYSE: WPI) today announced that Sigurdur Oli Olafsson has joined the Company as Executive Vice President, Global Generics, effective September 1, 2010. In this position, Mr. Olafsson will have responsibility for global generic sales and marketing, with an emphasis on leading the expansion of Watson's position in global mar... |
| | | Aug.03.10 | Watson Promotes Robert Stewart to Executive Vice President, Global Operations| Generic R&D Incorporated into Global Operations Function
MORRISTOWN, N.J., Aug 03, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals (NYSE: WPI) today announced that Robert Stewart, who joined the Company in November 2009 as Senior Vice President, Global Operations, has been promoted to Executive Vice President, Global Operations. Mr. Stewart will continue to report to Paul Bisaro, President and Chief Executive Officer of Watson.
Mr. Stewart will assume responsibility for managin... |
| | | Jul.15.10 | Watson and Itero Enter Worldwide License Agreement on Biologic Development Candidate|
Recombinant Follicle Stimulating Hormone (rFSH) Would Expand Watson's Global Presence in Women's Health
Will Capitalize on Watson's Eden Biodesign Biologics Capabilities
MORRISTOWN, N.J., and SAN MATEO, Calif.,, July 15, 2010 /PRNewswire via COMTEX/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant... |
| | | Jul.12.10 | Watson Confirms Renvela(R) for Oral Suspension Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., July 12, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet. Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela(R) f... |
| | | Jul.08.10 | Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings| MORRISTOWN, N.J., July 8, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its second quarter 2010 financial results on Thursday, August 5, 2010 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on August 5, 2010 to discuss its financial results and provide an update on the Company's out... |
| | | Jul.02.10 | Watson Completes Acquisition of CRINONE(R) and PROCHIEVE(R) Product Line and Shares of Columbia Laboratories|
-Further Expands Women's Health Product Line
-Adds New Treatment Categories to Brand Portfolio
MORRISTOWN, N.J., July 2, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today completed the acquisition of the U.S. rights to Columbia Laboratories' CRINONE(R) and PROCHIEVE(R) progesterone gel product line and 11,200,000 shares of Columbia common stock.
"We are pleased to add CRINONE(R) and PROCHIEVE(R) to our growing number of women's health products. The addition o... |
| | | Jul.02.10 | Watson's Generic Prograf(R) 5 mg Receives FDA Approval| MORRISTOWN, N.J., July 2, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf(R) capsules. Watson intends to begin shipping the product immediately.
Prograf (R) 5 mg had total U.S. sales of approximately $108 millio... |
| | | Jul.01.10 | Watson Launches Generic Exelon(R)| MORRISTOWN, N.J., July 1, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon(R) (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon(R) is used to treat dementia (a brain disorder that affects the ab... |
| | | Jul.01.10 | Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets| MORRISTOWN, N.J., July 1, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia's CRINONE(R) and PROCHIEVE(R) progesterone gel product line and 11,200,000 shares of Columbia common stock.
The acquisition remains subject to customary closing conditions. After the close of the ... |
| | | Jun.23.10 | Watson Receives Tentative FDA Approval for Fentanyl Buccal Tablets| MORRISTOWN, N.J., June 23, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg. Watson's Fentanyl Citrate Buccal tablets are a generic version of Cephalon's Fentora(R). Fentora(R) is u... |
| | | Jun.18.10 | Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference| MORRISTOWN, N.J., June 18, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Watson management will provide an overview and update of the Company's business at the Wells Fargo Securities 2010 Healthcare Conference on Wednesday, June 23, 2010 at 11:15am Eastern Daylight Time at the Intercontinental Hotel, Boston. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Rela... |
| | | Jun.08.10 | Watson to Present at the Goldman Sachs 31st Annual Global Healthcare Conference| MORRISTOWN, N.J., June 8, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's CEO & President will provide an overview and update of the Company's business at the 2010 Goldman Sachs 31st Annual Global Healthcare Conference on Wednesday, June 16, 2010 at 10:00am Pacific Time at the Hyatt Regency Century Plaza, Los Angeles. The presentation will be webcast live and can be accessed on Wa... |
| | | Jun.01.10 | Watson Confirms Columbia Laboratories' Filing of Definitive Proxy Relating to Watson's Acquisition of U.S. Rights to CRINONE(R) Progesterone Gel Product Line| Provides Columbia with Financial Support For Progesterone Franchise Product Development -
MORRISTOWN, N.J., June 1, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Columbia Laboratories, Inc. has filed with the Securities and Exchange Commission a definitive proxy seeking Columbia shareholder approval of the previously announced agreement under which Watson would acquire the U.S. rights to Columbia's CRINONE(R) and PROCHIEVE(R) product line and 11... |
| | | May.25.10 | Watson Confirms Renvela(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., May 25, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate 800mg tablets. Watson's sevelamer carbonate tablet is the generic version of Genzyme's Renvela(R). Renvela (R) is a phosphate binder indicated for the co... |
| | | May.24.10 | Watson's Generic VALTREX(R) 500 mg and 1000 mg Receives FDA Approval| MORRISTOWN, N.J., May 24, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg strengths, the generic equivalent to GlaxoSmithKline, LLC's VALTREX(R) tablets. Watson intends to begin shipping the product shortly.
VALTREX(R) ... |
| | | May.19.10 | Watson Launches Generic Version of LIPITOR® in Canada| MORRISTOWN, N.J., May 19, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Cobalt Pharmaceuticals has received a Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets in the 10, 20, 40 and 80 mg strengths. Watson has initiated shipments of this product.
Atorvastatin Calcium is the generic equivalent to Pfizer's LIPITOR(R) tablets and is indicated to reduce the risk of heart attack, stroke, certain kinds of he... |
| | | May.19.10 | Watson to Expand NJ Administrative Headquarters | - New Parsippany Facility Supports Growth Resulting from Global Expansion,
Unites NJ Operations in Single Location -
MORRISTOWN, NJ – May 19, 2010 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has signed a lease for a new Administrative Headquarters in New Jersey. The Company plans to relocate to the new site in Parsippany in late 2010 or early 2011. Watson, which currently employs approximately 250 people in New Jersey, expects total employment at the new fac... |
| | | May.14.10 | Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference| MORRISTOWN, N.J., May 14, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Fred Wilkinson, Watson's Executive Vice President, Global Brands, will provide an overview of the Company's business at the 2010 Citi Investment Research Global Healthcare Conference on Wednesday, May 26, 2010 at 4:30pm Eastern Daylight Time. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor... |
| | | May.10.10 | Watson Q1 Net Revenue Climbs 28 Percent to $857 Million|
- First Quarter 2010 GAAP EPS of $0.57; Adjusted Cash EPS of $0.81
- Adjusted EBITDA Increases 26 percent to $198.9 Million
- Company Increases 2010 Forecast
MORRISTOWN, N.J., May 10, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3... |
| | | May.07.10 | Watson Reaches Settlement with Teva Over Seasonale(R)| MORRISTOWN, N.J., May 7, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale(R) (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.
On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Je... |
| | | May.05.10 | Watson Confirms SIMCOR(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., May 5, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its 1000 mg/20 mg form of niacin extended-release/simvastatin tablets. Watson's 1000 mg/20 mg niacin extended-release/simvastatin tablets are generic versions of Ab... |
| | | May.05.10 | Watson Confirms EVISTA(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., May 5, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA(R). EVISTA (R) is indicated for the treatment and preve... |
| | | May.03.10 | Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference| MORRISTOWN, N.J., May 3, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Bank Of America/Merrill Lynch 2010 Healthcare Conference on Tuesday, May 11, 2010 at 1:40pm Eastern Daylight Time at The Grand Hyatt, New York.
This presentation will be webcast live and can be accessed o... |
| | | May.03.10 | Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th| MORRISTOWN, N.J., May 3, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company will conduct a live webcast of its 2010 Annual Meeting of Stockholders on Friday May 7, 2010 beginning at 9:00am Eastern Daylight Time. As part of the meeting, Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business.
The webcast can be accessed at Watson... |
| | | Apr.30.10 | Watson Confirms Trilipix(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., April 30, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for choline fenofibrate delayed-release capsules in the 45 mg and 135 mg strengths. Watson's ANDA is for a generic equivalent of ... |
| | | Apr.28.10 | Watson Confirms Rapamune(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., April 28, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for sirolimus tablets in the 1 mg and 2 mg strengths. Watson's ANDA is for a generic equivalent of Wyeth's Rapamune(R) tablets product. The suit ... |
| | | Apr.26.10 | Watson Confirms Cenestin(R) Patent Challenge| Paragraph IV Litigation Underway -
MORRISTOWN, N.J., April 26, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equiv... |
| | | Apr.26.10 | Watson Says Appeals Court Affirms Concerta(R) Patent Invalid| MORRISTOWN, N.J., April 26, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Court of Appeals for the Federal Circuit Court has affirmed a March 31, 2009 District Court decision that the asserted claims of ALZA's United States Patent No. 6,919,373 "the '373 Patent" are invalid. The original suit by ALZA Corporation and McNeil-PPC, Inc. alleged that Watson's generic versions of Concerta(R) (methylphenidate hydrochloride extended-release tablet... |
| | | Apr.15.10 | Watson's Generic Toprol XL(R) 100 mg and 200 mg Receives FDA Approval| MORRISTOWN, N.J., April 15, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL(R) tablets. Watson intends to begin shipping the product next week.... |
| | | Apr.12.10 | Watson to Host Conference Call and Webcast to Discuss First Quarter 2010 Earnings| MORRISTOWN, N.J., April 12, 2010 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its first quarter 2010 financial results on Monday, May 10, 2010 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on May 10, 2010 to discuss its financial results and provide an update on the Company's outlook ... |
| | | Mar.16.10 | Watson to Present at Barclay's 2010 Global Healthcare Conference| MORRISTOWN, N.J., March 16, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Barclay's 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 11:15 am Eastern Daylight Savings Time at the Loews Miami Beach Hotel.
This presentation will be webcast live and can be accesse... |
| | | Mar.15.10 | Watson Receives FDA Approval for Generic Cardizem(R) LA| MORRISTOWN, N.J., March 15, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, the generic equivalent to Biovail Laboratories International SRL's Cardizem(R) LA product. Watson intends to launch its generic version of Cardizem(R) ... |
| | | Mar.11.10 | FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer| - New formulation maintains mean testosterone levels similar to those achieved with surgical castration in just two doses each year - - May 2010 launch expands TRELSTAR(R) options; currently available in one- and three-month formulations -MORRISTOWN, N.J., March 11, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly... |
| | | Mar.10.10 | Watson Announces Actos(R) Patent Challenge Settlement| MORRISTOWN, N.J., March 10, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos(R) (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets. Under terms of the agreement, Takeda granted Watson a non-exclusive royalty free license to its U... |
| | | Mar.08.10 | Watson Confirms Filing of Generic Opana(R) ER Application| Patent Challenge Litigation Underway -MORRISTOWN, N.J., March 8, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg. Watson's Oxymorphone Hydrochloride... |
| | | Mar.04.10 | Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line| - Established, patient-preferred infertility treatment - - Expands Watson's Women's Health brand product portfolio - - Preterm birth clinical trials currently underway - - Company acquires 11.2 million shares of Columbia common stock -MORRISTOWN, N.J., March 4, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'... |
| | | Mar.03.10 | Watson to Present at Cowen and Company 30th Annual Healthcare
Conference| MORRISTOWN, NJ, Mar 03, 2010 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Cowen and Company 30th Annual
Healthcare Conference on Tuesday, March 9, 2010 at 11:05 am Eastern
Standard Time at the Boston Marriott Copley Place.
This presentation will be webcast live and can be ac... |
| | | Mar.01.10 | Watson Licenses Population Council's Novel Contraceptive Ring| Phase 3 clinical development product expands Watson's global brand contraceptive portfolioMORRISTOWN, N.J. and NEW YORK, March 1, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced an exclusive licensing agreement to commercialize the Population Council's investigational contraceptive vaginal ring in the United States, Canada, and Mexico. The ring, which contains two hormonal products - ethinyl estradiol and Nestorone(R), a novel, synthetic progestin - is cu... |
| | | Mar.01.10 | Watson Signs Agreement to Divest Equity Interest in ScinoPharm| Intends to Use Proceeds to Support Business Development, General Business PurposesMORRISTOWN, N.J., March 1, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it signed an agreement on February 26, 2010 to divest its equity ownership position of approximately 31% of ScinoPharm Taiwan Ltd. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as well as other customary closing conditions. Assuming all ... |
| | | Feb.26.10 | Watson to Present at CLSA/Asia USA Investor's Forum| MORRISTOWN, N.J., Feb 26, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview of the Company's business at the CLSA/Asia Investor's Forum on Tuesday, March 2, 2010 at 4:30 pm Eastern Standard Time at the Westin St. Francis in San Francisco, CA.
This presentation will be webcast live and can be accessed on Watson Pharmaceuti... |
| | | Feb.23.10 | Watson Reports Net Revenue of $786 Million for the Fourth Quarter 2009| - Fourth Quarter 2009 GAAP EPS of $0.51; Adjusted Cash EPS $0.85 - Full Year 2009 Net Revenues of $2.8 Billion - Full Year 2009 GAAP EPS of $1.96; Adjusted Cash EPS $3.04 - Company Affirms 2010 Outlook
MORRISTOWN, N.J., Feb 23, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue for the fourth quarter ended December 31, 2009 climbed 22 percent to $785.7 million, compared to $645.2 million in the fourth quarter 2008. Watson's results include Arrow ... |
| | | Feb.22.10 | Watson Files FDA Application for Generic Aplenzin(TM) ER| Paragraph IV Litigation Underway -MORRISTOWN, N.J., Feb 22, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's... |
| | | Feb.02.10 | Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook| MORRISTOWN, N.J., Feb 02, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2010 financial results on Tuesday, February 23, 2010 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30 a.m. Eastern Standard Time on February 23, 2010 to discuss its financial results and provide an update on the Company'... |
| | | Feb.01.10 | Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.| New data published in The Lancet demonstrate effective pregnancy prevention as compared to currently available emergency contraceptive options -MORRISTOWN, N.J., Feb 01, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and HRA Pharma today announced an exclusive licensing agreement for Watson to become the commercial partner for ulipristal acetate (UPA), a selective progesterone receptor modulator in the U.S. UPA is a novel next-generation emergency contraceptive develo... |
| | | Jan.28.10 | Watson Completes Acquisition of Eden Biodesign| - Establishes Strong Foundation in Biologics - - Extensive Intellectual Expertise, State-of-the Art Facilities -MORRISTOWN, N.J., Jan 28, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Eden Biopharm Group Limited for approximately $15 million. Eden is a biopharmaceutical development and contract manufacturing company located in Liverpool, UK. As a result of the acquisition of the Arrow Group in December 2009, Wats... |
| | | Jan.21.10 | Watson Provides Overview of Global Operations; Delivers Outlook for Continued Growth| --Meeting Highlights: - Positioned for continued growth in U.S.; Strong foundation in key markets and opportunities in other international markets - Expanding brand pipeline with near, mid-term opportunities; Urology and women's health opportunities are areas of key focus and anticipated growth - Expanded global operations and supply chain supports increased efficiencies in production; Continued opportunities to enhance profit and support corporate growth - Revenue forecasted to be approximately... |
| | | Jan.19.10 | Watson Confirms Filing of FDA Application for Generic Lidoderm(R)| MORRISTOWN, N.J., Jan 19, 2010 /PRNewswire via COMTEX/ -- In the news release, Watson Confirms Filing of FDA Application for Generic Lidoderm(R), issued Jan. 19 by Watson Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first paragraph, second and third sentences should read "lidocaine topical patch 5%" rather than "lidocaine topical patch 8%" as originally issued inadvertently. The complete, corrected release follows:
Watson Confirms Filing of FDA Application ... |
| | | Jan.13.10 | Watson Announces Preliminary Financial Performance for FY 2009| - 2009 Net Revenue Estimated to Exceed $2.7 Billion - - 2009 Adjusted EPS and Adjusted EBITDA Expected to Meet or Exceed Prior Forecast - - Company to Provide 2010 Outlook at January 21st Investor Day -SAN FRANCISCO, Jan 13, 2010 /PRNewswire via COMTEX/ -- At the 28th Annual J.P. Morgan Healthcare Conference, Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it expects to report an increase in net revenues of approximately 9 percent to more than $2.7 billion for 2009, compared to 200... |
| | | Jan.12.10 | Watson Pharmaceuticals to Host 'Investor Day 2010' on Thursday, January 21st in New York City| MORRISTOWN, NJ, Jan 12, 2010 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will be hosting an Investor Day on January 21, 2010 in New York City. The presentations are scheduled to begin at 8:30 a.m., Eastern Time and will be simultaneously webcast.
At the meeting, the Company plans to discuss its strategy accompanying the recent acquisition of Arrow Group and provide a preliminary outlook for 2010. The presenters will include: Paul Bisaro, Watson's... |
| | | Jan.08.10 | Watson Files FDA Application for Generic LoSeasonique(R)| Paragraph IV Litigation Underway -MORRISTOWN, N.J., Jan 08, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.10 mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. Patent No. ... |
| | | Jan.06.10 | Watson to Present at 28th Annual JPMorgan Healthcare Conference| MORRISTOWN, N.J., Jan 06, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the 28th Annual JPMorgan Healthcare Conference on Wednesday, January 13, 2010 at 12:00 pm Eastern Standard Time, at the Westin St. Francis, San Francisco, CA.
This presentation will be webcast live and can b... |
| | | Jan.06.10 | Watson Files FDA Application for Generic Nuvigil(R)| Paragraph IV Litigation Underway -MORRISTOWN, N.J., Jan 06, 2010 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents o... |
| | | Dec.14.09 | Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy|
MORRISTOWN, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT). Nearly two million men are receiving ADT, a palliative treatment for prostate cancer that, while highly effective and considered the "gold therapy," can cause bone loss and increase a man's risk for osteoporosis.
As pa... |
| | | Dec.09.09 | New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief| - Secondary trial endpoint reinforces prior, positive, sustained efficacy data -CORONA, Calif., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO(R) (silodosin) for up to 52 weeks of treatment. RAPAFLO(R) is an effective and uniquely selective alph... |
| | | Dec.04.09 | Watson Files FDA Application for Generic Rozerem(R)| - Paragraph IV Litigation Underway -
MORRISTOWN, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited. Watson's... |
| | | Dec.02.09 | Watson Completes Acquisition of Arrow Group| Combined Global Company Has:
Over $3 Billion Annual Revenue
Operations in 20 Countries
Strong Product Franchise and Pipeline
MORRISTOWN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Arrow Group for a combination of cash and stock. The purchase creates a financially strong, global specialty pharmaceutical company with over $3 billion in annual revenues and operations in more than 20 countries.
"T... |
| | | Dec.02.09 | Watson Receives FTC Clearance for Arrow Acquisition| MORRISTOWN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has accepted a proposed consent order for public comment relating to Watson's pending acquisition of privately held Arrow Group and has granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction. The parties have now obtained all regulatory approvals required to close the transaction. ... |
| | | Nov.16.09 | Watson Names Robert A. Stewart Senior Vice President, Global Operations| Restructures to Create Global Operations, Global Generics Commercial FunctionsMORRISTOWN, N.J., Nov 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technical operations.
The Company also announced th... |
| | | Nov.10.09 | Watson Announces Presentation Time Change at Credit Suisse Healthcare Conference|
MORRISTOWN, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today a change for the Company's presentation at the Credit Suisse 18th Annual Healthcare Conference scheduled for Wednesday, November 11, 2009. Watson's presentation will take place at 11:00 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at http:... |
| | | Nov.06.09 | Watson to Present at Credit Suisse Healthcare Conference|
MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson Pharmaceu... |
| | | Nov.04.09 | Watson Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66| MORRISTOWN, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter was $76.1 million, or $0.66 per diluted share, an increase of $22.1 million or 41 percent over the adjusted net income for the third quarter ended September 30, 2008. As detail... |
| | | Oct.30.09 | Watson Names R. Todd Joyce Senior Vice President and Chief Financial Officer; Succeeds Mark W. Durand|
MORRISTOWN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that R. Todd Joyce has been named Senior Vice President and Chief Financial Officer (CFO) effective immediately. Mr. Joyce succeeds Mark W. Durand, who has departed as CFO for personal reasons. On July 27, 2009, Watson announced that Mr. Durand had taken a leave of absence for health reasons, and named Mr. Joyce as Acting Principal Financial Officer.
"I, the Board of Directors and the s... |
| | | Oct.28.09 | Watson and Barr Settle Lawsuit Over Oxytrol(R)|
CORONA, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that its subsidiary Watson Laboratories, Inc. has reached a settlement with Barr Laboratories, Inc. on outstanding patent litigation related to Watson's Oxytrol® (Oxybutynin Transdermal System, 3.9mg/24hr.) product.
On August 19, 2008, Barr submitted an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version o... |
| | | Oct.13.09 | Watson to Host Third Quarter 2009 Earnings Conference Call and Webcast| MORRISTOWN, NJ, Oct 13, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its third quarter 2009 financial results on Wednesday,
November 4, 2009 prior to the open of the U.S. financial markets.
The Company will also host a conference call and webcast at 8:30 a.m.
Eastern Standard Time on November 4, 2009 to discuss its financial
results and provide an update on the Comp... |
| | | Sep.29.09 | New Data Suggest that GELNIQUE(R) (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults| - Previous research suggests oral oxybutynin formulations can impair cognition -
SAN FRANCISCO, Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced findings of a double-blind study which demonstrate that GELNIQUE was comparable to placebo in its effect on memory tests and other cognitive functions in older healthy adult subjects when compared to immediate release oral oxybutynin treatments.... |
| | | Sep.21.09 | Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands|
MORRISTOWN, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that G. Frederick Wilkinson has joined the Company as Executive Vice President, Global Brands. In this newly expanded position Mr. Wilkinson will be responsible for all aspects of the Company's global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product busi... |
| | | Sep.08.09 | Watson to Present at the Bank of America Merrill Lynch Global Healthcare Conference| MORRISTOWN, NJ, Sep 08, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Bank of America Merrill Lynch
Global Healthcare Conference on Tuesday, September 15, 2009 at 2:30
p.m. (BST) (9:30 a.m. EDT).
This presentation will be webcast live and can be accessed on Watson
Pharm... |
| | | Aug.28.09 | Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use|
MORRISTOWN, N.J., Aug. 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Levonorgestrel Tablets, 0.75 mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17. Levonorge... |
| | | Aug.18.09 | Watson Announces Offering of Senior Unsecured Notes| MORRISTOWN, N.J., Aug 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.
Watson intends to use the net proceeds from the offering to fund a portion of the cash consideration for Watson's previously announced acquisition of the privately-held Arrow Group, to redeem th... |
| | | Aug.18.09 | Watson Prices $850 Million of Senior Unsecured Notes| MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today
announced the pricing of a debt offering of $450.0 million of 5.000% senior
notes due 2014 and $400.0 million of 6.125% senior notes due 2019, for a total
offering of $850.0 million in aggregate principal amount. The offering is
expected to close on August 24, 2009, subject to market conditions and other
factors.
Watson intends to use the net proc... |
| | | Aug.07.09 | Watson Announces Limited Recall Of Fentanyl Transdermal System| MORRISTOWN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the
United States is being voluntarily recalled from wholesalers and pharmacies.
The recalled patches are from Lot Number 145287A, have expiration dates of
February 2011 and were manufactured by Watson Laboratories, Inc. and
distributed by Watson Pharma, Inc. The a... |
| | | Aug.06.09 | Watson Pharmaceuticals and Arrow Group Receive FTC Second Request| MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that it has received a request for additional information from the Federal
Trade Commission ("FTC") in connection with Watson's pending acquisition of
privately held Arrow Group. The information request was issued under
notification requirements of the Hart.Scott.Rodino Antitrust Improvements Act
of 1976, as amended ("HSR Act"). The ... |
| | | Aug.03.09 | Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG| MORRISTOWN, N.J., Aug 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths. Metoprolol succinate extended-release tablets are the generic eq... |
| | | Jul.29.09 | Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook| MORRISTOWN, N.J., July 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today reported net income of $53.0 million, or $0.46 per diluted share. Excluding special items as detailed in the reconciliation table below, adjusted net income for the second quarter was $70.4 million, or $0.61 per diluted share, an increase of $15.8 million or 29 percent. Adjusted EBITDA for the second quarter 2009 was $164.... |
| | | Jul.28.09 | Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)| MORRISTOWN, N.J., July 28, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced a license agreement with GeneraMedix, Inc., for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients receiving supplemental epoetin therapy.
GeneraMedix has... |
| | | Jul.27.09 | Watson CFO Mark W. Durand to Take Leave of Absence| MORRISTOWN, N.J., July 27 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded
pharmaceuticals, announced that effective today Mark W. Durand, Senior Vice
President and Chief Financial Officer, has taken a leave of absence from the
Company for health reasons. Paul Bisaro, President and Chief Executive
Officer of Watson, announced that R. Todd Joyce, Vice President, Corporate
Controller and Treasurer, will serve as Acting Princip... |
| | | Jul.15.09 | Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)| - Paragraph IV Litigation Underway -
MORRISTOWN, N.J., July 15 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida
("Watson"), has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration seeking approval to market its trospium chloride
extended-release 60 mg capsules prior to the expiration of... |
| | | Jul.14.09 | Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA| - Company to Address Agency Requests in a Timely Manner -
MORRISTOWN, N.J., July 14 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
announced today that it received a Complete Response Letter from the U.S. Food
and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR
22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation
of TRELSTAR for the palliative treatme... |
| | | Jul.10.09 | Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)| MORRISTOWN, N.J., July 10 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
announced today that it has resumed shipments to reintroduce its intravenous
iron replacement therapy INFeD (iron dextran injection,USP). The product,
which had been out of stock due to changes in the final product manufacturing
site and issues with raw material supply, is re-entering the market earlier
than expected. Watson expects to be in a norm... |
| | | Jul.10.09 | Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast| MORRISTOWN, N.J., July 10 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
announced today that the Company intends to release its second quarter 2009
financial results on Wednesday, July 29, 2009 prior to the open of the U.S.
financial markets. The Company will also host a conference call and webcast
at 8:30 a.m. Eastern Daylight Time on July 29, 2009 to discuss its financial
results and provide an update on the Company's... |
| | | Jul.08.09 | Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums| MORRISTOWN, N.J., July 8, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, 2 mg and 4 mg strengths in the coated fruit and cinnamon flavors.
Nicotine Polacrilex Gum coated fruit and cinnamon flavors are the ... |
| | | Jun.29.09 | Watson Pharmaceuticals Appoints Christopher W. Bodine to Board of Directors| --Former President, Health Care Services for CVS Caremark Corporation Brings Added Global Supply Chain Experience and Expertise to the BoardMORRISTOWN, N.J., June 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced the appointment of Christopher W. Bodine to its Board of Directors, effective immediately. The addition of Mr. Bodine expands Watson's Board to ten members, of whom nine are... |
| | | Jun.24.09 | Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)| MORRISTOWN, N.J., June 24 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
today announced that its subsidiary, Watson Laboratories, Inc., has received
approval today from the United States Food and Drug Administration on its
Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg,
for women seventeen years and younger. Levonorgestrel is the generic
equivalent to Duramed Pharmaceuticals' PLAN B(R), whic... |
| | | Jun.18.09 | Watson to Present at Wachovia's 19th Annual Mid-Year Equity Conference| CORONA, CA, Jun 18, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at Wachovia's 19th Annual Mid-Year
Equity Conference on Tuesday, June 23, 2009 at 2:30 p.m. Eastern
Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor R... |
| | | Jun.17.09 | Watson to Acquire Arrow Group| -- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth ProfileMORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a glo... |
| | | Jun.10.09 | Watson Files FDA Application for Generic Mucinex(R) D| - Paragraph IV Litigation Underway -
CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that its subsidiary, Watson Laboratories, Inc. - Florida, has filed an
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration seeking approval to market its guaifenesin pseudoephedrine HCI
extended-release 600mg/60mg and 1200mg/120mg tablets prior to the expiration
of... |
| | | Jun.08.09 | Watson to Present at Upcoming Investor Conferences| Goldman Sachs 30th Annual Healthcare Conference; 8th Annual Needham Life Sciences ConferenceCORONA, CA, Jun 08, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Goldman Sachs 30th Annual
Healthcare Conference on Wednesday, June 10, 2009 at 9:40 a.m.
Eastern Daylight Time. M... |
| | | May.29.09 | Watson to Present at the UBS Global Specialty Pharmaceuticals Conference 2009| CORONA, CA, May 29, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Mark Durand, Watson's
senior vice president and chief financial officer, will provide an
overview and update of the Company's business at the UBS Global
Specialty Pharmaceuticals Conference 2009 on Wednesday, June 3, 2009
at 1:30 p.m. London Daylight Saving Time (DST) (8:30 a.m. EDT).
This presentation will be webcast live and can be... |
| | | May.22.09 | Watson to Present at the Sanford C. Bernstein & Co. Twenty-Fifth Annual Strategic Decisions 2009 Conference| CORONA, CA, May 22, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Sanford C. Bernstein & Co.
Twenty-Fifth Annual Strategic Decisions 2009 Conference on Wednesday,
May 27, 2009 at 9:00 a.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed ... |
| | | May.21.09 | Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)| - Bold and innovative marketing campaign will target women and highlight
product's efficacy, ease of use and excellent tolerability -
CORONA, Calif., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, a
leader in generic and specialty branded pharmaceuticals, announced today the
launch of GELNIQUE(TM) (oxybutynin chloride) gel 10%, first and only topical
gel for the treatment of overactive bladder (OAB) with symptoms of urge
urinary incontinence, urgency, and frequency.
... |
| | | May.18.09 | Watson Provides Update on Ferrlecit(R) Supply and Distribution Agreement| --Watson to Market and Sell Ferrlecit(R) through December 31, 2009 CORONA, Calif., May 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that the Swiss Chambers of Commerce Court of Arbitration has ruled that the Ferrlecit(R) (sodium ferric gluconate complex in sucrose) supply and distribution agreements between Watson and Sanofi-aventis will expire on December 31, 2009. As a result of today's... |
| | | May.18.09 | Watson Promotes Patricia Eisenhaur to VP Investor Relations and Corporate Communications| CORONA, CA, May 18, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced the promotion of Patricia L.
Eisenhaur, 46, to Vice President, Investor Relations and Corporate
Communications.
"Since joining the company, Patty has played a key role in building
our investor relations function and raising Watson's visibility with
shareholders, analysts and the media," said Paul Bisaro, Watson's
President and Chief Exec... |
| | | May.08.09 | RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days| - Significant peak urine flow (Qmax) improvements within 2-6 hours of the
first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a
new, uniquely selective alpha blocker for the treatment of the signs and
symptoms of BPH, produces rapid improvements of both irritative and
obstructive urinary symptoms that were sustained for 12 weeks, according to
data published in the June issue of The Journal of Urology. RAPAFLO(TM) was
... |
| | | May.07.09 | Watson to Present at Bank of America and Merrill Lynch 2009 Health Care Conference|
CORONA, CA, May 07, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Bank of America and Merrill
Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 at 8:40
a.m. Eastern Daylight Time.
This presentation will be webcast live and can be acce... |
| | | May.01.09 | Watson Pharmaceuticals to Webcast Its 2009 Annual Meeting of Stockholders| CORONA, CA, May 01, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company will conduct
a live webcast of its 2009 Annual Meeting of Stockholders on Friday,
May 8, 2009 at 9:00 a.m. Pacific Daylight Time. As part of the
meeting, Paul Bisaro, Watson's president and chief executive officer,
will provide an overview and update of the Company's business.
The webcast can be accessed at Watson Pharm... |
| | | Apr.30.09 | Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook|
Record Total Net Revenue of $667 Million;
GAAP EPS $0.43; Adjusted EPS $0.58
CORONA, Calif., April 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2009.
First Quarter 2009 Results
Net revenue for the first quarter 2009 increased $40.4 million or six percent from the first quarter 2008 to a record $667.4 million, and net inco... |
| | | Apr.28.09 | Watson Confirms Filing of Abbreviated New Drug Application for Generic Enablex(R)| - Paragraph IV Litigation Underway -
CORONA, Calif., April 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration seeking approval to market its darifenacin
hydrobromide extended-release 7.5 mg and 15 mg product prior to the expiration
of a patent owned by Novartis AG. Watson's darifenacin hydrobromide
e... |
| | | Apr.28.09 | Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients| - Uniquely Selective Agent Offers Significant Improvement -
CHICAGO, April 28 /PRNewswire-FirstCall/ -- Data to be presented at the
American Urological Association's (AUA) Annual Conference show that
RAPAFLO(TM) (silodosin) produces rapid and sustained improvements of both
irritative and obstructive urinary symptoms associated with BPH, with
statistically significant symptom relief within three to four days of starting
treatment. RAPAFLO(TM) is a new, uniquely selective alpha block... |
| | | Apr.27.09 | New Data Presented at AUA's Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients| - First and Only Topical Gel for OAB to Launch in U.S. Next Month -
CHICAGO, April 27 /PRNewswire-FirstCall/ -- Data to be presented at the
American Urological Association's (AUA) Annual Conference show that
GELNIQUE(TM) (oxybutynin chloride) 10% gel significantly improves symptoms of
OAB and urinary urge incontinence in women with the condition. By the end of
the 12-week study period, 27 percent of women treated with GELNIQUE achieved
complete urinary continence versus 15.6 per... |
| | | Apr.22.09 | Watson Files FDA Applications for Generic Mucinex(R)| - Paragraph IV Litigation Underway -
CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S.
Food and Drug Administration seeking approval to market its guaifenesin
extended-release 600mg and 1200mg tablets and its dextromethorphan
HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to
t... |
| | | Apr.22.09 | Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting| - Company to Highlight Data for its Two Newest Urological Products -
CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a global leader in the development and distribution of
pharmaceuticals, announced today that management will host and webcast a
meeting for the investment community at the American Urological Association
(AUA) Annual Meeting taking place in Chicago, Illinois, April 25-30, 2009.
The company will be hosting the meeting t... |
| | | Apr.20.09 | Watson to Host First Quarter 2009 Earnings Conference Call and Webcast| CORONA, CA, Apr 20, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its first quarter 2009 financial results on Thursday, April
30, 2009 prior to the open of the U.S. financial markets. The
Company will also host a conference call and webcast at 8:30 a.m.
Eastern Daylight Time on April 30, 2009 to discuss its financial
results and provide an update on the Company's ou... |
| | | Apr.07.09 | Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)| -- New product, now available in pharmacies, will provide rapid symptom
relief for number one reason men visit a urologist --
CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that RAPAFLO(TM) (silodosin), the company's new, uniquely selective alpha
blocker for the treatment of the signs and symptoms of benign prostatic
hyperplasia (BPH), is available for patients by prescription. ... |
| | | Mar.31.09 | Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid| CORONA, Calif., March 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the United States District Court for the District of Delaware has ruled
that Watson's generic version of Concerta (methylphenidate hydrochloride
extended-release tablets) does not infringe United States Patent No. 6,919,373
(the '373 Patent) and that the '373 Patent is invalid. The opinion, dated
March 30, 2009, was issued by Jud... |
| | | Mar.23.09 | Watson Announces a Nationwide Voluntary Recall of Propafenone HCL Tablets Due to Oversized Tablets| Lot Number 112680A, Expiration Date July 31, 2010CORONA, CA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that one lot of Propafenone
HCL 225 mg Tablets sold in 100 count bottles in the United States is
being voluntarily recalled to the consumer level as a precautionary
measure. The lot is being recalled because some tablets may contain
slightly higher levels of the active ingredient than spec... |
| | | Mar.16.09 | New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability| -- First and only topical gel for OAB expected to launch in May --
Corona, Calif., March 16, 2009 - New Phase 3 data, published in the April issue of The Journal of Urology, show that GELNIQUE™ (oxybutynin chloride) Gel 10%, the first and only topical gel approved for the treatment of overactive bladder (OAB), is effective at improving the symptoms of urge urinary incontinence, urgency and frequency, and is extremely well tolerated in adults.
GELNIQUE is a quick drying, clear and color... |
| | | Mar.10.09 | Watson to Present at Cowen and Company 29th Annual Health Care Conference| CORONA, CA, Mar 10, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Mark Durand, Watson's
senior vice president and chief financial officer, will provide an
overview and update of the Company's business at the Cowen and
Company 29th Annual Health Care Conference on Monday, March 16, 2009
at 2:25 p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmac... |
| | | Mar.06.09 | Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium| CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has reached a settlement with Elan Corporation, Plc on outstanding
patent litigation related to Watson's generic version of Naprelan(R) (naproxen
sodium) tablets.
Under the terms of the agreement, Watson will pay Elan $18 million in full
settlement of all disputes related to Watson's development, manufacturing,
marketing an... |
| | | Mar.02.09 | Watson to Present at Barclays Capital Global Healthcare Conference| CORONA, CA, Mar 02, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Barclays Capital Global
Healthcare Conference on Tuesday, March 10, 2009 at 9:30 a.m. Eastern
Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals'
Investo... |
| | | Feb.19.09 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook| Fourth Quarter 2008 Total Net Revenue of $645.2 Million;
Adjusted EPS $0.53;
GAAP EPS $0.50;
Full Year 2008 Total Net Revenue of $2.54 Billion
Adjusted EPS $2.03; GAAP EPS $2.09
CORONA, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals,
today reported financial results for its fourth quarter and fiscal year ende... |
| | | Feb.02.09 | Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement| CORONA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Federal Trade Commission (FTC) and the State of California have
filed a lawsuit in the United States District Court for the Central District
of California alleging that the Company's 2006 patent lawsuit settlement with
Solvay Pharmaceuticals Inc. related to AndroGel(R) 1% (testosterone gel) CIII
is unlawful.
"We are di... |
| | | Jan.29.09 | Watson to Host Fourth Quarter and Full Year 2008 Earnings Conference Call and Webcast| Company to Provide 2009 Outlook CORONA, CA, Jan 29, 2009 (MARKET WIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its fourth quarter and full year 2008 financial results on
Thursday, February 19, 2009 prior to the open of the U.S. financial
markets. The Company will also host a conference call and webcast at
8:30 a.m. Eastern Standard Time on February 19, 2009 to discuss its
fi... |
| | | Jan.27.09 | Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder| CORONA, Calif., Jan 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- First and Only Topical Gel Provides Ease, Efficacy and Excellent Tolerability
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, an... |
| | | Jan.12.09 | Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation| - Companies Enter Into Co-Promotion Agreement for Femring(R) and License and
Supply Agreements for Development-Stage Oral Contraceptive -
HAMILTON, Bermuda and CORONA, Calif., Jan. 12 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) and Warner Chilcott Limited (Nasdaq:
WCRX) announced today that they have entered into Settlement and License
Agreements to resolve pending patent litigation related to Warner Chilcott's
oral contraceptive products, Loestrin(R) 24... |
| | | Jan.06.09 | Watson to Present at the JP Morgan 27th Annual Healthcare Conference| CORONA, CA, Jan 06, 2009 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the JP Morgan 27th Annual
Healthcare Conference on Monday, January 12, 2009 at 9:00 a.m.
Pacific Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceutica... |
| | | Dec.31.08 | Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum| CORONA, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals,
today announced that its subsidiary, Watson Laboratories, Inc., has received
approval from the United States Food and Drug Administration to market its
over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg
and 4 mg strengths.
Nicotine Polacrilex Gum, coated mint flavor, is the generic equivalent of
GlaxoSmith... |
| | | Dec.29.08 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)| CORONA, CA — December 29, 2008 — Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets, 0.15 mg/0.02 mg and 0.01 mg and placebo tablets (28- day regimen). Desogestrel/ethinyl estradiol and ethinyl... |
| | | Dec.16.08 | Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules| CORONA, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its subsidiary, Watson Laboratories, Inc., has received approval today
from the United States Food and Drug Administration on its Abbreviated New
Drug Application (ANDA) for galantamine hydrobromide extended-release
capsules, eq. to 8 mg, 16 mg and 24 mg (galantamine base). Galantamine
hydrobromide extended-release capsules are th... |
| | | Nov.26.08 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg| CORONA, Calif., Nov. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its subsidiary, Watson Laboratories, Inc., has received final approval
today from the United States Food and Drug Administration on its Abbreviated
New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release
Tablets (XL) in the 150 mg strength. Bupropion Hydrochloride Extended-Release
Tablets is the generic equivalent... |
| | | Nov.25.08 | Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr| CORONA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
a definitive agreement to acquire a portfolio of generic pharmaceutical
products that are being divested as a result of the proposed merger between
Teva Pharmaceutical Industries, Ltd. and Barr Pharmaceuticals, Inc. The
closing of the product acquisition is contingent upon the consummation of
Teva's merger with Barr.
The portfolio... |
| | | Nov.13.08 | Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer| CORONA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R)
(triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist,
has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Watson is seeking marketing approval of this TRELSTAR(R) formulation for the
palliative treatment of adva... |
| | | Nov.06.08 | Watson to Present at the 2008 Annual Credit Suisse Health Care Conference| CORONA, CA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the 2008 Annual Credit Suisse
Health Care Conference on Wednesday, November 12, 2008 at 8:00 a.m.
Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pha... |
| | | Oct.29.08 | Watson Pharmaceuticals Reports Third Quarter 2008 Results| Total Net Revenue of $641 Million; GAAP EPS $0.62; Adjusted EPS $0.47
CORONA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its third quarter ended September 30, 2008.
Third Quarter 2008 Results
Net revenue for the third quarter 2008 increased $46.0 million or
8 percent from the third quarter 2007 to $640.7 million, and net income was
$71.1 million, or $0.... |
| | | Oct.24.08 | Watson Files Lawsuit Against Barr for OXYTROL Patent Infringement| CORONA, CA, Oct 24, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced that its subsidiary Watson
Laboratories, Inc. has filed a lawsuit in the U.S. District Court of
Delaware against Barr Pharmaceuticals, Inc. and its subsidiary Barr
Laboratories, Inc. for infringement of patents listed in the Orange
Book for Watson's product OXYTROL(R) (Oxybutynin Transdermal System).
The lawsuit is based upo... |
| | | Oct.17.08 | Watson to Host Third Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Oct 17, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its third quarter 2008 financial results on Wednesday,
October 29, 2008 prior to the open of the U.S. financial markets.
The Company will also host a conference call and webcast at 8:30 a.m.
Eastern Daylight Time on October 29, 2008 to discuss its financial
results and provide an update o... |
| | | Oct.08.08 | Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference| - New Research shows that oxybutynin topical gel may be a convenient alternative to currently available treatments for OAB -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented clinical pharmacokinetic data on oxybutynin
chloride topical gel (OTG), its investigational therapy for overactive bladder
(OAB).
Previously, the efficacy and safety of OTG were dem... |
| | | Oct.08.08 | Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)| - RAPAFLO launch anticipated in early 2009 -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM)
(silodosin), the company's new alpha blocker for the treatment of the signs
and symptoms of BPH.
BPH is the number one reason patients visit urologists and is
characterized by urination problems, including decreased... |
| | | Oct.01.08 | Watson Notified of OXYTROL(R) Patent Challenge| CORONA, Calif., Oct 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
the receipt of a Paragraph IV Certification Notice Letter relating to an
Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug
Administration (FDA) by a generic filer requesting approval to market and sell
a generic version of OYXTROL(R) (Oxybutynin Transdermal System). In its Notice
Letter... |
| | | Sep.29.08 | Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences| - Results demonstrate the efficacy, safety and tolerability of RAPAFLO(TM) alone or in combination with treatments for erectile dysfunction -
CORONA, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented efficacy and safety data on silodosin, its
investigational treatment for benign prostatic hyperplasia (BPH, or prostate
enlargement), at two regional meetings of the A... |
| | | Sep.05.08 | Watson Announces Change to Presentation Time at the Morgan Stanley Global Healthcare Unplugged Conference| CORONA, CA, Sep 05, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced a change to its presentation
time at the Morgan Stanley Global Healthcare Unplugged Conference
that is being held on Tuesday, September 9, 2008. Paul Bisaro,
Watson's president and chief executive officer, will provide an
overview and update of the Company's business at 8:00 a.m. Eastern
Daylight Time.
This presentation wil... |
| | | Sep.03.08 | Watson to Present at the Morgan Stanley Global Healthcare Unplugged Conference| CORONA, CA, Sep 03, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Morgan Stanley Global
Healthcare Unplugged Conference on Tuesday, September 9, 2008 at 4:30
p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
P... |
| | | Aug.13.08 | Watson Announces District Court Ruling in Naproxen Sodium Patent Suit| CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the United States District Court for the Southern District of Florida
ruled today that Watson's Naproxen Sodium ER tablets, the generic version of
Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent").
The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially
brought by Elan in October 199... |
| | | Aug.08.08 | Watson Announces Limited Recall Of Fentanyl |
CORONA, CA - August 8, 2008 - Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that one lot of 75 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies. The recalled patches are from Lot Number 92461850, have expiration dates of August 31, 2009 and were manufactured by Watson Laboratories, Inc. The affected lot of Fentanyl Transdermal System patches was shipped to customers b... |
| | | Aug.06.08 | Watson Pharmaceuticals Reports Second Quarter 2008 Results| Total Net Revenue of $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48
CORONA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its second quarter ended June 30, 2008.
Second Quarter 2008 Results
Net revenue for the second quarter 2008 was $622.6 million and net income
was $60.3 million, or $0.53 per diluted share. Net income for the second
quarter 2008 includ... |
| | | Aug.05.08 | Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes| - QTc profile particularly important among BPH patients with cardiovascular
risk factors -
CORONA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- A paper published in the
current issue of Reviews in Urology (2008; 10(2):85-91) concludes that
urologists and other physicians treating benign prostatic hyperplasia (BPH)
should prescribe medications that do not affect the heart's electrical
activity (heart repolarization), especially since most men with BPH are ol... |
| | | Jul.28.08 | Watson Names Clare Carmichael Senior VP Human Resources| CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Clare Carmichael as Senior Vice President, Human Resources.
Ms. Carmichael's appointment follows the planned retirement of long-time
industry professional, Susan Skara, Senior Vice President, Human Resources.
Ms. Carmichael brings to Watson more than 25 years of human resources
experience within the pharmaceutical... |
| | | Jul.28.08 | Mylan Acquires Remaining Interest in Somerset Joint Venture From Watson| PITTSBURGH and CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Mylan
Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today
that Mylan has acquired Watson's 50 percent interest in the Somerset
Pharmaceuticals, Inc. (Somerset) joint venture. Details of the transaction
remain confidential.
Somerset, a proprietary research and development company located in Tampa,
Florida, was formed in 1986, and since 1988, has been owned jointly by both
Mylan and Watson. ... |
| | | Jul.25.08 | Watson Launches Omeprazole Delayed-Release Capsules, 40MG| - 180-Days of Marketing Exclusivity Begins -
CORONA, Calif., July 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that its subsidiary has commenced commercial shipment of its Omeprazole
Delayed-Release Capsules USP product in the 40mg strength from its Davie,
Florida manufacturing facility. In conjunction with the launch, Watson has
180 days of marketing exclusivity for being the first ... |
| | | Jul.21.08 | Watson to Host Second Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Jul 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its second quarter 2008 financial results on Wednesday,
August 6, 2008 prior to the open of the U.S. financial markets. The
Company will also host a conference call and webcast at 8:30 a.m.
Eastern Daylight Time (EDT) on August 6, 2008 to discuss its financial
results and provide an updat... |
| | | Jun.30.08 | Watson Launches Generic MARINOL(R) Capsules| CORONA, Calif., June 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has
launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg
once daily dosage strengths. Dronabinol is the generic version of Solvay
Pharmaceuticals' MARINOL(R) (dronabinol) CIII Capsules, indicated to treat
nausea and vomiting associated wit... |
| | | Jun.05.08 | Watson to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference| CORONA, CA, Jun 05, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Goldman Sachs Twenty-Ninth
Annual Global Healthcare Conference on Wednesday, June 11, 2008 at
8:00 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Wa... |
| | | Jun.03.08 | Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules| CORONA, Calif., June 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received approval from the U.S. Food and Drug Administration
("FDA") of its Abbreviated New Drug Application (ANDA) for Potassium-Chloride
Extended-Release Capsules USP in the 8mEq and 10mEq strengths.
Potassium-Chloride is the generic equivalent to KV Pharmaceutical's
Micro-K(R) Extencaps(R) USP and is indicated for the ... |
| | | Jun.02.08 | Watson Receives Final Approval of Omeprazole Delayed-Release Capsules| CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the U.S. Food and Drug Administration
("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole
Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.
Watson has been awarded 180 days of marketing exclusivity for being the
first to file an ANDA containing a paragraph IV... |
| | | May.28.08 | Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder| CORONA, Calif., May 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that its New Drug Application (NDA) for oxybutynin chloride topical gel (OTG),
has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Watson is seeking marketing approval of this novel transdermal gel of
oxybutynin hydrochloride for the treatment of overactive bladder (OAB).
OTG is a clear,... |
| | | May.23.08 | Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference| CORONA, Calif., May 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the UBS Global Specialty
and Generic Pharmaceuticals Conference on Wednesday, May 28, 2008 at 2:30 p.m.
London BST (9:30 a.m. EDT).
This presentation will be webcast live and can be ... |
| | | May.21.08 | Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder|
- Innovative pipeline products highlight Watson's commitment to urology -
Embargoed Until 2:10 PM EDT
ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that investigators presented clinical data on two Phase 3 products at the
American Urological Association's annual meeting. The abstracts include a
cardiac safety trial involving silodosin, an in... |
| | | May.13.08 | Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting| - Company to Highlight Significant and Expanding Commitment to the Treatment
of Urological Diseases -
CORONA, Calif., May 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that management will host and webcast a meeting for the investment community
at the American Urological Association (AUA) Annual Meeting taking place in
Orlando, Florida May 17-22, 2008.
The company will ... |
| | | May.12.08 | Watson Pharmaceuticals Announces Appointment of Andrew L. Turner as Chairman of the Board of Directors| - Allen Chao, Ph.D., to Resign from the Board of Directors -
CORONA, Calif., May 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that following the Company's Annual
Stockholder meeting, Allen Chao, Ph.D., Founder and Chairman of the Board,
informed the Company of his decision to resign, effective May 12, 2008, from
his position as a member of the Board of Directors, in order to pursue other
business activities. Dr. Chao was a co-founder o... |
| | | May.09.08 | Watson to Present at the Bank of America 2008 Healthcare Conference| CORONA, Calif., May 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the Bank of America 2008
Healthcare Conference on Wednesday, May 14, 2008 at 12:40 p.m. Pacific
Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investo... |
| | | May.06.08 | Watson Pharmaceuticals to Webcast Its 2008 Annual Meeting of Stockholders| CORONA, Calif., May 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2008 Annual Meeting of
Stockholders on Friday, May 9, 2008 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watson.com. An archived version of the
webcast will be available for 30 days begin... |
| | | May.01.08 | Watson Pharmaceuticals Reports First Quarter 2008 Results| Total Net Revenue of $627 Million; GAAP EPS $0.45; Adjusted EPS $0.55
CORONA, Calif., May 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its first quarter ended March 31, 2008.
First Quarter 2008 Results
Net revenue for the first quarter 2008 was $626.9 million and net income
was $50.6 million, or $0.45 per diluted share. Net income for the first
quarter 2008 included c... |
| | | Apr.30.08 | FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA| - New system addresses the needs of the medical community; builds on proven
efficacy and safety of TRELSTAR(R) -
CORONA, Calif., April 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration has approved MIXJECT(TM), the new
delivery system for TRELSTAR(R) (triptorelin pamoate for injectable
suspension), a palliative treatment for advanced prostate... |
| | | Apr.29.08 | Watson Announces Removal of FDA Official Action Indicated Status at Its Davie, Florida Facility| - Company Announces Completion of FDA Inspection -
CORONA, Calif., April 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration ("FDA") has completed the
inspection of the company's Florida manufacturing facilities and has informed
the Company that it has removed the Official Action Indicated ("OAI") status
at Watson's Davie, Florida site. As a result of... |
| | | Apr.24.08 | Watson Files FDA Application for Generic FENTORA(R)| CORONA, Calif., April 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that its subsidiary Watson Laboratories, Inc. (a Nevada Corporation) has filed
an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market its Fentanyl Buccal Tablets
C-II product prior to the expiration of patents owned by Cephalon, Inc.
Watson's Fentanyl Buccal Tablets C-II p... |
| | | Apr.21.08 | Watson Files FDA Application for Generic YASMIN(R)| Paragraph IV Patent Challenge UnderwayCORONA, CA, Apr 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today confirmed that it has filed an
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market its Drospirenone and
Ethinyl Estradiol tablets (3.00 mg/0.03 mg) combination oral
contraceptive product prior to the expiration of patents owned by
Bay... |
| | | Apr.21.08 | Watson to Host First Quarter 2008 Earnings Conference Call and Webcast| CORONA, CA, Apr 21, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the Company intends to
release its first quarter 2008 financial results on Thursday, May 1,
2008 prior to the open of the U.S. financial markets. The Company
will also host a conference call and webcast at 8:30 a.m. Eastern
Daylight Time (EDT) on May 1, 2008 to discuss its financial results
and provide an update on the... |
| | | Mar.13.08 | Watson Files FDA Application for Generic LYBREL(R)| - Paragraph IV Patent Challenge Underway -
CORONA, Calif., March 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market its
Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg)
extended-cycle oral contraceptive product prior to the expiration o... |
| | | Mar.12.08 | Watson to Present at Two Upcoming Healthcare Conferences| Cowen's 28th Annual Healthcare Conference on March 17, 2008; Lehman Brothers' 11th Annual Global Healthcare Conference on March 19, 2008CORONA, CA, Mar 12, 2008 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that the company will provide
an overview and update of the Company's business at two upcoming
healthcare conferences:
-- Paul Bisaro, Watson's President and Chief Executive Officer, wil... |
| | | Mar.04.08 | Watson Files Application for Generic SEASONIQUE(R)| CORONA, Calif., March 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market its
levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral
contraceptive product, prior to the expiration of patents owned by Duramed
Pharmaceuticals, Inc.... |
| | | Feb.20.08 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook|
Fourth Quarter 2007:
Total Net Revenue of $627 Million;
GAAP EPS $0.34; Adjusted EPS $0.35
Fiscal Year 2007:
Total Net Revenue Reaches $2.50 Billion;
2007 GAAP EPS $1.27; 2007 Adjusted EPS $1.37
CORONA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company,... |
| | | Feb.13.08 | Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities| CORONA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the U.S. Food and Drug Administration ("FDA") has initiated an inspection
of the company's Florida facilities. No information regarding the duration or
outcome of the inspection is known.
Since September 2005, the Davie, Florida manufacturing facility has been
under Official Action Indicated ("OAI"). During that time, Watson h... |
| | | Feb.12.08 | Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia| CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that its New Drug Application (NDA) for silodosin, a novel alpha(1)-
adrenoreceptor antagonist, has been accepted for filing by the U.S. Food and
Drug Administration (FDA). Watson is seeking marketing approval of silodosin
from the FDA for the treatment of the signs and symptoms associated with
benign prostatic hyperplasia (BPH), or en... |
| | | Feb.07.08 | Watson Names Francois Menard Senior VP Generics Research and Development| CORONA, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Francois A. Menard, Ph.D., 48, as Senior Vice President,
Generics Research and Development.
Dr. Menard brings to Watson more than 20 years of pharmaceutical research
and development experience, specifically in the areas of pharmaceutical and
analytical development, biopharmaceutics, project management and regulator... |
| | | Feb.05.08 | Watson to Distribute Alendronate Tablets| CORONA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the company expects to initiate shipments of alendronate sodium in the 35
and 70 mg once weekly dosage strengths when Fosamax(R) loses market
exclusivity, which is anticipated to occur at the close of business on
February 6, 2008. Alendronate sodium is the generic version of Merck's
Fosamax(R) tablets, indicated for the treatment o... |
| | | Feb.01.08 | Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| CORONA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Paul Bisaro, Watson's president and chief executive officer, will provide
an overview and update of the Company's business at the 2008 Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday,
February 5, 2008 at 1:40 p.m. Eastern Standard Time.
This presentation will be webcast live and can be... |
| | | Jan.24.08 | Watson to Host Fourth Quarter and Full Year 2007 Earnings Conference Call and Webcast| CORONA, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its fourth quarter and full year 2007
financial results on Wednesday, February 20, 2008 prior to the open of the
U.S. financial markets. The Company will also host a conference call and
webcast at 8:30 a.m. Eastern Standard Time (EST) on February 20, 2008 to
discuss its financial results and provide ... |
| | | Jan.07.08 | Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder| - Company on Target to File NDA in Second Quarter of 2008 -
CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced
positive results today from its Phase 3 study of oxybutynin topical gel (OTG)
in patients with overactive bladder (OAB). The study met its primary endpoint
of a statistically significant reduction in incontinence episodes, and
secondary endpoints of reduction in frequency an... |
| | | Jan.03.08 | Watson Launches Generic Biaxin(R) XL| CORONA, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg
strength. Watson's Clarithromycin Extended-Release product is the generic
equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent
infections that are proven or strongly suspected to be caused by susceptible
bacteria. For the 12-months ending ... |
| | | Jan.02.08 | Watson Receives FDA Approval for Generic DuoNeb(R)| CORONA, Calif., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
Ipratropium Bromide and Albuterol Sulfate Inhalation Solution in the
0.5 mg/3 mg strength.
Watson's Ipratropium Bromide and Albuterol Sulfate product is the gene... |
| | | Dec.31.07 | Watson to Present at the JP Morgan 26th Annual Healthcare Conference| CORONA, CA, Dec 31, 2007 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the JP Morgan 26th Annual
Healthcare Conference on Monday, January 7, 2008 at 4:30 p.m. Pacific
Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceutical... |
| | | Dec.14.07 | Watson Confirms Patent Litigation With Barr Related to Seasonale(R)| CORONA, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, confirmed today
that Duramed Pharmaceuticals, Inc., a wholly owned subsidiary of Barr
Pharmaceuticals, Inc., has filed a patent lawsuit against Watson and certain
of its subsidiaries related to Quasense(TM) (levonorgestrel/ethinyl estradiol
tablets USP), Watson's generic version of Seasonale(R), an extended cycle oral
contraceptive. The lawsuit assert... |
| | | Dec.06.07 | Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation| CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has reached a settlement with Novartis Pharmaceuticals Corporation,
Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd.,
and Proterra AG (collectively "Novartis") on outstanding patent litigation
related to Watson's generic version of Exelon(R) (rivastigmine tartrate)
capsules.
Under the terms of the ... |
| | | Dec.04.07 | Watson and Biovail Settle Lawsuit Over Cardizem(R) LA| - Watson to Launch Generic Version in April 2009 -
CORONA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has reached a settlement with Biovail Laboratories International SRL
on outstanding patent litigation against Andrx Pharmaceuticals, Inc., a
subsidiary of Watson, related to Andrx's generic version of Cardizem(R) LA
(diltiazem extended-release tablets).
Under t... |
| | | Nov.27.07 | Watson Receives FDA Approval For Generic Combunox(R)| CORONA, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg
strength. Watson's Oxycodone Hydrochloride and Ibuprofen product is the
generic equivalent to Forest Laboratories I... |
| | | Nov.16.07 | Watson Names Mark Durand Chief Financial Officer| CORONA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Mark W. Durand, 48, as Senior Vice President and Chief
Financial Officer.
Mr. Durand brings to Watson more than 20 years of executive pharmaceutical
experience in finance, operations, business development and marketing. As
Senior Vice President and Chief Financial Officer for Watson, Mr. Durand will
be responsib... |
| | | Nov.13.07 | Watson Announces Presentation Time Change at Credit Suisse Healthcare Conference| CORONA, CA, Nov 13, 2007 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today a time change for the
Company's presentation at the 2007 Credit Suisse Healthcare
Conference scheduled for Thursday, November 15, 2007. Watson's
presentation will take place on November 15, 2007 at 9:00 a.m.
Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals'
Inves... |
| | | Nov.09.07 | Watson to Present at the 2007 Credit Suisse Healthcare Conference| CORONA, CA, Nov 09, 2007 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Watson's senior
management will provide an overview and update of the Company's
business at the 2007 Credit Suisse Healthcare Conference on Thursday,
November 15, 2007 at 11:00 a.m. Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site ... |
| | | Nov.07.07 | Watson Files FDA Application for Generic YAZ(R)| - Paragraph IV Patent Challenge Underway -
CORONA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market a generic
version of YAZ(R) tablets prior to the expiration of patents owned by Bayer
Schering Pharma AG and Bayer Healthcare Pharmaceuticals... |
| | | Nov.06.07 | Watson Pharmaceuticals Reports Third Quarter 2007 Results|
- Company Reports Total Net Revenue of $595 Million -
- GAAP EPS of $0.31 and Adjusted EPS of $0.33 -
CORONA, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its third quarter ended September 30, 2007.
Net revenue for the third quarter 2007 was $594.7 million and net income
was $34.6 million, or $0.31 per diluted share. Exc... |
| | | Nov.01.07 | Watson to Present at the CIBC World Markets 18th Annual Healthcare Conference| CORONA, CA, Nov 01, 2007 (MARKET WIRE via COMTEX News Network) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, announced today that Watson's senior
management will provide an overview of the Company's business at the
CIBC World Markets 18th Annual Healthcare Conference on Wednesday,
November 7, 2007 at 10:55 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site a... |
| | | Oct.29.07 | Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe| FAJARDO, Puerto Rico and CORONA, Calif., Oct. 29 /PRNewswire-FirstCall/ --
Warner Chilcott Company, Inc. and Watson Pharmaceuticals, Inc. announced today
that under a supply agreement between Warner Chilcott and Watson Pharma, Inc.,
Watson has launched Tilia(TM) Fe (norethindrone acetate and ethinyl estradiol
tablets, USP and ferrous fumarate tablets), the generic version of Warner
Chilcott's oral contraceptive Estrostep(R) Fe.
Under the terms of the agreement, Warner Chilcott will... |
| | | Oct.08.07 | Watson to Host Third Quarter 2007 Earnings Conference Call and Webcast| CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its third quarter 2007 financial results
on Tuesday, November 6, 2007 prior to the open of the U.S. financial markets.
The Company will also host a conference call and webcast at 8:30 a.m. Eastern
Standard Time (EST) on November 6, 2007 to discuss its financial results and
provide an outlook for the re... |
| | | Oct.03.07 | Watson Files Application for Generic FEMCON(R) Fe| - Paragraph IV Patent Challenge Underway -
CORONA, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market a generic
version of FEMCON(R) Fe tablets prior to the expiration of patents owned by
Warner Chilcott Company, Inc., a subsidiary of Warner C... |
| | | Sep.26.07 | Watson Receives FDA Approval for Generic Accuneb(R)| CORONA, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
albuterol sulfate inhalation solution in the 0.021% (base) and 0.042% (base)
strengths. Watson has been awarded 180 days of marketing exclusivity for being
the first to file an ANDA con... |
| | | Sep.25.07 | Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field| MENLO PARK, Calif. & CORONA, Calif.--(BUSINESS WIRE)--Sept. 25,
2007--Depomed, Inc. (NASDAQ: DEPO) and Watson Pharmaceuticals, Inc.
(NYSE: WPI) announced today that the companies have expanded their
co-promotion agreement to grant Watson the right to promote Depomed's
ProQuin(R) XR in the obstetrics/gynecology (Ob/Gyn) specialty market
area. ProQuin XR is a once-daily, extended-release formulation of
ciprofloxacin hydrochloride for the treatment of uncomplicated urinary
tract infectio... |
| | | Sep.04.07 | Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility| CORONA, Calif., Sept 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received its first U.S. Food and Drug Administration (FDA) product
approval at its Goa, India facility. During the next several months the
company plans to seek FDA approval to manufacture additional solid dosage
products at the facility. By early 2008, the Goa facility is expected to be
producing... |
| | | Sep.04.07 | Watson to Present at the Bear Stearns 20th Annual Healthcare Conference| CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bear Stearns 20th Annual Healthcare Conference on Monday,
September 10, 2007 at 3:30 p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wats... |
| | | Aug.21.07 | Watson Receives FDA Approval For Generic Duragesic(R)| CORONA, Calif., Aug 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
fentanyl transdermal system in the 25, 50, 75 & 100 mcg/hour strengths.
Fentanyl transdermal system is the generic equivalent to ALZA Corporation's
Duragesic(R),... |
| | | Aug.02.07 | Watson Announces CEO Succession Plan| - Allen Chao, Ph.D., to Retire as CEO -
- Paul Bisaro to Succeed Chao as President and Chief Executive Officer -
CORONA, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that Allen Chao, Ph.D., 61, its Chairman,
President and Chief Executive Officer, will retire as President and Chief
Executive Officer, effective September 4, 2007. Dr. Chao will remain Chairman
of the Board and, until the end of 2007, will assume ... |
| | | Aug.02.07 | Watson Pharmaceuticals Reports Second Quarter 2007 Results| - Company Reports Total Net Revenue of $603 Million - - GAAP EPS of $0.33 and Adjusted EPS of $0.34 -CORONA, Calif., Aug 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its second quarter ended June 30, 2007.
Net revenue for the second quarter 2007 was $603.0 million and net income
was $36.4 million, or $0.33 per diluted share. Excluding special items as
... |
| | | Jul.23.07 | Depomed Enters Into Promotion Agreement With Watson For Proquin® XR |
MENLO PARK, Calif. and CORONA, Calif. July 23, 2007 - Depomed, Inc. (NASDAQ: DEPO) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that Depomed and Watson Pharma have entered into a co-promotion agreement for ProQuin® XR, Depomed's extended release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections.
Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care s... |
| | | Jul.23.07 | Watson to Host Second Quarter 2007 Earnings Conference Call and Webcast| CORONA, Calif., July 23 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its second quarter 2007 financial results
on Thursday, August 2, 2007 prior to the open of the U.S. financial markets.
The Company will also host a conference call and webcast at 8:30 a.m. Eastern
Daylight Time (EDT) on August 2, 2007 to discuss its financial results and
provide an outlook for the res... |
| | | Jun.13.07 | Watson Receives FDA Final Approval for Generic Wellbutrin XL(R) 300 Mg| CORONA, Calif., June 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that
it has received final approval from the United States (U.S.) Food and Drug
Administration on its Abbreviated New Drug Application (ANDA) for bupropion
hydrochloride extended-release tablets, 300 mg. Bupropion hydrochloride
extended-release is the generic equivalent to GlaxoSmithKline's Wellbutrin
XL(R) tablets, which is indicated for th... |
| | | Jun.05.07 | Watson to Present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference| CORONA, Calif., June 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Goldman Sachs Twenty-Eighth Annual Global Healthcare
Conference on Wednesday, June 13, 2007 at 4:00 p.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at ... |
| | | May.23.07 | Watson Pharmaceuticals to Present at the Bank of America 2007 Health Care Conference| CORONA, Calif., May 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bank of America 2007 Health Care Conference on Wednesday,
May 30, 2007 at 1:20 p.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at... |
| | | May.21.07 | Watson Enters Into Agreement to Permit Sandoz to Launch Metoprolol Succinate Extended-Release 50 mg Tablets; Relinquishes 180-Day Market Exclusivity| CORONA, Calif., May 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that pursuant to an agreement with Sandoz, a subsidiary of Novartis AG, Watson
has relinquished its rights to a 180-day period of marketing exclusivity for
its 50 mg strength of metoprolol succinate extended-release tablets (the
generic equivalent to AstraZeneca PLC's Toprol XL(R) 50 mg product). Watson
was awa... |
| | | May.01.07 | Watson Pharmaceuticals Reports First Quarter 2007 Results| - Company Reports Total Net Revenue of $672 Million - - GAAP EPS of $0.29 and Adjusted EPS of $0.34 - - Company Reports Strong Adjusted EBITDA and Operating Cash Flow -CORONA, Calif., May 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its first quarter ended March 31, 2007.
Net revenue for the first quarter 2007 was $671.6 million and net income
was $31.6 m... |
| | | Apr.27.07 | Watson Pharmaceuticals to Webcast Its 2007 Annual Meeting of Stockholders| CORONA, Calif., April 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2007 Annual Meeting of
Stockholders on Friday, May 4, 2007 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watsonpharm.com. An archived version of the
webcast will be available for 30 da... |
| | | Apr.25.07 | Watson to Host First Quarter 2007 Earnings Conference Call and Webcast| CORONA, Calif., April 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its first quarter 2007 financial results
on Tuesday, May 1, 2007 following the close of the U.S. financial markets.
The Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) on May 1, 2007 to discuss its financial results and
provide an outlook for the rest of ... |
| | | Apr.09.07 | Watson Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference| CORONA, Calif., April 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference on Wednesday, April 11, 2007 at 8:00 a.m. Eastern
Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Rela... |
| | | Mar.16.07 | Watson Pharmaceuticals to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference| CORONA, Calif., March 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an update on the Company's
business at the Lehman Brothers Tenth Annual Global Healthcare Conference on
Monday, March 19, 2007 at 10:15 a.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relatio... |
| | | Feb.27.07 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Results|
Company Reports Fourth Quarter Total Net Revenue of $621 Million;
2006 Total Net Revenue Reaches $1.98 Billion;
2006 Operating Cash Flow Reaches $471 Million;
Company Provides Outlook for 2007
CORONA, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
fourth quarter and full year 2006 financial results, which i... |
| | | Feb.12.07 | Watson and GlaxoSmithKline Settle Lawsuit Over Wellbutrin Xl(R)| CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has reached a settlement with GlaxoSmithKline on outstanding patent
litigation related to Wellbutrin XL(R) (bupropion hydrochloride)
extended-release tablets 150mg.
In December 2005, Andrx Corporation filed a patent infringement lawsuit in
the U.S. District Court for the Southern District of Florida against
GlaxoSmithKline ... |
| | | Feb.01.07 | Watson to Host Fourth Quarter and Full Year 2006 Earnings Conference Call and Webcast| CORONA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its fourth quarter and full year 2006
financial results on Tuesday, February 27, 2007 following the close of the
U.S. financial markets. The Company will also host a conference call and
webcast at 5:00 p.m. Eastern Standard Time (EST) that afternoon to discuss the
results and provide an outlook for 20... |
| | | Jan.16.07 | Watson Announces Positive Phase 3 Study Results on Silodosin for Treatment of Benign Prostatic Hyperplasia| - Statistical Significance Reached on Primary and Secondary Endpoints -
CORONA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
positive top-line data from two Phase 3 studies of silodosin, the Company's
investigational drug being studied for the treatment of signs and symptoms of
benign prostatic hyperplasia (BPH).
The primary objective of the trials was to demonstrate that 8mg silod... |
| | | Dec.11.06 | Watson Appoints Thomas Giordano as Senior Vice President, Chief Information Officer| CORONA, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc., (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Thomas R. Giordano as Senior Vice President, Chief
Information Officer. Mr. Giordano will be responsible for all facets of
Watson's information technology strategy and operations domestically. Mr.
Giordano will report to Allen Chao, Ph.D., Watson's Chairman and Chief
Executive Officer.
Mr. Giordano joins Watso... |
| | | Nov.14.06 | Watson Pharmaceuticals to Present at the Credit Suisse 2006 Healthcare Conference| CORONA, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an update on the Company's
business at the Credit Suisse 2006 Healthcare Conference on Friday,
November 17, 2006 at 10:00 a.m. Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watsonpharm... |
| | | Nov.07.06 | Watson Pharmaceuticals Reports Third Quarter 2006 Results| CORONA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its third quarter ended September 30, 2006.
Net revenue for the third quarter increased seven percent to $440.5
million, compared to $410.3 million for the third quarter ended September 30,
2005. Third quarter total net revenue growth was driven by higher product
sales in the Company's Generic division as a resu... |
| | | Nov.03.06 | Watson to Present at the CIBC World Markets 17th Annual Healthcare Conference| CORONA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an update on the Company's
business at the CIBC World Markets 17th Annual Healthcare Conference on
Wednesday, November 8, 2006 at 11:30 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir... |
| | | Oct.18.06 | Watson Certifies Substantial Compliance With FTC Second Request| CORONA, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today announced that it has certified to the Federal Trade
Commission (FTC) that it believes it is in substantial compliance with the
FTC's May 1, 2006 request for additional information (also known as a second
request). The FTC issued the second request in connection with its review of
Watson's pending acquisition of Andrx Corporation (Nasdaq: ADRX) under the
Hart-Scott-Rodino Antitrust Improve... |
| | | Oct.10.06 | Watson Pharmaceuticals Announces Resignation of Chief Financial Officer| CORONA, Calif., Oct 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that Charles P. Slacik, Executive Vice President and Chief Financial Officer,
has resigned effective October 20, 2006, to take the position of Senior Vice
President and Chief Financial Officer of Beckman Coulter, Inc. Beckman
Coulter is a leading global manufacturer of biomedical testing instrument
systems and ... |
| | | Oct.10.06 | Watson to Host Third Quarter 2006 Earnings Conference Call and Webcast| CORONA, Calif., Oct 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its third quarter 2006 financial results
on Tuesday, November 7, 2006 following the close of the U.S. financial
markets. The Company will also host a conference call and webcast on
November 7, 2006 at 5:00 p.m. Eastern Standard Time (EST) to discuss the
results and provide an... |
| | | Sep.13.06 | Watson and Unimed Pharmaceuticals, Inc. Settle Lawsuit Over AndroGel(R) Testosterone Gel| - Companies Enter Into Co-Promotion Agreement for AndroGel(R) -
CORONA, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has reached a settlement with Unimed Pharmaceuticals, Inc., a wholly
owned subsidiary of Solvay Pharmaceuticals, Inc., and Laboratories Besins
Iscovesco on outstanding patent litigation related to AndroGel(R) 1%
(testosterone gel) CIII, a topical testosteron... |
| | | Sep.07.06 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Seasonale(R)| CORONA, Calif., Sept 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that
it has received final approval from the United States (U.S.) Food and Drug
Administration on its Abbreviated New Drug Application (ANDA) for
levonorgestrel / ethinyl estradiol tablets USP, 0.15 mg / 0.03 mg.
Levonorgestrel / ethinyl estradiol tablets, USP, is the generic equivalent to
Duramed Pharmaceuticals' Se... |
| | | Sep.05.06 | Watson Names Thomas Russillo as President, U.S. Generics Division| - Andrew Boyer Promoted to Senior VP, Sales and Marketing, U.S. Generics Division -CORONA, Calif., Sept 05, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc., (NYSE: WPI) today announced the appointment of Thomas R. Russillo as
Executive Vice President of the Corporation and President, U.S. Generics
Division.
"I am delighted to welcome Tom into the Watson organization," began Allen
Chao, Ph.D., Chairman and Chief Executive Officer. "I know Tom to be a
t... |
| | | Aug.08.06 | Watson Pharmaceuticals Reports Second Quarter 2006 Results| CORONA, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
financial results for its second quarter ended June 30, 2006.
Net revenue for the second quarter increased 23 percent to $510.4 million,
compared to $416.3 million for the second quarter ended June 30, 2005. Second
quarter total net revenue growth was driven by higher product sales in the
Company's Generic division as a result of new... |
| | | Jul.14.06 | Watson to Host Second Quarter 2006 Earnings Conference Call and Webcast| CORONA, Calif., July 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its second quarter 2006 financial results
on Tuesday, August 8, 2006 following the close of the U.S. financial markets.
The Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) that afternoon to discuss the results and provide an
outlook for the rest of 2006. ... |
| | | Jul.10.06 | Watson and Andrx Amend Merger Agreement; Deadline Extended to November 13, 2006 to Allow for Further FTC Review| CORONA, Calif. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--July 10,
2006--Watson Pharmaceuticals, Inc. (NYSE:WPI) and Andrx Corporation
(Nasdaq:ADRX) today announced that they have entered into an amendment
to their March 12, 2006 definitive merger agreement pursuant to which,
subject to certain conditions, the deadline to close the transaction
has been extended from September 12, 2006 until November 13, 2006. The
amendment will allow the parties additional time to confer with the
Feder... |
| | | Jun.09.06 | Watson Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference| CORONA, Calif., June 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an update on the Company's
business at the Goldman Sachs Global Healthcare Conference on Thursday, June
15, 2006 at 10:40 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watsonpharm.c... |
| | | Jun.01.06 | Watson Pharmaceuticals Receives FDA Approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1mg / 0.02mg| CORONA, Calif., June 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application for
levonorgestrel and ethinyl estradiol tablets USP, 0.1mg / 0.02mg, a generic
version of Berlex's Levlite(R) product which is indicated for the prevention
of pregnancy.
The Company intends to... |
| | | May.12.06 | Watson Pharmaceuticals to Present at the Bank of America 2006 Health Care Conference| CORONA, Calif., May 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bank of America 2006 Health Care Conference on Thursday, May
18, 2006 at 10:40 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watsonpharm... |
| | | May.09.06 | Watson Pharmaceuticals Reports First Quarter 2006 Results|
- Company Reports Total Revenue of $407 Million -
- Operating Cash Flow Remains Strong at $136 Million -
CORONA, Calif., May 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its first quarter ended March 31, 2006.
Net revenue for the first quarter increased two percent to $407.2 million,
compared to $400.8 million for the first quarter ended ... |
| | | May.09.06 | Watson Pharmaceuticals Receives FDA Tentative Approval for Generic Seasonale(R)| CORONA, Calif., May 9, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that
it has received tentative approval today from the United States (U.S.) Food
and Drug Administration on its Abbreviated New Drug Application (ANDA) for
levonorgestrel / ethinyl estradiol tablets USP, 0.15 mg / 0.03 mg.
Levonorgestrel / ethinyl estradiol tablets USP is the generic equivalent
to Duramed Pharmaceuti... |
| | | May.03.06 | Watson Pharmaceuticals to Host First Quarter 2006 Earnings Conference Call and Webcast| CORONA, Calif., May 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its first quarter 2006 financial results
on Tuesday, May 9, 2006 prior to the open of the U.S. financial markets. The
Company will also host a conference call and webcast at 8:30 a.m. Eastern
Daylight Time (EDT) that morning to discuss the results and provide an outlook
for the rest of 2006. The dial-... |
| | | May.01.06 | Watson Pharmaceuticals to Webcast Its 2006 Annual Meeting of Stockholders| CORONA, Calif., May 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2006 Annual Meeting of
Stockholders on Friday, May 5, 2006 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watsonpharm.com. An archived version of the
webcast will be available for up to 30... |
| | | Apr.25.06 | Watson Pharmaceuticals Launches Pravastatin Tablets| CORONA, Calif., April 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that under a distribution agreement with Bristol-Myers Squibb Company
(NYSE: BMY), the Company has initiated shipments of pravastatin sodium tablets
in the 10, 20 and 40 mg. strengths.
Pravastatin sodium distributed by Watson, is the authorized generic
version of Bristol-Myers Squibb's Pravachol(R) product a... |
| | | Apr.13.06 | Watson Completes Acquisition of Mumbai-Based Sekhsaria Chemicals Ltd.| CORONA, Calif., April 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced it has
completed its acquisition of Sekhsaria Chemicals Ltd. of Mumbai, India.
Sekhsaria provides process research and development and contract
manufacturing services to the global pharmaceutical industry, including the
development and manufacture of active pharmaceutical ingredients (API) and
related intermediates. The company curren... |
| | | Apr.03.06 | Watson Pharmaceuticals to Present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference| CORONA, Calif., April 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the CIBC Biotechnology and Specialty Pharmaceuticals Conference on
Tuesday, April 4, 2006 at 2:15 p.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http:... |
| | | Mar.30.06 | Watson Pharmaceuticals to Divest Injectable Manufacturing Facility in Arizona| CORONA, Calif., March 30 /PRNewswire-FirstCall/ -- As part of an ongoing
effort to optimize its manufacturing operations, Watson Pharmaceuticals, Inc.
(NYSE: WPI), a leading specialty pharmaceutical company, today announced its
plan to divest its injectable manufacturing facility located in Phoenix,
Arizona.
The Phoenix facility currently manufactures fifteen products, including
several manufactured for third parties. Over the next twelve months, the
Company plans to establish co... |
| | | Feb.16.06 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Results|
- Company Reports Fourth Quarter Total Net Revenue of $419 Million;
2005 Total Net Revenue Reaches $1.65 Billion;
Board Authorizes Up to $300 Million Share Repurchase Program;
Company Provides Outlook for 2006 -
CORONA, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its fourth quarter and full year ended Dec... |
| | | Feb.07.06 | Watson Pharmaceuticals to Host Meeting to Discuss Fourth Quarter and Full Year 2005 Results| CORONA, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will host a meeting with financial analysts at 4:30 p.m. Eastern
Standard Time on Thursday, February 16, 2006. Watson's senior management will
discuss the Company's fourth quarter and full year 2005 financial results,
outlook for 2006 and recent corporate developments. The Company plans to
release its earnings and outlook on Fe... |
| | | Jan.30.06 | Watson Pharmaceuticals Receives FDA Approval for Testosterone Gel Product| CORONA, Calif., Jan. 30 PRNewswire-FirstCall-- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
testosterone gel 1% CIII. Testosterone gel 1% CIII is the generic equivalent
to Solvay Pharmaceutical's AndroGel(R), which is indicated for replacement
therapy in males for conditions asso... |
| | | Jan.09.06 | Watson Pharmaceuticals to Present at the 24th Annual JPMorgan Healthcare Conference| CORONA, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the 24th Annual JPMorgan Healthcare Conference on Wednesday,
January 11, 2006 at 4:00 p.m. Pacific Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watsonph... |
| | | Nov.15.05 | Watson Pharmaceuticals to Present at the Credit Suisse First Boston Annual Healthcare Conference| CORONA, Calif., Nov 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Credit Suisse First Boston Annual Healthcare Conference on
Friday, November 18, 2005 at 8:30 a.m. Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relati... |
| | | Nov.04.05 | Watson Pharmaceuticals to Present at the CIBC World Markets 16th Annual Healthcare Conference| CORONA, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the CIBC World Markets 16th Annual Healthcare Conference on
Tuesday, November 8, 2005 at 3:00 p.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.... |
| | | Nov.02.05 | Watson Pharmaceuticals Reports Third Quarter 2005 Results|
- Company Reports Total Revenue of $410.3 Million;
Earnings per Share of $0.36 -
- Nine Month Cash Flow From Operations Approaches $280 Million -
CORONA, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its third quarter ended September 30, 2005. Net
revenues increased one percent to $410.3 million, as compared to
$40... |
| | | Oct.18.05 | Watson Pharmaceuticals Named Exclusive Distributor of Authorized Generic OxyContin(R) Tablets| CORONA, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with Purdue Pharma L.P., Watson has been
appointed as the exclusive distributor of authorized generic oxycodone HCl
controlled-release tablets C-II in 10, 20, 40 and 80 mg dosage strengths.
Oxycodone HCl is the generic version of Purdue's OxyContin(R) (C-II) Tablets,
a narcotic analgesic indicated for the ... |
| | | Oct.12.05 | Watson Pharmaceuticals to Host Third Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its third quarter 2005 financial results
on Wednesday, November 2, 2005 after the close of the U.S. financial markets.
The Company will also host a conference call and webcast at 5:00 p.m. Eastern
Standard Time (EST) on Wednesday, November 2, 2005 to discuss the results and
provide an outlook for the ... |
| | | Oct.11.05 | Watson Pharmaceuticals to Consolidate Solid Dosage Manufacturing Facilities| CORONA, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
its plan to consolidate certain of its solid dosage manufacturing operations,
as part of an ongoing effort to optimize the Company's manufacturing
operations.
Over the last several years, Watson has made significant improvements and
enhancements to its solid dosage manufacturing facilities, creating the
opportunity for its Carmel, ... |
| | | Sep.15.05 | Watson Pharmaceuticals Pledges Support for Hurricane Katrina Relief Effort| CORONA, Calif., Sept 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will donate $600,000 worth of brand and generic prescription drug
products and cash to support relief efforts for victims of Hurricane Katrina
in the Gulf States.
In collaboration with a number of major chain drug stores, the Company
will provide access to pharmaceutical products at no cost for pati... |
| | | Sep.13.05 | Watson Pharmaceuticals Announces Completion of $300 Million Share Repurchase Program| CORONA, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that the company has completed its $300 million share repurchase program. The
share repurchase program was announced in February 2005 and authorized the
repurchase of up to $300 million of the company's common stock over a one year
period. Watson has repurchased a total of approximately 9.4 million shares,
or $300 million of its common ... |
| | | Sep.07.05 | Watson Pharmaceuticals to Present at the Bear Stearns 18th Annual Healthcare Conference| CORONA, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bear Stearns 18th Annual Healthcare Conference on Monday,
September 12, 2005 at 9:00 a.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watson... |
| | | Aug.08.05 | Watson Pharmaceuticals Dedicates New Distribution Facility in Gurnee, Illinois| GURNEE, Ill., Aug. 8 /PRNewswire/ -- Watson Pharmaceuticals, Inc., a
leading specialty pharmaceutical company, today dedicated a new distribution
facility in Gurnee, Illinois, celebrating the completion of a distribution
operations enhancement initiative. The new 272,000 square-foot facility
nearly doubles Watson's capacity to meet its customers' growing demand for
generic and brand pharmaceutical products.
"We are thrilled to move into our new Gurnee Distribution Center and to
bec... |
| | | Aug.01.05 | Watson Pharmaceuticals Receives FDA Approval for Desogestrel and Ethinyl Estradiol Tablets USP, 0.15MG / 0.03MG| CORONA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application for
desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg, a generic
version of Ortho-McNeil's Ortho-Cept(R) and Organon's Desogen(R) products
which are indicated for the prevention of pregnanc... |
| | | Jul.27.05 | Watson Pharmaceuticals Reports Second Quarter 2005 Results| - Company Reports Total Revenue of $416 Million; Earnings Per Share of $0.35 -
- Six Month Cash Flow From Operations Exceeds $177 Million -
CORONA, Calif., July 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its second quarter ended June 30, 2005. Net revenues
increased 4 percent to $416.3 million, as compared to $399.4 million for the
second quarter ended June 30, ... |
| | | Jul.14.05 | Watson Pharmaceuticals to Host Second Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., July 14 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
(NYSE: WPI), a leading specialty pharmaceutical company, announced today that
the Company intends to release its second quarter 2005 financial results on
Wednesday, July 27, 2005 after the close of the U.S. financial markets. The
Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) on Wednesday, July 27, 2005 to discuss the results and
provide an outlook for the rest of 2005. ... |
| | | Jun.16.05 | Somerset Files Response to EMSAM(R) Action Letter| FDA Considers Response Complete - Issues PDUFA Review Date
PITTSBURGH and CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Mylan
Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI),
today announced that Somerset Pharmaceuticals, Inc. has submitted a response
to the United States Food and Drug Administration's Action letter, dated
January 30, 2004, related to EMSAM(R) (selegiline transdermal system). The
FDA has accepted Somerset's May 26, 2005 response as com... |
| | | Jun.13.05 | Watson Pharmaceuticals Commences Phase 3 Studies on Silodosin for Treatment of Benign Prostatic Hyperplasia| CORONA, Calif., June 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that it has commenced Phase 3 clinical studies on silodosin, its
investigational drug being studied to treat the signs and symptoms of Benign
Prostatic Hyperplasia (BPH). This condition is characterized by a non-
cancerous enlarged prostate that leads to obstructive and irritative urinary
symptoms. In the United States (US) BPH affects more... |
| | | Jun.10.05 | Watson Pharmaceuticals to Present at the Goldman Sachs 26th Annual Global Healthcare Conference| CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview and update of the
Company's business at the Goldman Sachs 26th Annual Global Healthcare
Conference on Thursday, June 16, 2005 at 11:00 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at... |
| | | May.16.05 | Watson Pharmaceuticals to Present at the Banc of America Securities Health Care Conference 2005| CORONA, Calif., May 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Banc of America Securities Health Care Conference on
Wednesday, May 18, 2005 at 1:20 p.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at ht... |
| | | May.09.05 | Watson Pharmaceuticals to Webcast Its 2005 Annual Meeting of Stockholders| CORONA, Calif., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2005 Annual Meeting of
Stockholders on Friday, May 13, 2005 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watsonpharm.com. An archived version of the
webcast will be availabl... |
| | | May.05.05 | Watson Pharmaceuticals Reports First Quarter 2005 Results|
- Company Reports Total Revenue of $401 Million;
Earnings per Share of $0.33 -
- Cash Flow from Operations Tops $105 Million -
CORONA, Calif., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its first quarter ended March 31, 2005. Net revenues
declined two percent to $400.8 million, as compared to $409.7 million for t... |
| | | Apr.25.05 | Watson Pharmaceuticals to Host First Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., April 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its first quarter 2005 financial results
on Thursday, May 5, 2005 after the close of the U.S. financial markets. The
Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) on Thursday, May 5, 2005 to discuss the results and
provide an outlook for 2005. The dial-in... |
| | | Apr.18.05 | Watson Pharmaceuticals Names Edward F. Heimers, Jr. President of Watson's Brand Division| Industry Veteran to Lead Company's Brand Products Initiatives CORONA, Calif., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today announced the appointment of Edward F. Heimers, Jr.,
58, as Executive Vice President of the company and President of Watson's Brand
division.
"I am very pleased to welcome Ed to the executive management team," began
Allen Chao, Ph.D., Chairman and Chief Executive Officer. "Ed's broad mix of
marketing, sales an... |
| | | Apr.04.05 | Watson Pharmaceuticals' TRELSTAR(R) DEPOT and TRELSTAR(R) LA (Triptorelin Pamoate for Injectable Suspension) Now Available Nationwide| CORONA, Calif., April 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, has made
available nationwide TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate
for injectable suspension) for the palliative treatment of advanced prostate
cancer when orchiectomy (surgical removal of the testicles) or estrogen
administration are either not indicated or are unacceptable to the patient.
TRELSTAR(R), a synthetic hor... |
| | | Mar.28.05 | Watson Pharmaceuticals to Present at the Lehman Brothers Eighth Annual Global Healthcare Conference| CORONA, Calif., March 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Lehman Brothers 8th Annual Global Healthcare Conference on
Wednesday, March 30, 2005 at 9:00 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://... |
| | | Mar.14.05 | Watson Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Healthcare Conference| CORONA, Calif., March 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the SG Cowen & Co. 25th Annual Healthcare Conference on Thursday,
March 17, 2005 at 10:30 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wats... |
| | | Feb.10.05 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Results| - Fourth Quarter Total Net Revenue Reaches $424 Million -
-2004 Total Net Revenue Grows to Over $1.6 Billion -
-Board Authorizes Up To $300 Million Share Repurchase Program -
-Company Provides Outlook for 2005 -
CORONA, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, reported today
its financial results for the fourth quarter and full year ended December 31,
2004. Total... |
| | | Feb.03.05 | Watson Pharmaceuticals to Host Fourth Quarter and Full Year 2004 Earnings Conference Call and Webcast| CORONA, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its fourth quarter and full year 2004
financial results on Thursday, February 10, 2005 after the close of the U.S.
financial markets. The Company will also host a conference call and webcast
at 5:00 p.m. Eastern Standard Time (EST) on Thursday, February 10, 2005 to
discuss the results and provide an outlo... |
| | | Jan.07.05 | Watson Pharmaceuticals to Present at the 23rd Annual JPMorgan Healthcare Conference| CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview and update of the
Company's business at the 23rd Annual JPMorgan Healthcare Conference on
Monday, January 10, 2005 at 4:00 p.m. Pacific Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wa... |
| | | Dec.22.04 | Watson Pharmaceuticals Launches Generic Bupropion Hydrochloride Sustained-Release 200mg Tablets| CORONA, Calif., Dec. 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with GlaxoSmithKline (GSK), Watson has
initiated shipments of bupropion hydrochloride sustained-release 200mg
tablets; the generic version of GSK's Wellbutrin SR(R) 200mg, which is
indicated for the treatment of depression. For the 12-months ending October
2004, Wellbutrin SR(R) 200mg had sales of approximate... |
| | | Nov.22.04 | Watson Pharmaceuticals to Present at the Lazard Life Sciences Conference| CORONA, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Lazard Life Sciences Conference on Tuesday, November 30, 2004
at 1:00 p.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watsonp... |
| | | Nov.22.04 | Watson Pharmaceuticals Receives FDA Approval For Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1MG / 0.02MG|
CORONA, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application for levonorgestrel and ethinyl estradiol tablets USP, 0.1mg / 0.02mg, a generic version of Wyeth's Alesse(R), which is indicated for the prevention of pregnancy.
The Company intends to in... |
| | | Nov.08.04 | Watson Pharmaceuticals Receives FDA Approval for Citalopram Hydrobromide Tablets 10MG, 20MG and 40MG| CORONA, Calif., Nov 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
citalopram hydrobromide tablets, in the 10 mg, 20 mg and 40 mg strengths.
Citalopram hydrobromide tablets are the generic version of Forest
Laboratories' Celexa(R), which is indi... |
| | | Nov.04.04 | Watson Pharmaceuticals to Present at the CIBC World Markets 15th Annual Healthcare Conference| CORONA, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the CIBC World Markets 15th Annual Healthcare Conference on
Wednesday, November 10, 2004 at 11:30 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://i... |
| | | Oct.27.04 | Watson Pharmaceuticals Reports Third Quarter 2004 Results|
- Total Net Revenue Increases to $408 Million -
- Strong Cash Flow From Operations at $110 Million -
CORONA, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, reported today
its financial results for the three and nine months ended September 30, 2004.
Total net revenue for the third quarter of 2004 increased 14 percent to
$408.0 million, as compared to $358.8 million for... |
| | | Oct.25.04 | Watson Pharmaceuticals Announces Senior Management Change|
- Company Initiates Search for Two Business Unit Presidents -
- Watson's President and Chief Operating Officer to Depart -
CORONA, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the strategic decision to create the position of President for each of its
business units, Brands and Generics, reporting directly to Allen Chao, Ph.D.,
Watson's Chairman and Chief Executive... |
| | | Oct.20.04 | Watson Pharmaceuticals to Host Third Quarter 2004 Earnings Conference Call and Webcast| CORONA, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its third quarter 2004 financial results
on Wednesday, October 27, 2004 after the close of the trading day. The
Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time on that day to discuss the results and provide an outlook for
the fourth quarter and full year 2004. The... |
| | | Oct.05.04 | Watson Pharmaceuticals Provides Update on Genelabs Technologies' Clinical Trial GL02-01 in Women With Systemic Lupus Erythematosus| CORONA, Calif., Oct 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
that Genelabs Technologies, Inc. has announced preliminary results of its
Phase III clinical trial, Study GL02-01, for Genelabs' investigational drug,
Prestara(TM) (prasterone). Watson holds exclusive North American rights to
Prestara.
According to Genelabs' announcement, a preliminary analysis of the
clinical trial indi... |
| | | Sep.29.04 | Watson Pharmaceuticals and Debiopharm S.A. Enter Into an Exclusive Licensing Agreement for Two Approved Urology Products - TRELSTAR(R) DEPOT and TRELSTAR(R) LA| CORONA, Calif. and LAUSANNE, Switzerland, Sept. 29 /PRNewswire/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company,
announced today that it has entered into a licensing agreement with Debiopharm
S.A., the independent drug-development company specializing in oncology,
endocrinology, CNS and niche diseases, to market TRELSTAR(R) DEPOT 3.75mg and
TRELSTAR(R) LA 11.25mg (triptorelin pamoate), within the United States (U.S.)
and Canada. Debiopharm will supp... |
| | | Sep.20.04 | Watson Pharmaceuticals to Present at the Banc of America Securities 34th Annual Investment Conference| CORONA, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Banc of America Securities 34th Annual Investment Conference
on Thursday, September 23, 2004 at 8:30 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at... |
| | | Sep.08.04 | Watson Pharmaceuticals to Present at the Bear Stearns 17th Annual Healthcare Conference| CORONA, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bear Stearns 17th Annual Healthcare Conference on Tuesday,
September 14, 2004 at 3:45 p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watso... |
| | | Aug.03.04 | Watson Pharmaceuticals Reports Second Quarter 2004 Results| - Earnings in Line With Recent Forecasts - CORONA, Calif., Aug 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, reported today
its financial results for the second quarter of 2004. Total net revenue
increased 12 percent to $399.4 million, as compared to $355.9 million for the
second quarter ended June 30, 2003. Second quarter total net revenue growth
was driven by a strong performance in the Company's Gener... |
| | | Aug.02.04 | Watson Pharmaceuticals Receives FDA Approval for Mint Flavor Nicotine Gum| CORONA, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.
Nicotine polacrilex gum, mint flavor, is the generic version of
GlaxoSmithKline Consumer Healthcare's Nicorette(R) Mint gum, which ... |
| | | Jul.21.04 | Watson Names James Nash as Executive Vice President, Supply Chain| CORONA, Calif., July 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the appointment of James A. Nash, 54, as Executive Vice President, Supply
Chain, responsible for manufacturing operations and quality assurance for
Watson's business. He will report to Joseph Papa, Watson's President and
Chief Operating Officer. The Company's compliance function concerning the
quality initiatives at the Company's Corona, ... |
| | | Jul.19.04 | Watson Pharmaceuticals to Host Second Quarter 2004 Earnings Conference Call and Webcast| CORONA, Calif., July 19 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its second quarter 2004 financial results
on Tuesday, August 3, 2004 before the open of the trading day. The Company
will also host a conference call and webcast at 8:30 a.m. Eastern Daylight
Time on that day to discuss the results and provide an outlook for the third
quarter and full year 2004. The dia... |
| | | Jun.28.04 | Watson Pharmaceuticals Refocuses Business Strategy| - Concentration on Urology, Nephrology and Generic Products Allows Company to Streamline Its Operational Structure and Gain Cost Efficiencies - CORONA, Calif., Jun 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that following an extensive strategic and operational review of its business,
the Company is refocusing its product development and sales and marketing
resources to concentrate on th... |
| | | Jun.28.04 | Watson Pharmaceuticals Updates Second Quarter and Full Year 2004 Estimates| - Company Anticipates Lower Oral Contraceptives Product Sales
Partially Offset By Stronger Generic Revenue -
CORONA, Calif., June 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company has revised its total net revenue and earnings estimates for
the second quarter of 2004. Net revenue for the second quarter of 2004 is
estimated to be approximately $400.0 million, due to lower... |
| | | Jun.23.04 | Health Canada Approves Watson Pharmaceuticals' OXYTROL(R) for the Treatment of Overactive Bladder| CORONA, Calif., June 23 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Therapeutic Products Directorate of Health Canada has approved
OXYTROL(R) (oxybutynin transdermal system), Watson's novel transdermal patch
for the treatment of overactive bladder, with symptoms of urge urinary
incontinence, urgency, and frequency.
OXYTROL(R) was accepted for regulatory review by the Therapeutic Products
Dir... |
| | | Jun.21.04 | Watson Pharmaceuticals' Transdermal Therapy for Urge Incontinence Approved for Marketing in the European Union| CORONA, Calif., Jun 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the European Union's Commission of the European Communities has granted
marketing authorization to Watson's oxybutynin transdermal product for the
symptomatic treatment of urge incontinence and/or increased urinary frequency
and urgency as may occur in patients with unstable bladder.
Approval of the application, fil... |
| | | Jun.16.04 | Watson Pharmaceuticals Receives New Patent on OXYTROL(R)| - Patent Covers Methods for Administration, Extending OXYTROL(R) Intellectual Property Position to 2020 - CORONA, Calif., Jun 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the issuance by the United States Patent and Trademark Office of patent number
6,743,441, entitled "Compositions and Methods for Minimizing Adverse Drug
Experiences Associated with Oxybutynin Therapy." This patent covers... |
| | | Jun.16.04 | Watson Pharmaceuticals Announces Launch of New Acute Pain Product in Collaboration With Interpharm| REPREXAIN(TM) Combines the Most Commonly Prescribed Dose of Hydrocodone in a
Combination, with the Most Commonly Prescribed Non Steroidal
Anti-Inflammatory, Ibuprofen, Providing a New Treatment Option
for Millions of Pain Sufferers
CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the launch of REPREXAIN(TM) CIII (5 mg hydrocodone bitartra... |
| | | Jun.03.04 | Watson Pharmaceuticals to Present at the Goldman Sachs 25th Annual Global Healthcare Conference| CORONA, Calif., June 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Goldman Sachs 25th Annual Global Healthcare Conference on
Wednesday, June 9, 2004 at 4:40 p.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wa... |
| | | May.28.04 | Watson Pharmaceuticals Launches Generic Zyban(R)| CORONA, Calif., May 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with GlaxoSmithKline (GSK), Watson has
initiated shipments of bupropion hydrochloride sustained-release tablets, in
the 150mg strength. The product is the generic version of GlaxoSmithKline's
Zyban(R), which is indicated for smoking cessation. For the 12-months ending
March 2004, Zyban(R) 150mg had sales of a... |
| | | May.14.04 | Watson Pharmaceuticals to Present at the Banc of America Securities 2004 Healthcare Conference| CORONA, Calif., May 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Banc of America Securities 2004 Healthcare Conference on
Friday, May 21, 2004 at 10:40 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watso... |
| | | May.12.04 | Watson Pharmaceuticals to Webcast Its 2004 Annual Meeting of Stockholders| CORONA, Calif., May 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2004 Annual Meeting of
Stockholders on Monday, May 17, 2004 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watsonpharm.com. An archived version of the
webcast will be available at the same ... |
| | | May.07.04 | Watson Pharmaceuticals to Present at the Credit Suisse First Boston Specialty Pharmaceuticals/Generics Conference| CORONA, Calif., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Credit Suisse First Boston Specialty Pharmaceuticals/Generics
Conference on Thursday, May 13, 2004 at 1:30 p.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site... |
| | | May.04.04 | Watson Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference| CORONA, Calif., May 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Morgan Stanley Global Healthcare Unplugged Conference on
Thursday, May 6, 2004 at 10:30 a.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watso... |
| | | Apr.28.04 | Watson Pharmaceuticals Reports First Quarter 2004 Results| - Total Net Revenue Increases 22 Percent to Record $410 Million -
CORONA, Calif., April 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its first quarter ended March 31, 2004. Net revenues
increased 22 percent to $409.7 million, compared to $336.9 million for the
first quarter ended March 31, 2003. First quarter revenue growth was driven
by strong performance in the Compan... |
| | | Apr.26.04 | Watson Pharmaceuticals Announces Senior Management Departure| CORONA, Calif., April 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that Ian McInnes, Ph.D., Executive Vice President, Supply Chain, is leaving
Watson to accept a position at another pharmaceutical company. A search for
Dr. McInnes' replacement has been initiated.
"As a result of Ian's leadership and the efforts of our operational teams,
we have made tremendous strides in enhancing and solidifying o... |
| | | Apr.22.04 | Watson Pharmaceuticals Announces Agreement With Kissei for Novel Urology Drug Candidate| CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has entered into an exclusive licensing agreement with Kissei
Pharmaceutical Co., Ltd. to develop and market KMD-3213, Kissei's novel agent
for the treatment of the signs and symptoms of benign prostatic hyperplasia
(BPH).
KMD-3213, silodosin, is a highly selective alpha-1a adrenoceptor
antagonist that relaxes smooth muscles... |
| | | Apr.22.04 | Watson Pharmaceuticals to Host First Quarter 2004 Earnings Conference Call and Webcast| CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will release its first quarter 2004 financial results on Wednesday,
April 28, 2004 after the close of the trading day. The Company will also host
a conference call and webcast at 2:00 p.m. Pacific Daylight Time on that day
to discuss the results and provide an outlook for the second quarter and full
year 2004. The dial-in number ... |
| | | Apr.15.04 | Watson Pharmaceuticals Announces Vacating of Consent Decree at Its Steris Laboratories Facility| CORONA, Calif., April 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the United States District Court for the District of Arizona has entered
an order vacating the Consent Decree of Condemnation and Permanent Injunction
previously entered against Steris Laboratories, Inc. (Steris) on October 21,
1998. The court entered the order vacating the consent decree upon Steris'
request, which the United States... |
| | | Apr.08.04 | Watson Pharmaceuticals Launches Terconazole Vaginal Cream 0.8%| CORONA, Calif., April 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has initiated shipments of terconazole in a 3-day cream. Terconazole
vaginal cream 0.8% is the equivalent of Terazol(R) 3 (terconazole) vaginal
cream 0.8%, and is indicated for the local treatment of vulvovaginal
candidiasis. For the 12-months ending February 2004, Terazol(R) 3 vaginal
cream 0.8% had sales of approximately $27.7 m... |
| | | Mar.26.04 | Watson Pharmaceuticals Appoints Catherine M. Klema to Board Of Directors| CORONA, Calif., Mar 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Catherine Klema has been appointed to the Company's Board of Directors.
Ms. Klema currently is President, Nettleton Advisors LLC, a financial
advisory and strategic consulting company, where she is responsible for
assisting healthcare clients in developing acquisition strategies, analyzing
business prospects and exe... |
| | | Mar.24.04 | Watson Pharmaceuticals Launches Generic Macrobid(R)| CORONA, Calif., March 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with Procter & Gamble Pharmaceuticals, the
Company has initiated shipments of nitrofurantoin monohydrate/macrocrystals
capsules, the authorized generic version of Procter & Gamble's Macrobid(R).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Macrobid(R) is indicated for the trea... |
| | | Mar.22.04 | Watson Pharmaceuticals Launches Generic Bupropion HCL Sustained-Release 150mg| CORONA, Calif., Mar 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with GlaxoSmithKline (GSK), Watson has
initiated shipments of bupropion hydrochloride sustained-release tablets, in
the 150mg strength. The product is the generic version of GlaxoSmithKline's
Wellbutrin SR(R), which is indicated for the treatment of depression. For the
12-months ending Januar... |
| | | Mar.15.04 | Watson Names Gordon Munro, Ph.D., Senior Vice President, Quality Assurance| CORONA, Calif., Mar 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the appointment of Gordon Munro, Ph.D., 57, to Senior Vice President, Quality
Assurance. Dr. Munro replaces Donald Britt, who will be retiring later this
year.
"We are extremely delighted to welcome Gordon to the Watson organization
and to our senior management team," began Allen Chao, Ph.D., Chairman and
Chief Executi... |
| | | Mar.09.04 | Watson Pharmaceuticals Announces Expiration of Tender Offer for 7 1/8% Senior Notes| CORONA, Calif., Mar 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today the expiration of its previously announced
cash tender offer for all of its $150 million principal amount of 7 1/8%
Senior Notes due 2008 (the "Notes"). The tender offer expired on March 5,
2004 at 5:00 p.m., New York City time (the "Expiration Date"). All Notes
validly tendered and not properly withdrawn pursuant to the tender offer have
been accepted for payment by ... |
| | | Mar.05.04 | Watson Pharmaceuticals to Present at the SG Cowen Securities 24th Annual Healthcare Conference| CORONA, Calif., March 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the SG Cowen 24th Annual Healthcare Conference on Thursday, March
11, 2004 at 8:00 a.m. and 9:00 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com. Click on... |
| | | Mar.01.04 | Watson Pharmaceuticals to Present at the Raymond James 25th Annual Institutional Investors Conference| CORONA, Calif., March 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Raymond James 25th Annual Institutional Investors Conference
on Wednesday, March 3, 2004 at 11:00 a.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com. Click on Investors, a... |
| | | Mar.01.04 | Watson Pharmaceuticals to Present at the Lehman Brothers Healthcare Conference| CORONA, Calif., Mar 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Lehman Brothers Healthcare Conference on Thursday,
March 4, 2004 at 2:30 p.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com . Click on Inves... |
| | | Feb.25.04 | Watson Pharmaceuticals Announces Agreement With Novartis Consumer Health, Inc.| CORONA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has entered into an agreement with Novartis Consumer Health, whereby,
on Watson's behalf, Novartis will promote Watson's nicotine polacrilex gum,
2mg and 4mg, to specified retail outlets to which Watson does not currently
promote. Watson's nicotine polarcrilex gum is used as an aid for smoking
cessation. Terms of the agreement wer... |
| | | Feb.20.04 | Watson Pharmaceuticals to Present at the Fourth Annual Smith Barney Citigroup Specialty Pharmaceuticals Conference| CORONA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Fourth Annual Smith Barney Citigroup Specialty Pharmaceuticals
Conference on Wednesday, February 25, 2004 at 1:00 p.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com . Clic... |
| | | Feb.20.04 | Watson Pharmaceuticals Announces Receipt of Required Consents in Connection With Tender Offer for 7 1/8 Percent Senior Notes| CORONA, Calif., Feb 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that in connection with its cash tender offer to purchase all of its
outstanding 7 1/8 percent Senior Notes due 2008 (the "Securities") and the
related consent solicitation, the Company has received the required consents
to eliminate substantially all of the restrictive covenants of the indenture
governing the Securities and... |
| | | Feb.05.04 | Watson Pharmaceuticals Reports Earnings Per Share Of $0.48 for Fourth Quarter 2003| - Total Net Revenue Increases 23 Percent to Record $406 Million - - Company Provides Outlook for Growth in 2004 - CORONA, Calif., Feb 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its fourth quarter and full year ended December 31,
2003. Net revenue increased 23 percent to a record $406.2 million, compared
to $329.6 million for the fourth quarter ended December 31, 2... |
| | | Feb.05.04 | Watson Pharmaceuticals Announces Tender Offer To Repurchase Its 7 1/8% Senior Notes| CORONA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today commenced
a cash tender offer and consent solicitation for all of its $150,000,000
principal amount of 7 1/8% Senior Notes due 2008 (the "Notes").
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Under the terms of the tender offer, Watson is offering to purchase the
Notes at a price (referred to as the "Tender Offer Consi... |
| | | Feb.02.04 | Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of 'Approvable' Letter for EMSAM| PITTSBURGH & CORONA, Calif.--(BUSINESS WIRE)--Feb. 2, 2004--Mylan
Laboratories Inc. (NYSE: MYL - News ) and Watson Pharmaceuticals, Inc.
(NYSE: WPI - News ) announced today that Somerset Pharmaceuticals, Inc. has
received an "Approvable" letter from the U.S. Food and Drug
Administration (FDA) for EMSAM(TM) (selegiline transdermal system),
the company's transdermal therapy for which they are seeking an
indication for the treatment of major depressive disorder. Somerset is
a joint ventu... |
| | | Jan.29.04 | Watson Pharmaceuticals to Host Meeting to Discuss Fourth Quarter and Full Year 2003 Results| CORONA, Calif., Jan 29, 2004 /PRNewswire-FirstCall via Comtex/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will host a meeting with financial analysts at 5:00 p.m. Eastern
Standard Time on Thursday, February 5, 2004. Watson's senior management will
discuss the Company's fourth quarter and full year 2003 financial results,
outlook for 2004 and recent corporate events. The Company plans to release
its earnings and outlook... |
| | | Jan.16.04 | Watson Pharmaceuticals Launches Generic Bupropion HCl Sustained Release 100mg| CORONA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with GlaxoSmithKline (GSK), the Company has
initiated shipments of bupropion hydrochloride sustained-release tablets, in
the 100mg strength. The product is the generic version of GlaxoSmithKline's
Wellbutrin SR(R) which is indicated for the treatment of depression. For the
12-months ending November 2003, Wel... |
| | | Jan.08.04 | Watson Pharmaceuticals Enters Into Licensing Agreement With Paladin for OXYTROL(R) in Canada| CORONA, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has entered into a Canadian licensing agreement with Paladin Labs Inc.
(TSX: PLB) to market OXYTROL(R), (oxybutynin transdermal system), Watson's
novel transdermal patch for the treatment of overactive bladder, with symptoms
of urge urinary incontinence, urgency, and frequency. Terms of the agreement
were not disclosed. According t... |
| | | Jan.07.04 | Watson Pharmaceuticals to Present at the 22nd Annual JPMorgan Healthcare Conference| CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the 22nd Annual JPMorgan Healthcare Conference on Thursday,
January 15, 2004 at 9:00 a.m. PST.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
This presentation will be webcast live and can be accessed at Watson
Pharmaceutical... |
| | | Dec.29.03 | Watson Pharmaceuticals Launches TriNessa(TM) Oral Contraceptive| - Represents Watson's 5th Oral Contraceptive Product Launch in 2003 -
CORONA, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has initiated shipments of TriNessa(TM) (norgestimate and ethinyl
estradiol tablets), the authorized brand equivalent of the oral contraceptive
Ortho Tri-Cyclen(R), marketed by Ortho-McNeil Pharmaceutical, Inc.
TriNessa(TM) is indicated for the prevention of... |
| | | Dec.12.03 | Watson Pharmaceuticals Reports Receipt of Subpoena From Office of Inspector General| CORONA, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it's subsidiary, Watson Pharma, Inc., received a subpoena duces tecum
from the Office of the Inspector General (OIG) of the Department of Health and
Human Services. The subpoena requests documents related specifically to
physician meetings sponsored by Watson Pharma during 2002 and 2003 with
respect to Ferrlecit(R) (sodium ferric gluc... |
| | | Dec.10.03 | Watson Pharmaceuticals Announces Preliminary Results From Phase III Onychomycosis Trials| CORONA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
preliminary results from two Phase III trials of its topical anti-fungal
therapy for the treatment of onychomycosis, or nail fungus.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Two multi-center, double blind, randomized Phase III trials compared the
safety, efficacy and tolerability of the topical anti-fung... |
| | | Nov.28.03 | Watson Pharmaceuticals Expands Alliance with Cipla Ltd.| - Companies Identify Additional Generic Products for Development -
CORONA, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
the expansion of its generic product development alliance with Cipla Ltd., the
second largest pharmaceutical company in India. The companies' original
agreement was announced in December 2002.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
... |
| | | Nov.24.03 | Watson Pharmaceuticals' OXYTROL(R) Receives Positive Opinion for Approval in the European Union| CORONA, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the European Agency for the Evaluation of Medicinal Products' (EMEA)
Committee for Proprietary Medicinal Products (CPMP) provided a positive
opinion on the Company's European marketing authorization application for its
oxybutynin transdermal product for the treatment of overactive bladder. The
CPMP opinion serves as the basis for a Eu... |
| | | Nov.19.03 | Watson Pharmaceuticals Launches Generic Glucotrol XL(R) 5 mg and 10 mg Tablets| - Represents Watson's 16th Generic Product Launch in 2003 -
CORONA, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has initiated shipments of glipizide extended-release tablets in the
5 mg and 10 mg strengths. Glipizide extended-release is the generic
equivalent of Pfizer Inc.'s Glucotrol XL(R) and is indicated as an adjunct to
diet for the control of hyperglycemia and its associ... |
| | | Nov.10.03 | Watson Pharmaceuticals Receives FDA Final Approval for Generic Glucotrol XL(R) 10 mg Tablets| CORONA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
glipizide extended-release tablets in the 10 mg strength. Glipizide
extended-release is the generic equivalent of Pfizer Inc.'s Glucotrol XL(R)
and is indicated as an adjunct to diet for the contr... |
| | | Nov.06.03 | Watson Pharmaceuticals to Present At The Fourteenth Annual CIBC Healthcare Conference| CORONA, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that Watson's senior management will provide
an overview of the Company's business at the Fourteenth Annual CIBC Healthcare
Conference on Wednesday, November 12, 2003 at 2:00 p.m. EST.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com . Click o... |
| | | Nov.05.03 | Watson Pharmaceuticals Reports Earnings Per Share Growth of 24 Percent To $0.47 for Third Quarter 2003| Click
here for a printable (PDF) version of this release - Revenues Increase 17 Percent to Record $359 Million -
CORONA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
record revenue for its third quarter ended September 30, 2003. Net revenue
increased 17 percent to $358.8 million, compared to $307.9 million for the
third quarter ended September 30, 2002. The Company's General... |
| | | Oct.28.03 | Watson Pharmaceuticals Acquires Research and Development Subsidiary From Amarin Corporation| - Significantly Expands Company's Drug Delivery Platform and R&D Resources - CORONA, Calif., Oct 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has acquired Amarin Development AB (ADAB), a wholly-owned drug
development subsidiary of Amarin Corporation plc (Nasdaq: AMRN). Under the
terms of the agreement, Watson made a cash payment of approximately
$15 million to Amarin. On a repor... |
| | | Oct.21.03 | Watson to Host Third Quarter 2003 Earnings Conference Call| CORONA, Calif., Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will host a conference call and webcast on Wednesday, November 5, 2003
at 8:30 a.m. Eastern Standard Time to discuss the Company's third quarter 2003
financial results, outlook for the fourth quarter and full year 2003, and
recent corporate developments. The dial-in number to access the call is
(877) 251-7980, or fr... |
| | | Oct.20.03 | Watson Pharmaceuticals Launches Generic Percocet(R) 7.5 Mg / 325 Mg and 10 Mg / 325 Mg| - Company Exceeds Target With 14 Generic Product Launches Year-to-Date - CORONA, Calif., Oct 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has initiated shipments of oxycodone and acetaminophen (APAP) tablets
in 7.5 mg / 325 mg and 10 mg / 325 mg strengths. Oxycodone/APAP is the
generic equivalent to Endo Pharmaceuticals' Percocet(R) tablets and is
indicated for the relief of mode... |
| | | Sep.24.03 | Watson Pharmaceuticals Announces European Commercialization Agreement With UCB Pharma for OXYTROL(TM)| CORONA, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has entered into a marketing and supply agreement, whereby UCB Pharma
will market Watson's oxybutynin transdermal product in Europe. Watson
currently markets the product in the United States as OXYTROL(TM).
OXYTROL(TM) is the first and only transdermal therapy for the treatment of
overactive bladder with symptoms of urge urinary i... |
| | | Sep.16.03 | Watson Pharmaceuticals to Present at The Banc of America Securities 33rd Annual Investment Conference| CORONA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Banc of America Securities 33rd Annual Investment Conference
on Thursday, September 18, 2003 at 3:00p.m. Pacific Daylight Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
The presentation will be webcast live and can... |
| | | Sep.16.03 | Watson Receives FDA Final Approval for Nefazodone HCl| CORONA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
nefazodone hydrochloride tablets in the 100 mg, 150 mg, 200 mg and 250 mg
strengths. Nefazodone hydrochloride is the generic equivalent of
Bristol-Myers Squibb's Serzone(R) and is indicated for t... |
| | | Sep.09.03 | Watson Receives FDA Final Approval For Generic Glucotrol XL(R) 5 mg Tablets| Company Receives Tentative Approval on Glucotrol XL(R) 10 mg Tablets
CORONA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received approval from the United States Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
glipizide extended-release tablets in the 5 mg strength. Additionally, the
company received tentative approval for the 10 mg s... |
| | | Sep.08.03 | Watson Receives FDA Approval for Generic Percocet(R) 7.5mg/325mg and 10mg/325mg| Will Represent Watson's 12th Generic Product Launch in 2003
CORONA, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States Food and Drug
Administration on its Abbreviated New Drug Application for Oxycodone and
Acetaminophen (APAP) tablets in 7.5mg/325mg and 10mg/325mg strengths.
Oxycodone/APAP is the generic equivalent to Endo Pharmaceut... |
| | | Sep.02.03 | Watson Pharmaceuticals to Present at the Bear Stearns 16th Annual Healthcare Conference| CORONA, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bear Stearns 16th Annual Healthcare Conference on Monday,
September 8, 2003 at 11:30 a.m. EDT.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
This presentation will be webcast live and can be accessed at Watson
Pharmaceu... |
| | | Aug.27.03 | Watson Pharmaceuticals Files Abbreviated New Drug Application For Generic AndroGel(R)| - Patent Challenge Underway for Potential 180-Day Exclusivity - CORONA, Calif., Aug 27, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed
that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market a generic
version of AndroGel(R) (testosterone gel) prior to the expiration of a patent
owned by Unimed Pharmaceuticals, Inc.... |
| | | Aug.21.03 | Mylan Laboratories and Watson Pharmaceuticals Announce FDA Acceptance of Resubmission of New Drug Application for EMSAM Antidepressant Patch| Supplemental Clinical Data Supporting Safety and Efficacy Provided to FDA
PITTSBURGH & CORONA, Calif.--(BUSINESS WIRE)--Aug. 21, 2003--
Mylan Laboratories Inc. (NYSE: MYL - News ) and Watson Pharmaceuticals,
Inc. (NYSE: WPI - News ) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing Somerset Pharmaceutical,
Inc.'s EMSAM(TM) selegiline transdermal therapy for which Somerset is
seeking marketing clearance for the treatment of depression. Somerse... |
| | | Aug.05.03 | Watson Pharmaceuticals Reports Second Quarter 2003 Financial Results| Click
here for a printable (PDF) version of this release
- Revenues Increase 19 Percent to Record $356 Million - - Company Reports EPS of $0.47 - CORONA, Calif., Aug 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
net revenues increased 19 percent to a record $355.9 million for the second
quarter ended June 30, 2003, compared to $300.1 million for the second quarter
ended June 30, 2002.... |
| | | Aug.04.03 | Watson Launches Generic Ceftin(R)| CORONA, Calif., Aug. 4 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, announced today that it has launched a generic equivalent of
GlaxoSmithKline's Ceftin(R) (cefuroxime axetil) tablets in 250mg and 500mg.
Cefuroxime Axetil is indicated for mild to moderate infections caused by
susceptible strains of bacteria which include infections of the throat, lungs,
ears, skin, sinuses, and urinary tract. It is also used for treatment... |
| | | Aug.01.03 | Watson to Host Second Quarter 2003 Earnings Conference Call| Click
here for a printable (PDF) version of this release
CORONA, Calif., Aug 1, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will host a conference call and webcast on Tuesday, August 5, 2003 at
8:30 a.m. Pacific Daylight Time to discuss the Company's second quarter 2003
financial results and outlook for the third quarter and full year 2003. The
dial-in number to access the cal... |
| | | Jun.19.03 | Watson Receives FDA Approval for Generic Remeron(R)| CORONA, Calif., June 19 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, announced today that it has received final approval from the United
States Food and Drug Administration on its Abbreviated New Drug Application
for mirtazapine tablets in 15mg, 30mg and 45mg strengths. Mirtazapine is the
generic equivalent to Organon's Remeron(R) tablets and is indicated for the
treatment of major depressive disorder. Watson intends to s... |
| | | Jun.16.03 | Watson Names Ian McInnes, Ph.D. as Executive Vice President, Supply Chain| Industry Veteran to Oversee All Supply Chain Operations
CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
the appointment of Ian McInnes, Ph.D., 51, as Executive Vice President, Supply
Chain. In this new position, Dr. McInnes will be responsible for
manufacturing operations, quality assurance and quality control for Watson's
business. He will report to Joseph Papa, Watson's Preside... |
| | | Jun.10.03 | Watson Pharmaceuticals to Present at the Goldman Sachs 24th Annual Global Healthcare Conference| CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Goldman Sachs 24th Annual Global Healthcare Conference on
Wednesday, June 11, 2003 at 4:40 p.m. PDT.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com . Click on Investors, and t... |
| | | Jun.02.03 | Watson Launches JOLIVETTE(TM) Oral Contraceptive| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jun 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has launched JOLIVETTE(TM) (norethindrone tablets), a brand equivalent
of the oral contraceptive Ortho-Micronor(R), marketed by Ortho-McNeil
Pharmaceutical, Inc. In 2002, Ortho-Micronor(R) had annual sales of
approximately $51 million. JOLIVETTE(TM) is i... |
| | | May.30.03 | Watson Pharmaceuticals to Present at the UBS Warburg Global Specialty Pharmaceutical Conference| CORONA, Calif., May 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the UBS Warburg Global Specialty Pharmaceutical Conference on
Thursday, June 5, 2003 at 11:30 a.m. EDT.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' Web site www.watsonpharm.com. Click on Investors, and then... |
| | | May.27.03 | Watson Pharmaceuticals to Present at the Friedman Billings Ramsey Seventh Annual Technology and Growth Investor Conference| Click
here for a printable (PDF) version of this release
CORONA, Calif., May 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Friedman Billings Ramsey Seventh Annual Technology and Growth
Investor Conference on Wednesday, May 28, 2003 at 3:30 p.m. EDT.
This presentation will be webcast live and can be a... |
| | | May.23.03 | Watson's New Drug Submission for OXYTROL(TM) Accepted for Review in Canada| Click
here for a printable (PDF) version of this release
CORONA, Calif., May 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that its New Drug Submission for OXYTROL(TM) (oxybutynin transdermal system)
has been accepted for review by the Canadian regulatory authorities.
OXYTROL(TM) (oxybutynin transdermal system), the first and only transdermal
therapy to treat overactive bladder (OAB)... |
| | | May.15.03 | Watson Pharmaceuticals to Webcast Its 2003 Annual Meeting of Stockholders| Click
here for a printable (PDF) version of this release
CORONA, Calif., May 15 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, announced today that the Company will conduct a live webcast of its
2003 Annual Meeting of Stockholders on Monday, May 19, 2003 at 9:00 a.m. PDT.
The live presentation can be accessed at Watson Pharmaceuticals' Web site
www.watsonpharm.com . Click on Investors, and then click on Eve... |
| | | May.06.03 | Watson Pharmaceuticals Reports First Quarter 2003 Results| Click
here for a printable (PDF) version of this release
First Quarter Revenues Increase to Record $337 Million; Earnings Per Share Increases to $0.44 -
CORONA, Calif., May 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, announced today that for the first quarter ended March 31, 2003, net
revenues increased 18 percent to a record $336.9 million, compared to
$285.7 million for the first quarter of 20... |
| | | May.05.03 | Watson Names Charles P. Slacik as Executive Vice President and Chief Financial Officer| Click
here for a printable (PDF) version of this release
Veteran to Run Company's Financial Operations CORONA, Calif., May 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the appointment of
Charles P. Slacik, 49, as Executive Vice President and Chief Financial
Officer.
"I am pleased to welcome Charlie to the executive management team and to
our expanding Watson family," began Allen Chao, Ph.D., Chairman and Chief
Executive Offi... |
| | | May.05.03 | Watson Pharmaceuticals Expands Alliance With Cipla Ltd.| Click
here for a printable (PDF) version of this release
Generic Product Pipeline Grows to More Than 60 Products, Including 20 ANDAs and Several Near-Term Product Launch Opportunities
CORONA, Calif., May 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, today announced the expansion of its generic product development
alliance with Cipla Ltd.
Under the terms of the expanded agreement, Cipla will dev... |
| | | Apr.30.03 | Data Presentations Support Efficacy and Tolerability of OXYTROL(TM) (Oxybutynin Transdermal System) in Treating Women Suffering From Symptoms of Overactive Bladder| Click
here for a printable (PDF) version of this release
Additional Analyses of OXYTROL's(TM) Phase 3 Study Data Presented During the
Annual Meeting of the American College of Obstetricians and Gynecologists
NEW ORLEANS, April 30 /PRNewswire/ -- OXYTROL(TM) (oxybutynin transdermal
system) is effective, well tolerated, and significantly reduces the number of
incontinent episodes associated with overactive bladder (OAB) with a low
incidence of anticholinergic side effects, accordin... |
| | | Apr.29.03 | Percent Reduction in Urinary Incontinence Episodes Better Reflects Patient Perception of Clinical Efficacy With OXYTROL(TM)| Click
here for a printable (PDF) version of this release
- OXYTROL(TM) Data Used to Investigate Correlation Between Decrease in Urinary Incontinence Episodes and Changes in Patient Quality of Life Measures -
CHICAGO, April 29 /PRNewswire-FirstCall/ -- A study of patients taking
OXYTROL(TM) (oxybutynin transdermal system) showed that a percent reduction in
urinary incontinence (UI) episodes and not absolute change from baseline is
the better correlate of patient's perception of UI i... |
| | | Apr.28.03 | Watson Pharmaceuticals' OXYTROL(TM) Now Available Nationwide; Shipments to More Than 45,000 Pharmacies| Click
here for a printable (PDF) version of this release
OXYTROL(TM) Addresses Unmet Market Need at a Competitive Price
CORONA, Calif., Apr 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, today announced that OXYTROL(TM) (oxybutynin transdermal system), the
first and only transdermal therapy to treat overactive bladder (OAB), with
symptoms of urge urinary incontinence, urgency and frequency, is now ... |
| | | Apr.28.03 | Watson to Host First Quarter 2003 Earnings Conference Call| Click
here for a printable (PDF) version of this release
CORONA, Calif., April 28 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it will host a
conference call and webcast on Tuesday, May 6, 2003 at 8:30 a.m. Pacific
Daylight Time to discuss the Company's first quarter 2003 financial results
and recent corporate developments. The dial-in number to access the call is
(877) 251-7980, or from international locations, (706) 643-1573.
... |
| | | Apr.25.03 | Watson Pharmaceuticals to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference| Click
here for a printable (PDF) version of this release
CORONA, Calif., Apr 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that Watson's senior management will provide
an overview of the Company's business at the CIBC Annual Biotechnology &
Specialty Pharmaceuticals Conference on Wednesday, April 30, 2003 at
1:30 p.m. EDT.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.wat... |
| | | Apr.08.03 | Watson Launches Microgestin(R) Oral Contraceptive| CORONA, Calif., April 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that it has launched Microgestin(R)
(norethindrone acetate and ethinyl estradiol tablets), a generic version of
the oral contraceptive Loestrin(R), marketed by Pfizer. Microgestin(R) is
indicated for the prevention of pregnancy and will be launched in 1mg /20mcg
and 1.5mg /30mcg strengths.
"The launch of Microgestin(R), paired with our previously launched
Microgestin(R) FE, co... |
| | | Mar.25.03 | Watson Pharmaceuticals to Present at the Banc of America Securities 2003 Healthcare Conference| Click
here for a printable (PDF) version of this release
CORONA, Calif., March 25 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's senior
management will provide an overview of the Company's business at the Banc of
America Securities 2003 Healthcare Conference on Wednesday, March 26, 2003 at
1:55 p.m. PST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com ... |
| | | Mar.18.03 | Watson Pharmaceuticals & Ventiv Health, Inc. Announce U.S. Sales Force Agreement for OXYTROL(TM)| Click
here for a printable (PDF) version of this release
CORONA, Calif. and SOMERSET, N.J., Mar 18, 2003 /PRNewswire-FirstCall via
COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Ventiv Health, Inc.
(Nasdaq: VTIV) today announced that they have entered into a multi-year service
agreement with Ventiv Health providing a nationwide sales force including
recruitment, training and operational support to Watson Pharmaceuticals.
Under the terms of the agreement, Ventiv Health wil... |
| | | Mar.18.03 | Watson Pharmaceuticals to Present at the SG Cowen Securities Corporation 23rd Annual Health Care Conference| Click
here for a printable (PDF) version of this release
CORONA, Calif., Mar 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's senior
management will provide an overview of the Company's business at the SG Cowen
Health Care Conference in Boston on Wednesday, March 19, 2003 at 11:00 a.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click on ... |
| | | Mar.11.03 | Watson Pharmaceuticals Announces European Filing for OXYTROL(TM)| CORONA, Calif., Mar 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), announced today that it has filed a European
Marketing Authorization Application seeking European marketing approval for
OXYTROL(TM) (oxybutynin transdermal system) as part of a qualified centralized
procedure with the European Medicines Control Agency (EMEA), which consists of
15 member states. OXYTROL(TM), recently approved by the U.S. Food and Drug
Administration, is the first and... |
| | | Mar.10.03 | Watson Pharmaceuticals Announces Closing of $500 Million Convertible Contingent Senior Debentures Offering|
CORONA, Calif., Mar 10, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that on March 7, 2003 it
closed its $500 million offering of its 1.75% Convertible Contingent Senior
Debentures due 2023. The debentures are convertible into shares of Watson's
common stock at a conversion price of $40.05 per share of common stock.
Watson has used approximately $300 million of the net proceeds to pay off its
credit facility and intends to use the ... |
| | | Mar.05.03 | Watson Pharmaceuticals Announces Pricing of Convertible Senior Debentures Offering| Click
here for a printable (PDF) version of this release
Offering Increased to $500 Million
CORONA, Calif., Mar 5, 2003 /PRNewswire-FirstCall via COMTEX/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it increased to $500
million the size of its offering of convertible senior debentures due 2023 (plus
an option to the initial purchasers of the debentures to acquire up to an
additional $75 million principal amount of the debentures). The debentures will
be conver... |
| | | Mar.04.03 | Watson Obtains Commitment Letters for $300 Million Credit Facility| Click
here for a printable (PDF) version of this release
CORONA, Calif., Mar 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has obtained
commitment letters from a syndicate of lenders for a $300 million, five-year,
senior unsecured revolving credit facility. The credit facility is subject to
satisfaction of certain conditions. Watson expects the credit facility to be
available for general corporate purposes.
Watson Ph... |
| | | Mar.03.03 | Watson Pharmaceuticals Announces Offering of Convertible Senior Debentures| Click
here for a printable (PDF) version of this release
CORONA, Calif., Mar 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), announced today that it plans to offer $450
million of convertible senior debentures due 2023, subject to market and other
conditions (plus an option to the initial purchasers of the debentures to
acquire up to an additional $67.5 million principal amount of the debentures).
Watson expects to use the net proceeds from th... |
| | | Feb.28.03 | Watson Pharmaceuticals to Present at the Salomon Smith Barney 3rd Annual Specialty Pharmaceuticals Conference|
CORONA, Calif., Feb 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's senior
management will provide an overview of the Company's business at the Salomon
Smith Barney Specialty Pharmaceuticals Conference in New York City on Thursday,
March 6, 2003 at 1:00 p.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click on Investors, and then
click on E... |
| | | Feb.28.03 | Watson Pharmaceuticals to Present at the Lehman Brothers 6th Annual Global Healthcare Conference| CORONA, Calif., Feb 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's senior
management will provide an overview of the Company's business at the Lehman
Brothers Global Healthcare Conference in Miami, Florida on Wednesday, March 5,
2003 at 9:00 a.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click on Investors, and then
click on Events. The we... |
| | | Feb.26.03 | FDA Approves Watson's OXYTROL(TM), The First and Only Transdermal Therapy for Overactive Bladder| Click
here for a printable (PDF) version of this release
CORONA, Calif., Feb 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), announced today that the U.S. Food and Drug
Administration (FDA) has approved OXYTROL(TM) (oxybutynin transdermal system),
the first and only transdermal therapy to treat overactive bladder (OAB), with
symptoms of urge urinary incontinence, urgency and frequency. Estimated to
affect more than 33 million Americans, OAB is ... |
| | | Feb.06.03 | Watson Pharmaceuticals Completes Purchase of Fiorinal(R) and Fioricet(R) Pain Product Lines|
CORONA, Calif., Feb 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced that, following the early
termination of the waiting period under the Hart-Scott Rodino Act, it has
completed its acquisition of the United States rights to the Fioricet(R) and
Fiorinal(R) product lines for $178 million from Novartis AG and its
subsidiaries.
The Fioricet(R) and Fiorinal(R) lines of products are prescription treatments
for tension headaches. The pr... |
| | | Feb.04.03 | Watson Pharmaceuticals Reports Fourth Quarter and Year End 2002 Results| Click
here for a printable (PDF) version of this release
- Fourth Quarter Revenues Increase 12 Percent to Record $330 Million - - Reports Diluted Earnings Per Share of $0.40 - - Excluding Special Items, Earnings Per Share of $0.45 -
CORONA, Calif., Feb 4, 2003 /PRNewswire-FirstCall via COMTEX/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI) today reported its financial results for the
fourth quarter and year ended December 31, 2002.
For the fourth quarter of 2002, net revenues increa... |
| | | Jan.31.03 | Watson Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference|
CORONA, Calif., Jan 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's senior
management will provide an overview of the Company's business at the Merrill
Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New
York City on Thursday, February 6, 2003 at 9:20 a.m. EST.
This presentation will be webcast live and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click on Investo... |
| | | Jan.27.03 | Watson Launches Generic Mestinon®| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jan. 27 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has initiated
shipments of pyridostigmine bromide tablets, the generic version of
Mestinon®. Mestinon® is used in the treatment of myasthenia gravis, a
disorder of neuromuscular transmission, marked by fluctuating weakness and
fatigue of certain voluntary muscles.
Watson Pharmaceuticals, Inc., headq... |
| | | Jan.23.03 | Watson Provides 2003 Outlook for Continued Growth|
Long Term Strategy, Financial Outlook and Oxytrol Launch Plans Discussed
At Analyst Meeting -
NEW YORK, Jan. 23 /PRNewswire-FirstCall/ -- At its analyst meeting in New
York, Watson Pharmaceuticals, Inc. (NYSE: WPI) today provided estimates for
its 2003 financial performance. The company expects to see continued growth
in its brand and generics businesses, with product revenues reaching
approximately $1.34 billion to $1.44 billion and earnings per share in the
... |
| | | Jan.22.03 | Watson to Acquire Line of Pain Products| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jan. 22 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered
into an agreement whereby Watson will acquire United States rights to the
Fioricet(R) and Fiorinal(R) product lines from Novartis Pharmaceuticals
Corporation. The Fioricet(R) and Fiorinal(R) lines of products are indicated
for the treatment of tension headaches.
Under the terms of the ag... |
| | | Jan.22.03 | Watson Launches MonoNessa(TM) Oral Contraceptive| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jan. 22 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has launched
MonoNessa(TM) (norgestimate and ethinyl estradiol tablets), a generic version
of the oral contraceptive ORTHO-CYCLEN(R), marketed by Ortho-McNeil
Pharmaceutical Inc. For 2002, ORTHO-CYCLEN(R) annual sales were approximately
$140 million. MonoNessa(TM) is indicated for the prevention of pregnancy.... |
| | | Jan.15.03 | Watson Updates Fourth Quarter 2002 Financial Estimates| Click
here for a printable (PDF) version of this release
Company to Provide 2003 Outlook at January 23rd Analyst Meeting
CORONA, CA - January 15, 2003 - Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that based on a preliminary review of its operating results, the company expects to report (exclusive of special items) total revenues for the fourth quarter 2002 in the range of $320 to $330 million, and diluted earnings per share in the range of $0.44 to $0.45. Previo... |
| | | Jan.09.03 | Watson Launches Necon(R) 7/7/7 Oral Contraceptive| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jan. 9 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has launched
Necon(R) 7/7/7 (norethindrone and ethinyl estradiol tablets), a generic
version of the oral contraceptive ORTHO-NOVUM(R) 7/7/7, marketed by
Ortho-McNeil Pharmaceutical Inc. For 2002, ORTHO-NOVUM(R) 7/7/7 annual sales
are estimated to be approximately $150 million. Necon(R) 7/7/7 is indicated... |
| | | Jan.08.03 | Watson Pharmaceuticals to Present at 21st Annual JPMorgan H&Q Healthcare Conference| Click
here for a printable (PDF) version of this release
CORONA, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today announced that Dr. Allen Chao will provide an overview
of Watson's business, as part of a presentation at the JPMorgan Annual
Healthcare Conference on Thursday, January 9, 2003 at 1:30 p.m. Pacific Time.
This presentation is being webcast and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click... |
| | | Dec.27.02 | Watson Files ANDA for Generic Glucotrol XL(R)|
Paragraph IV Patent Challenge Underway -
CORONA, Calif., Dec. 27 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that it has filed an
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market a generic version of Glucotrol
XL(R) tablets 5 mg and 10 mg, prior to the expiration of patents owned by ALZA
Corporation. ALZA, together with Pfizer, Inc., the marketer of Glucotrol
XL(... |
| | | Dec.11.02 | Watson Announces Generic Product Development Alliance With Cipla, Ltd|
CORONA, Calif., Dec. 11 /PRNewswire-FirstCall/ --
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has entered
into a strategic alliance with Cipla Ltd. to develop, manufacture and
commercialize ten generic pharmaceutical products, many of which are currently
under development. The agreement also provides for the development of
additional products, as mutually agreed upon by the two companies.
Cipla, Ltd., the second largest pharmaceutical company in ... |
| | | Nov.21.02 | Watson Announces Senior Management Promotions|
CORONA, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc., (NYSE: WPI) today announced that David A. Buchen has been promoted to
Senior Vice President, General Counsel and Secretary and Susan K. Skara has
been promoted to the position of Senior Vice President, Human Resources.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
"The promotions of David and Susan are very well deserved," began Allen
Chao, Watson's Chairman ... |
| | | Nov.21.02 | Watson Pharmaceuticals Announces Senior Management Departure|
CORONA, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today announced that Michael E. Boxer, Watson's Senior Vice
President and Chief Financial Officer is leaving the company to assume a chief
financial officer position at another company. Mr. Boxer has agreed to stay
with Watson through the end of the year to ensure a smooth transition of
financial responsibilities. A search for Mr. Boxer's replacement has been
initiated.
(Ph... |
| | | Nov.11.02 | Watson Pharmaceuticals to Present at the CSFB Health Care Conference|
CORONA, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) announced today that Watson's senior management will provide
an overview of the Company's business at the Credit Suisse First Boston Health
Care Conference in Phoenix, AZ, on Wednesday, November 13, 2002 at 12:00 p.m.
MST.
This presentation is being webcast and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com. Click on Investors, and then
click o... |
| | | Nov.06.02 | Watson Pharmaceuticals Reports Financial Results for Third Quarter 2002| - Total Revenues Increase to Record $308 Million -
CORONA, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today reported its financial results for the three and nine
months ended September 30, 2002.
For the third quarter of 2002, net revenues increased 14 percent to a
record $307.9 million, compared to $270.9 million for the same period in 2001.
Net income for the third quarter was $40.7 million, or $0.38 per diluted
share, compared ... |
| | | Nov.01.02 | Watson Pharmaceuticals to Present at The CIBC World Markets Annual Health Care Conference| CORONA, Calif., Nov 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Watson's Senior
Management will provide an overview of the Company's business at the CIBC World
Markets Thirteenth Annual Health Care Conference in New York City, NY, on
Wednesday, November 6, 2002 at 1:30 p.m. EST.
This presentation is being webcast and can be accessed at Watson
Pharmaceuticals' website www.watsonpharm.com . Click on Investors, and then
cli... |
| | | Oct.28.02 | Watson Expands Oral Contraceptive Portfolio| CORONA, Calif., Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has entered into a
supply arrangement with OMJ Pharmaceutical Inc., an affiliate of Ortho-McNeil
Pharmaceutical Inc., for a portfolio of oral contraceptives.
The agreement provides Watson the ability to launch brand equivalent versions of
three oral contraceptives when market exclusivity on the branded products ends.
Under the terms of the agreement, Wa... |
| | | Oct.25.02 | Watson Announces Third Quarter 2002 Earnings Conference Call| CORONA, Calif., Oct 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it will host a conference
call and webcast on Wednesday, November 6, 2002 at 8:30 a.m. Eastern Standard
Time to discuss the Company's third quarter 2002 financial results and recent
corporate developments. The dial-in number to access the call is (877) 251-7980
or, from international locations, (706) 643-1573.
(Photo: http://www.newscom.com/cgi-bin/prnh/2002021... |
| | | Oct.25.02 | Watson Pharmaceuticals to Present at the Salomon Smith Barney 2002 Health Care Conference| CORONA, Calif., Oct 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Allen Chao, Watson's
Chairman and Chief Executive Officer, and Joseph Papa, Watson's President and
Chief Operating Officer, will provide an overview of the Company's business at
the Salomon Smith Barney 2002 Health Care Conference in New York City, NY, on
Tuesday, October 29, 2002 at 8:45 a.m. EST.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO... |
| | | Oct.23.02 | Watson's NDA for Oxytrol(TM) in Overactive Bladder Accepted for Review by the FDA| CORONA, Calif., Oct 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing the company's resubmitted New Drug
Application (NDA) for Oxytrol(TM) (oxybutynin transdermal system). The NDA seeks
marketing approval for the use of Oxytrol(TM) in the treatment of overactive
bladder with symptoms of urge incontinence, urgency and frequency.
The submission contains two Pha... |
| | | Oct.08.02 | Watson Promotes Joseph Papa to President and Chief Operating Officer| CORONA, Calif., Oct 08, 2002 /PRNewsire-FirstCall via Comtex/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced the promotion of Joseph Papa
to President and Chief Operating Officer. In his expanded role, Mr. Papa will
oversee Watson's research and development, business development, sales and
marketing and manufacturing operations. He has served as Watson's Chief
Operating Officer from November 2001 to the present and in his new role, he will
continue to report to Allen Chao, Ph.... |
| | | Sep.13.02 | Watson Pharmaceuticals to Present at The Bear Stearns 15th Annual Healthcare Conference| CORONA, Calif., Sep 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Allen Chao, Watson's
Chairman and Chief Executive Officer, and Joseph Papa, Watson's Chief Operating
Officer, will provide an overview of the Company's business at the Bear Stearns
15th Annual Healthcare Conference in New York City, NY, on Tuesday, September
17, 2002 at 3:30 p.m. EDT.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
This ... |
| | | Sep.03.02 | Watson Pharmaceuticals Resubmits Oxytrol(TM) NDA for Overactive Bladder| Company Provides Supplemental Clinical Data Supporting Safety and Efficacy -
CORONA, Calif., Sep 03, 2002 /PRNewsire-FirstCall via Comtex/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI), announced today that on August 30th it
resubmitted a New Drug Application (NDA) with the U.S. Food and Drug
Administration (FDA) for Oxytrol(TM) (oxybutynin transdermal system), the
Company's transdermal oxybutynin therapy for which Watson is seeking an
indication for the treatment of overactive bladder wit... |
| | | Aug.29.02 | Watson Notified of Approvable Letter for Aslera(TM)| CORONA, Calif., Aug 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that the U.S. Food and Drug
Administration (FDA) issued an approvable letter on August 28 to Genelabs
Technologies, Inc. (Nasdaq: GNLB) for its New Drug Application (NDA) for
Prestara(TM) (prasterone), formerly known as Aslera(TM) or GL701. Watson holds
exclusive North American rights to Prestara.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
... |
| | | Aug.23.02 | Watson Acquires U.S. Rights to Elan's Nifedipine ER Product, The Generic Equivalent to Adalat CC(R)| CORONA, Calif., Aug 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a
licensing and supply arrangement with Elan Corporation, plc. (Elan) (NYSE: ELN),
whereby Watson has been granted exclusive United States rights to the 30mg and
60mg dosage strengths of Elan's extended-release nifedipine tablets (nifedipine
ER), the generic version of Bayer AG's Adalat CC(R), indicated for the treatment
of hypertension.
(P... |
| | | Aug.14.02 | Watson Subsidiary to Launch Private Label Nicotine Gum| Rugby Laboratories, Inc. Expands Over-the-Counter Product Line -
CORONA, Calif., Aug 14, 2002 /PRNewswire-FirstCall via COMTEX/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that its subsidiary, Rugby
Laboratories, Inc., has expanded its line of over-the-counter products to
include Watson's nicotine polacrilex gum, 2mg and 4mg. Rugby Laboratories is
focused on providing a wide array of over-the-counter products to independent
pharmacies, managed health care facilities, mili... |
| | | Aug.07.02 | Watson Pharmaceuticals Reports Financial Results For the Second Quarter Ended June 30, 2002| Reports Diluted Earnings Per Share of $0.56 and $0.41 Per Share, Excluding Special Items -
CORONA, Calif., Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI) today reported its financial results for the
three and six months ended June 30, 2002.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
For the second quarter of 2002, net revenues increased to $300.1 million,
compared to $299.0 million for the same period in 2001. Net ... |
| | | Aug.06.02 | Watson Names Len Tenzer Vice President Sales and Marketing, Urology| CORONA, Calif., Aug 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced the appointment of Len Tenzer,
47, as Vice President Sales and Marketing, Urology.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Based at Watson's commercial headquarters in Morristown, New Jersey, Mr. Tenzer
will be responsible for managing sales and marketing activities related to
Watson's Urology product portfolio. He will report ... |
| | | Jul.24.02 | Watson Appoints Todd MacLaughlan Vice President, Business Development| CORONA, Calif., Jul 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Todd MacLaughlan has
joined the company as Vice President, Business Development.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Based at Watson's commercial headquarters in Morristown, New Jersey, Mr.
MacLaughlan will be responsible for product licensing and acquisitions, as well
as managing strategic alliance activities. He will report di... |
| | | Jul.24.02 | Watson Announces Second Quarter 2002 Earnings Conference Call| CORONA, Calif., Jul 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it will host a conference
call and webcast on Wednesday, August 7, 2002 at 8:30 a.m. Pacific Daylight Time
to discuss the Company's second quarter 2002 financial results and recent
corporate developments. The dial-in number to access the call is (800) 895-1075
or, from international locations, (212) 748-2704.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214... |
| | | Jul.09.02 | Watson Pharmaceuticals Responds to Recent Stock Activity| Affirms Guidance for 2nd Quarter and Full Year 2002
CORONA, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ --In response to
inquiries from stockholders, Watson Pharmaceuticals, Inc. (NYSE: WPI) announced
today that it knows of no corporate activity or developments that would account
for the unusual activity in its stock.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Watson further reaffirmed its prior earnings guidance of $0.38 to $0.41 per
share for t... |
| | | Jul.09.02 | Watson Receives FDA Approval for Nizatidine Capsules| CORONA, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has received final
approval from the United States Food and Drug Administration on its Abbreviated
New Drug Application for Nizatidine Capsules USP, 150 mg and 300 mg. Nizatidine
is the generic equivalent to Reliant Pharmaceuticals' Axid(R) capsules and is
indicated for the treatment and maintenance of duodenal ulcers, esophagitis and
associated heartburn with G... |
| | | Jul.01.02 | Watson Receives FDA Approval for Lisinopril and Lisinopril/HCTZ Tablets| CORONA, Calif., Jul 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has received final
approval from the United States Food and Drug Administration on its Abbreviated
New Drug Application (ANDA) for Lisinopril Tablets UPS, 2.5 mg, 5 mg, 10 mg, 20
mg, 30 mg and 40 mg and its ANDA for Lisinopril and Hydrochlorothiazide (HCTZ)
Tablets, 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.
(Photo: http://www.newscom.com/cgi-bin/prnh/200... |
| | | Jun.24.02 | Watson Receives FDA Approval for Tramadol Hydrochloride Tablets| CORONA, Calif., Jun 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has received final
approval from the United States Food and Drug Administration (FDA) on its
Abbreviated New Drug Application for Tramadol Hydrochloride Tablets, 50 mg.
Tramadol is the generic equivalent to Ortho-McNeil's Ultram(R) tablets, and is
indicated for the management of moderate to moderately severe pain. Watson will
begin shipping its Tramadol Hydroch... |
| | | Jun.11.02 | Watson Pharmaceuticals to Present at The 23rd Annual Goldman Sachs Global Healthcare Conference| CORONA, Calif., Jun 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Dr. Allen Chao, Watson's
Chairman and Chief Executive Officer, will provide an overview of the Company's
business at the 23rd Annual Goldman Sachs Global Healthcare Conference in Laguna
Niguel, CA, on Wednesday, June 12, 2002 at 11:40 a.m. PDT.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
A live audio webcast of the presentation may be... |
| | | Jun.04.02 | Watson Pharmaceuticals to Present at the UBS Warburg Global Specialty Pharmaceuticals Conference| CORONA, Calif., Jun 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Joseph Papa, Watson's
Chief Operating Officer, and Michael Boxer, Watson's Chief Financial Officer,
will provide an overview of the Company's business at the UBS Warburg Global
Specialty Pharmaceuticals Conference in New York City, NY, on Thursday, June 6,
2002 at 9:00 a.m. EDT.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
A live audi... |
| | | May.10.02 | Watson Pharmaceuticals Announces Senior Management Change| CORONA, Calif., May 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced that Robert C. Funsten,
Watson's Senior Vice President and General Counsel, is leaving the company to
pursue other opportunities. An active search for Mr. Funsten's replacement will
begin immediately. Michel J. Feldman, an attorney and Watson board member who
has worked with Watson since its formation, will serve as interim general
counsel.
(Photo: http://www.newsc... |
| | | May.08.02 | Watson Pharmaceuticals Reports Financial Results For the First Quarter Ended March 31, 2002| - Reports Diluted Earnings Per Share of $0.34, Excluding Special Items -
CORONA, Calif., May 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today reported its financial results for the
three months ended March 31, 2002.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
For the first quarter of 2002, net revenues were $285.7 million, compared to
$296.8 million reported in the first quarter of 2001. The decline was
attributab... |
| | | May.03.02 | Watson Pharmaceuticals Reaches Agreement With FDA On Terms of Corona, California Consent Decree| As Expected, the Decree Requires No Fine, Shutdown, Product Recalls or Reduction in Production or Service
CORONA, Calif., May 3, 2002 /PRNewswire-FirstCall via COMTEX/ --Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that it has reached an
agreement with the U.S. Food and Drug Administration (FDA) on the terms of a
consent decree with respect to Watson's Corona, California manufacturing
facility. As expected, the final agreement with FDA does not require any fine, a
facility sh... |
| | | Apr.29.02 | Watson Pharmaceuticals to Present at The CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference| CORONA, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) announced today that Joseph Papa, Watson's
Chief Operating Officer, and Michael Boxer, Watson's Chief Financial Officer,
will provide an overview of the Company's business at the CIBC Annual
Biotechnology & Specialty Pharmaceuticals Conference in New York City, NY, on
Wednesday, May 1, 2002 at 11:30 a.m. EDT.
(Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
A l... |
| | | Apr.25.02 | Watson Announces Fir |
|
Country websites